

## **British HIV Association guidelines for HIV-associated malignancies 2014**



NHS Evidence has accredited the process used by the British HIV Association (BHIVA) to produce guidelines. Accreditation is valid for five years from July 2012 and is applicable to guidance produced using the processes described in the British HIV Association (BHIVA) Guideline Development Manual. More information on accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation)

# British HIV Association guidelines for HIV-associated malignancies 2014

## Writing Group

**Prof Mark Bower (Chair)**

*Professor of Oncology, National Centre for HIV Malignancy, Chelsea & Westminster Hospital NHS Foundation Trust, London*

**Dr A Palfreeman (Vice Chair)**

*Consultant in Genitourinary Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK*

**Dr Maryam Alfa-Wali**

*Clinical Research Fellow, Imperial College School of Medicine at Chelsea & Westminster Hospital, London*

**Prof Chris Bunker**

*Consultant Dermatologist, University College and Chelsea & Westminster Hospitals, London*

**Dr Fiona Burns**

*Consultant Physician, Royal Free London NHS Foundation Trust, and Clinical Senior Lecturer, University College London*

**Dr Duncan Churchill**

*Consultant Physician in HIV and Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust*

**Mr Simon Collins**

*Senior Editor and Advocate, HIV i-Base, UK-CAB*

**Dr Kate Cwynarski**

*Consultant Haem-Oncologist, Department of Haematology, Royal Free Hospital, London*

**Dr Simon Edwards**

*Consultant Physician in HIV and Genitourinary Medicine, Central and North West London NHS Foundation Trust*

**Dr Paul Fields**

*Consultant Haematologist, Guy's & St Thomas' and King's College Hospitals, London*

**Dr Kate Fife**

*Consultant Clinical Oncologist, Cambridge University Hospital and Peterborough City Hospital*

**Dr Eve Gallop-Evans**

*Consultant Clinical Oncologist, Velindre Cancer Centre, Cardiff*

**Dr Shireen Kassam**

*Consultant Haematologist, King's College Hospital, London*

**Dr Ranjababu Kulasegaram**

*Consultant Physician in HIV and Genitourinary Medicine, Guy's & St Thomas' NHS Foundation Trust, London*

**Prof Charles Lacey**

*Professor of Medicine, University of York*

**Dr Robert Marcus**

*Consultant Haematologist, King's College Hospital, London*

**Dr Sylvia Montoto**

*Consultant in Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London*

**Dr Mark Nelson**

*Consultant Physician, Chelsea and Westminster Hospital NHS Foundation Trust, London, and Adjunct Professor and Reader in Human Immunodeficiency Virology, Imperial College London*

**Dr Tom Newsom-Davis**

*Consultant Medical Oncologist, Chelsea and Westminster Hospital NHS Foundation Trust, London*

**Dr Chloe Orkin**

*Consultant Physician and Lead for HIV Research, Barts Health NHS Trust, London*

**Ms Kate Shaw**

*Macmillan Clinical Nurse Specialist HIV-Oncology, Chelsea and Westminster Hospital, London  
NHIVNA Representative*

**Dr Melinda Tenant-Flowers**

*Consultant and Honorary Senior Lecturer in HIV and Sexual Health, King's College Hospital NHS Foundation Trust and King's College London*

**Dr Andrew Webb**

*Consultant Medical Oncologist, the Royal Sussex County Hospital, Brighton*

**Dr Sarah Westwell**

*Consultant Clinical Oncologist, the Royal Sussex County Hospital, Brighton*

**Mr Matt Williams**

*Community Representative, UK-CAB*

## Table of contents

- 1 Introduction
  - 1.1 Scope and purpose
  - 1.2 Methodology
    - 1.2.1 Guideline development process
    - 1.2.2 Patient involvement
    - 1.2.3 GRADE
    - 1.2.4 Good practice points
    - 1.2.5 Dissemination and implementation
    - 1.2.6 Guideline updates and date of next review
  - 1.3 Summary
  - 1.4 Key recommendations
  - 1.5 References
- 2 Summary of Recommendations/good practice points and auditable outcomes
- 3 Kaposi sarcoma (KS)
  - 3.1 Diagnosis, staging and prognosis
  - 3.2 Management
    - 3.2.1 Prevention
    - 3.2.2 Local therapy
      - 3.2.2.1 Radiotherapy
      - 3.2.2.2 Other local therapies
    - 3.2.3 Systemic therapy
      - 3.2.3.1 HAART
      - 3.2.3.2 Cytotoxic chemotherapy
      - 3.2.3.3 Liposomal anthracyclines
      - 3.2.3.4 Taxanes
      - 3.2.3.5 Immunotherapy
      - 3.2.3.6 Other systemic therapies
  - 3.3 Summary of recommendations
  - 3.4 References
- 4 Systemic AIDS-related non-Hodgkin lymphoma (ARL)
  - 4.1 Introduction
  - 4.2 Diagnosis, staging and prognosis
  - 4.3 Recommendation
  - 4.4 Management
    - 4.4.1 First-line chemotherapy for DLBCL in HIV-infected individuals
      - 4.4.1.1 Localized disease
      - 4.4.1.2 Disseminated disease
    - 4.4.2 Rituximab for DLBCL
    - 4.4.3 Treatment for high-risk patients
    - 4.4.4 The effect of adding HAART
    - 4.4.5 Recommendations for DLBCL
  - 4.5 Burkitt lymphoma/leukaemia
    - 4.5.1 Recommendations for BL
  - 4.6 Prevention of secondary CNS lymphoma
    - 4.6.1 Recommendations for IT prophylaxis
  - 4.7 Supportive care
  - 4.8 Treatment of relapsed/refractory AIDS-related lymphoma
    - 4.8.1 Recommendations for patients with relapsed/refractory aggressive ARL
  - 4.9 Response evaluation and follow-up
  - 4.10 References

- 5 Primary central nervous system lymphoma (PCNSL)
  - 5.1 Introduction
  - 5.2 Diagnosis, staging and prognosis
  - 5.3 Treatment of HIV-associated primary cerebral lymphoma
  - 5.4 Recommendations
  - 5.5 References
- 6 Primary effusion lymphoma (PEL)
  - 6.1 Introduction
  - 6.2 Pathogenesis
  - 6.3 Presentation
  - 6.4 Diagnosis
  - 6.5 Prognosis and management
  - 6.6 Recommendations
  - 6.7 References
- 7 Plasmablastic lymphoma
  - 7.1 Introduction
  - 7.2 Morphology
  - 7.3 Pathogenesis
  - 7.4 Clinical presentation
  - 7.5 Treatment
  - 7.6 Recommendation
  - 7.7 References
- 8 Cervical intraepithelial neoplasia (CIN) and cervical cancer
  - 8.1 Introduction
  - 8.2 Screening for cervical cancer and pre-cancer
  - 8.3 The effect of HAART on the natural history of CIN
  - 8.4 Diagnosis and management of CIN
  - 8.5 Diagnosis, staging, management and prognosis of cervical cancer
  - 8.6 Key recommendations
  - 8.7 References
- 9 Anal cancer
  - 9.1 Introduction
    - 9.1.1 Key recommendations of BHIVA, BASHH and FFPRHC 2008 guidelines on anal cancer in HIV
    - 9.1.2 Key recommendations of NICE 2004 guidelines on anal cancer
    - 9.1.3 Epidemiology
  - 9.2 Diagnosis
  - 9.3 Staging
  - 9.4 Management
    - 9.4.1 First-line treatment for anal cancer
    - 9.4.2 Benefit of adding antiretrovirals to anal cancer treatment
    - 9.4.3 Best treatment of relapse of anal cancer
    - 9.4.4 Best response evaluation and follow-up in anal cancer
  - 9.5 Summary of guidance
  - 9.6 References
- 10 Hodgkin Lymphoma (HL)
  - 10.1 Introduction
  - 10.2 Diagnosis, staging, prognostic factors
  - 10.3 Do antiretrovirals reduce the risk of HL?
  - 10.4 What is the best treatment for HL?
    - 10.4.1 Recommendations
  - 10.5 What is the benefit of adding ARVs to chemotherapy in HL?
    - 10.5.1 Recommendations

- 10.6 What is the benefit of adding rituximab to chemotherapy in HL?
- 10.7 What is the best treatment in second line for HL?
  - 10.7.1 Recommendation
- 10.8 What is the benefit of adding opportunistic infection prophylaxis in HL?
  - 10.8.1 Recommendation
- 10.9 What is the best response evaluation and follow-up in HL?
  - 10.9.1 Recommendations
- 10.10 References
- 11 Multicentric Castleman's disease
  - 11.1 Introduction
  - 11.2 Diagnosis
    - 11.2.1 Recommendations
  - 11.3 Staging
  - 11.4 Prognosis
    - 11.4.1 Observations
  - 11.5 Management
  - 11.6 Combination antiretroviral therapy (cART)
  - 11.7 Rituximab
  - 11.8 Chemotherapy
  - 11.9 Immunotherapy (excluding rituximab)
  - 11.10 Anti-human herpes virus-8 therapy
  - 11.11 Surgery
  - 11.12 Recommendations
  - 11.13 Auditable outcomes
  - 11.14 References
- 12 Non-AIDS-defining malignancies
  - 12.1 Introduction
  - 12.2 Testicular germ cell cancers
    - 12.2.1 Introduction
    - 12.2.2 Diagnosis, staging, prognostic factors
    - 12.2.3 Management
      - 12.2.3.1 Stage I disease
      - 12.2.3.2 Metastatic disease
      - 12.2.3.3 Relapsed disease
    - 12.2.4 Summary
  - 12.3 Non-small cell lung cancer
    - 12.3.1 Introduction
    - 12.3.2 Prognosis
    - 12.3.3 Management
      - 12.3.3.1 Operable disease
      - 12.3.3.2 Locally advanced disease
      - 12.3.3.3 Metastatic disease
    - 12.3.4 HAART
    - 12.3.5 Screening
    - 12.3.6 Summary
  - 12.4 Hepatocellular cancer
    - 12.4.1 Introduction
    - 12.4.2 Presentation and diagnosis
    - 12.4.3 Management
      - 12.4.3.1 Localized therapies
      - 12.4.3.2 Transplantation
      - 12.4.3.3 Sorafenib

- 12.4.4 Screening for HCC in patients with hepatitis and HIV co-infection
- 12.4.5 Summary
- 12.5 Other cancers
  - 12.5.1 Colorectal cancer
  - 12.5.2 Skin cancer
  - 12.5.3 Merkel cell carcinoma (MCC)
  - 12.5.4 Cutaneous lymphoma
  - 12.5.5 Penis precancer and cancer
  - 12.5.6 Others
  - 12.5.7 Summary
- 12.6 References
- 13 Opportunistic infection prophylaxis in HIV-associated malignancy
  - 13.1 Introduction
  - 13.2 PCP prophylaxis
  - 13.3 MAC prophylaxis
  - 13.4 Fungal prophylaxis
  - 13.5 Bacterial prophylaxis
  - 13.6 Antiviral prophylaxis
  - 13.7 Recommendations
  - 13.8 References
- 14 Acknowledgements
  - 14.1 Conflicts of interest statements
- 15 List of appendices
- Appendix 1 Summary modified GRADE system

## 1 Introduction

### 1.1 Scope and purpose

The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of adults with HIV infection and malignancy. The scope includes the management of diagnosed malignancies in people living with HIV but does not address screening for malignancies in this population. This is covered elsewhere in other BHIVA guidance where evidence is available to support it [1].

The guidelines are aimed at clinical professionals directly involved with, and responsible for, the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA guidelines.

### 1.2 Methodology

#### 1.2.1 Guideline development process

BHIVA revised and updated the Association's guideline development manual in 2011 [2]. BHIVA has adopted the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for the assessment, evaluation and grading of evidence and development of recommendations [3,4]. Full details of the guideline development process, including conflict of interest policy, are outlined in the manual.

The scope, purpose and guideline topics were agreed by the Writing Group. Questions concerning each guideline topic were drafted and a systematic literature review undertaken by an information scientist. BHIVA HIV-associated malignancy guidelines were last published in 2008 [5]. For the 2013 guidelines the literature search dates were 1 January 2008 to 16 July 2013 and included MEDLINE, Embase and the Cochrane Library. Abstracts from selected conferences were searched between 1 January 2009 and 16 July 2013. For each topic and healthcare question, evidence was identified and evaluated by Writing Group members with expertise in the field. Using the modified GRADE system (Appendix 1), panel members were responsible for assessing and grading the quality of evidence for predefined outcomes across studies and developing and grading the strength of recommendations. An important aspect of evaluating evidence is an understanding of the design and analysis of clinical trials, including the use of surrogate marker data.

For a number of questions, GRADE evidence profile and summary of findings tables were constructed, using predefined and rated treatment outcomes, to help achieve consensus for key recommendations and aid transparency of the process. Before final approval by the Writing Group, the guidelines were published online for public consultation and an external peer review was commissioned and conducted.

#### 1.2.2 Patient involvement

BHIVA views the involvement of patient and community representatives in the guideline development process as essential. The Writing Group included two patient representatives appointed through the UK HIV Community Advisory Board (UK-CAB) who were involved in all aspects of the guideline development process. In addition, two meetings with patients and community representatives were held to discuss and receive feedback and comments on the proposed guideline recommendations. The first was held before the Writing Group's consensus meeting and the second as part of the public consultation process.

#### 1.2.3 GRADE

The GRADE Working Group [4] has developed an approach to grading evidence that moves away from initial reliance on study design to consider the overall quality of evidence across outcomes. BHIVA has adopted the modified GRADE system for its guideline development.

The advantages of the modified GRADE system are (i) the grading system provides an informative, transparent summary for clinicians, patients and policy makers by combining an explicit evaluation of the strength of the recommendation with a judgement of the quality of the evidence for each recommendation, and (ii) the two-level grading system of recommendations has the merit of simplicity and provides clear direction to patients, clinicians and policy makers.

A *Grade 1 recommendation* is a strong recommendation to do (or not do) something, where the benefits clearly outweigh the risks (or vice versa) for most, if not all patients. Most clinicians and patients should and would want to follow a strong recommendation unless there is a clear rationale for an alternative approach. A strong recommendation usually starts with the standard wording 'We recommend'.

A *Grade 2 recommendation* is a weaker or conditional recommendation, where the risks and benefits are more



closely balanced or are more uncertain. Most clinicians and patients would want to follow a weak or conditional recommendation but many would not. Alternative approaches or strategies may be reasonable depending on the individual patient's circumstances, preferences and values. A weak or conditional recommendation usually starts with the standard wording 'We suggest'.

The *strength of a recommendation* is determined not only by the quality of evidence for defined outcomes but also the balance between desirable and undesirable effects of a treatment or intervention, differences in values and preferences and, where appropriate, resource use. Each recommendation concerns a defined target population and is actionable.

The *quality of evidence* is graded from A to D and for the purpose of these guidelines is defined as follows:

*Grade A evidence* means high-quality evidence that comes from consistent results from well-performed randomized controlled trials (RCTs), or overwhelming evidence of some other sort (such as well-executed observational studies with consistent strong effects and exclusion of all potential sources of bias). Grade A implies confidence that the true effect lies close to the estimate of the effect.

*Grade B evidence* means moderate-quality evidence from randomized trials that suffer from serious flaws in conduct, inconsistency, indirectness, imprecise estimates, reporting bias, or some combination of these limitations, or from other study designs with special strengths such as observational studies with consistent effects and exclusion of most potential sources of bias.

*Grade C evidence* means low-quality evidence from controlled trials with several very serious limitations or observational studies with limited evidence on effects and exclusion of most potential sources of bias.

*Grade D evidence* on the other hand is based only on case studies, expert judgement or observational studies with inconsistent effects and a potential for substantial bias, such that there is likely to be little confidence in the effect estimate.

#### 1.2.4 Good practice points

In addition to graded recommendations, the BHIVA Writing Group has also included good practice points (GPP), which are recommendations based on the clinical judgement and experience of the working group. GPPs emphasize an area of important clinical practice for which there is not, nor is there likely to be, any significant research evidence. They address an aspect of treatment and care that is regarded as such sound clinical practice that healthcare professionals are unlikely to question it and where the alternative recommendation is deemed unacceptable. It must be

emphasized that GPPs are not an alternative to evidence-based recommendations.

#### 1.2.5 Dissemination and implementation

The following measures have/will be undertaken to disseminate and aid implementation of the guidelines:

1. E-publication on the BHIVA website and the journal *HIV Medicine*.
2. Publication in the journal *HIV Medicine*.
3. Shortened version detailing concise summary of recommendations.
4. E-learning module accredited for CME.
5. Educational slide set to support local and regional educational meetings.
6. National BHIVA audit programme.

#### 1.2.6 Guideline updates and date of next review

The guidelines will be next fully updated and revised in 2018. However, the Writing Group will continue to meet regularly to consider new information from high-quality studies and publish amendments and addendums to the current recommendations before the full revision date where this is thought to be clinically important to ensure continued best clinical practice.

### 1.3 Summary

HIV infection is associated with three AIDS-defining malignancies (Kaposi sarcoma, high grade B-cell non-Hodgkin lymphoma and invasive cervical cancer) as well as an increased risk of many other malignancies. The clinical care of patients with these tumours requires a multidisciplinary approach drawing on the skills and experience of all healthcare professional groups. Moreover, optimal care can only be achieved by the close co-operation of oncologists, haematologists and HIV physicians, and unless all these clinicians are intimately involved in the care of patients it is likely that the outcome will be less favourable. Patients with HIV-associated malignancies should therefore only be managed in a centre dealing with large numbers of patients with these tumours.

The minimum number of patients that an HIV oncology service should manage has not been defined. Several studies and a Cochrane review have shown that the more HIV patients treated by a centre, the better the outcomes [6–8]. Similarly, *Improving outcomes in haematological cancer* published by NICE in 2003 included a systematic review of published evidence suggesting that higher patient volumes are associated with improved outcomes and that outcomes in specialist centres are better. They

advocated that all patients with haematological cancer should be managed by a multidisciplinary haematology team serving a population of at least 500 000 [9]. An audit study in North London confirmed the better management of patients with AIDS-related lymphomas in HIV centres with cohorts of >500 patients [10]. An audit from Canada also showed that clinicians treating larger numbers of patients with AIDS-related lymphoma provided better care [11] and a recent cohort study in the US published in 2013 attributed poorer results in some centres to a lack of access to optimal integrated cancer and HIV care [12]. An additional benefit of centralization could be greater uptake of HIV testing amongst patients diagnosed with cancers including lymphomas as advocated in BHIVA testing guidelines [13] and in the US [14]. This remains a concern since UK lymphoma clinicians are often overly reluctant to adopt universal testing [15] and uptake remains low even for AIDS-defining malignancies [16].

In line with national cancer waiting times, all patients with suspected cancers must be referred urgently and seen within 2 weeks of referral. Moreover, the NHS Cancer Plan sets out the goal that no patient should wait longer than 1 month from an urgent referral with suspected cancer, to the start of treatment [17].

We recommend that all patients with HIV and malignancy should be referred to centres that have developed expertise in the management of these diseases (level of evidence 1B). The multidisciplinary team managing these patients must include HIV physicians, oncologists, haematologists and palliative care physicians along with clinical nurse specialists, specialist HIV pharmacists and specialist chemotherapy pharmacists.

#### 1.4 Key recommendations

- We recommend that all patients with HIV and malignancy should be referred to centres that have developed expertise in the management of these diseases (level of evidence 1B).
- We recommend that clinical networks supporting regional centres of excellence for the treatment of both AIDS-defining and non-AIDS-defining cancers should be developed as advocated by the *Standards of Care for People Living with HIV 2013* [18] (level of evidence 1D).

#### 1.5 References

- 1 Asboe D, Aitken C, Boffito M *et al*. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. *HIV Med* 2012; 13: 1–44.
- 2 BHIVA. British HIV Association (BHIVA) Guideline Development Manual. 13 September 2011. Available at: <http://www.bhiva.org/GuidelineDevelopmentManual.aspx> (accessed December 2013).
- 3 Guyatt GH, Oxman AD, Kunz R *et al*. Going from evidence to recommendations. *BMJ* 2008; 336: 1049–1051.
- 4 Development and Evaluation (Short GRADE) Working Group. The grading of recommendations assessment. Available at <http://www.gradeworkinggroup.org> (accessed December 2013).
- 5 Bower M, Collins S, Cottrill C *et al*. British HIV Association guidelines for HIV-associated malignancies 2008. *HIV Med* 2008; 9: 336–388.
- 6 Curtis JR, Bennett CL, Horner RD *et al*. Variations in intensive care unit utilization for patients with human immunodeficiency virus-related *Pneumocystis carinii* pneumonia: importance of hospital characteristics and geographic location. *Crit Care Med* 1998; 26: 668–675.
- 7 Handford CD, Rackal JM, Tynan A-M *et al*. The association of hospital, clinic and provider volume with HIV/AIDS care and mortality: systematic review and meta-analysis. *AIDS Care* 2012; 24: 267–282.
- 8 Rackal JM, Tynan A-M, Handford Curtis D *et al*. Provider training and experience for people living with HIV/AIDS. *Cochrane Database Syst Rev* 2011; 6: CD003938.
- 9 National Institute for Clinical Excellence. *Guidance for Commissioning Cancer Services. Improving outcomes in haematological cancers: the research evidence*. Available at: <http://www.nice.org.uk/nicemedia/live/10891/28787/28787.pdf> (accessed December 2013).
- 10 Brook MG, Jones K, Bower M, Miller RF. Management of HIV-related lymphoma in HIV treatment centres in North Thames Region. *Int J STD AIDS* 2004; 15: 765–766.
- 11 Cheung MC, Imrie KR, Leitch HA *et al*. Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma. *Ann Hematol* 2007; 86: 631–638.
- 12 Dunleavy K, Wilson WH. Implications of the shifting pathobiology of AIDS-related lymphoma. *J Natl Cancer Inst* 2013; 105: 1170–1171.
- 13 Palfreeman A, Fisher M, Ong E *et al*. Testing for HIV: concise guidance. *Clin Med* 2009; 9: 471–476.
- 14 Chiao EY, Dezube BJ, Krown SE *et al*. Time for oncologists to opt in for routine opt-out HIV testing? *JAMA* 2010; 304: 334–339.
- 15 Bowman CA, Olarinde O, Wright J. Routine HIV testing in lymphoma patients. Overcoming the challenges. *HIV Med* 2010; 11(Suppl 1): 59 [Abstract P122].
- 16 Lebari D, Kaczmarek E. HIV testing in cancer: experience from a tertiary oncology hospital. *HIV Med* 2012; 13(Suppl 1): 34 [Abstract P70].

- 17 Department of Health. *The NHS plan. A plan for investment. A plan for reform*. Cm 4818-I. London: HMSO, July 2000. Available at: <http://pns.dgs.pt/files/2010/03/pnsuk1.pdf&tei=NJHKUpqHIqIR7AbF14GwAw&tusg=AFQjCNHQ7SYdrNz7Kv-Vcv77eIzYy1wkhw&tbvm=bv.58187178,d.bGQ>
- 18 BHIVA. *Standards of Care for People Living with HIV 2013*. Available at: <http://www.bhiva.org/documents/Standards-of-care/BHIVAStandardsA4.pdf> (accessed December 2013).

## 2 Summary of recommendations/good practice points and auditable outcomes

### 1 Introduction

#### 1.4 Key recommendations

- We recommend that all patients with HIV and malignancy should be referred to centres that have developed expertise in the management of these diseases (level of evidence 1B).
- We recommend that clinical networks supporting regional centres of excellence for the treatment of both AIDS-defining and non-AIDS-defining cancers should be developed as advocated by the *Standards of Care for People Living with HIV 2013* [18] (level of evidence 1D).

### 3 Kaposi sarcoma (KS)

#### 3.3 Summary of recommendations

- We recommend that KS should be confirmed histologically (level of evidence 1C).
- We suggest that CT scans, bronchoscopy and endoscopy are not warranted in the absence of symptoms (level of evidence 2D).
- We recommend that HAART should be started in all patients diagnosed with KS (level of evidence 1B)
- We suggest local radiotherapy or intralesional vinblastine for symptomatic or cosmetic improvement in early stage T0 KS (level of evidence 2C)
- We recommend that patients with T1 advanced stage KS, should receive chemotherapy along with HAART (level of evidence 1B).
- We recommend that liposomal anthracyclines (either DaunoXome 40 mg/m<sup>2</sup> q14d or Caelyx 20 mg/m<sup>2</sup> q21d) are first-line chemotherapy for advanced KS (level of evidence 1A).
- We recommend paclitaxel chemotherapy (100 mg/m<sup>2</sup> q14d) for second-line treatment of anthracycline refractory KS (level of evidence 1C).
- All patients should be considered for clinical trial enrolment if eligible (GPP).

### 4 Systemic AIDS-related non-Hodgkin lymphoma (ARL)

#### 4.3 Recommendation

- We recommend that all patients have pathology and treatment plans reviewed by a specialist multidisciplinary team (MDT) and that management is co-ordinated closely with an HIV physician and a haemato-oncologist familiar with the treatment of such patients (level of evidence 1D).

#### 4.4.5 Recommendations for DLBCL

- We recommend that patients should be entered into clinical trials, if available (GPP).
- We recommend that first-line treatment of DLBCL in HIV-positive individuals includes chemotherapy regimens used in HIV-negative patients, such as CHOP or infusional therapies such as EPOCH. No randomized studies have been published in the era of ART and hence there is no optimal 'gold-standard therapy' (level of evidence 1B).
- We recommend that chemotherapy regimens should be combined with HAART therapy (level of evidence 1B).
- We recommend the concomitant administration of rituximab (level of evidence 1B). Patients with CD4 cell counts <50 cells/ $\mu$ L may require closer surveillance (GPP).

#### 4.5.1 Recommendations for BL

- We recommend that first-line treatment of BL in HIV-infected individuals includes regimens such as CODOX-M/IVAC and DA-EPOCH. No comparative studies have been performed and hence there is no optimal 'gold-standard therapy' (level of evidence 1B).
- We recommend that chemotherapy regimens should be combined with HAART therapy (level of evidence 1B).
- We recommend the addition of rituximab (level of evidence 1C).

#### 4.6.1 Recommendations for IT prophylaxis

- We recommend that patients with DLBCL, considered to have a high risk of CNS relapse, should be given CNS prophylaxis (IT and/or IV methotrexate) according to the same criteria as HIV-negative patients (level of evidence 1C).
- We recommend that prophylactic intrathecal chemotherapy should be offered to all patients with Burkitt lymphoma (level of evidence 1B).

#### 4.8.1 Recommendations for patients with relapsed/refractory aggressive ARL

- We recommend that patients deemed fit for intensive chemotherapy should receive a second-line chemotherapy regimen (level of evidence 1C), which may contain platinum (level of evidence 2C).
- We recommend that those patients responding to second-line chemotherapy (CR or PR) should be considered for HDT with ASCT (level of evidence 1C).

### 5 Primary central nervous system lymphoma (PCNSL)

#### 5.4 Recommendations

- We recommend that all patients with PCNSL should be started on HAART if not already on it (level of evidence 1C).
- We recommend that patients with an adequate performance status should be treated, if possible, with high-dose methotrexate-containing chemotherapy regimen (level of evidence 1D).
- We recommend that whole brain radiotherapy is a useful palliative treatment modality for control of symptoms or should be considered as an alternative first-line treatment modality in those patients where the risks of toxicity from high-dose intravenous agents are considered unacceptable (level of evidence 1C).

### 6 Primary effusion lymphoma (PEL)

#### 6.6 Recommendations

- We suggest that first-line treatment of PEL in HIV-infected individuals includes CHOP-like regimens. No comparative studies have been performed and there is no optimal gold-standard therapy (level of evidence 2C).
- Patients, where possible, should be entered into clinical trials that are testing novel targeted approaches (GPP).
- We recommend that chemotherapy regimens should be combined with HAART (level of evidence 1C).

### 7 Plasmablastic lymphoma

#### 7.6 Recommendation

- We recommend that patients should receive HAART with systemic anthracycline-containing chemotherapy as first-line therapy (level of evidence 1C).

### 8 Cervical intraepithelial neoplasia (CIN) and cervical cancer

#### 8.6 Key recommendations

- We recommend that all women newly diagnosed with HIV should have cervical surveillance performed by, or in conjunction with, the medical team managing their HIV infection (level of evidence 1B). An initial colposcopy and annual cytology should be performed if resources permit (level of evidence 2C).
- We recommend that subsequent colposcopy for cytological abnormality should follow UK national guidelines, and the age range screened should be the same as for HIV-negative women (level of evidence 1B).
- We suggest that CIN 2/3 (HSIL) should be managed according to UK national guidelines. Lesions less severe than CIN 2 should probably not be treated according to CIN 2/3 recommendations, as these low-grade lesions represent persistent HPV infection of the cervix rather than pre-malignancy (level of evidence 2B). Women with HIV and CIN 2/3 treated by excisional procedures have a significantly higher treatment failure rate than HIV-negative women. A number of studies show such relapse is less frequent in the presence of HAART or higher CD4 cell counts or undetectable viral load. Multidisciplinary management of such women is thus recommended (GPP).
- We recommend that women with HIV who have invasive cervical cancer should be managed in the same way as HIV-negative women according to UK national guidelines, again within a multidisciplinary team framework (level of evidence 1B).

## 9 Anal cancer

### 9.5 Summary of guidance

- We recommend the examination under anaesthetic (EUA) of the anal canal and rectum with biopsy in all suspected cases (level of evidence 1D).
- We recommend that staging for anal cancer following EUA and biopsy includes computerized tomography (CT) of the chest, abdomen and pelvis and MRI of the pelvis in order to assess regional lymph nodes and tumour extension [2] (level of evidence 1B).
- We recommend that the management of HIV patients with anal cancer is in specialized centres where there is MDT experience in order to ensure optimal outcomes [2] (level of evidence 1C).
- We suggest that centres caring for these patients should be able to provide high-resolution anoscopy (HRA) services (level of evidence 2D).
- We recommend CRT with 5-fluorouracil and mitomycin C (level of evidence 1A).
- We recommend that all people living with HIV who are to be treated with CRT should start HAART (level of evidence 1C) and opportunistic infection prophylaxis (level of evidence 1D).
- We suggest that salvage surgery may be appropriate for people living with HIV who experience loco-regional disease persistence or relapse following CRT (level of evidence 2D).
- We suggest that best supportive care may be more appropriate for patients with metastatic disease or local relapse following salvage surgery (level of evidence 2D). We suggest a similar approach in people living with HIV (level of evidence 2D) and advocate surveillance for AIN by HRA (level of evidence 2D).

## 10 Hodgkin Lymphoma (HL)

### 10.4.1 Recommendations

- We recommend for early-favourable HL: ABVD x2–4 + IFRT 20–30 Gy (level of evidence 1B).
- We recommend for early-unfavourable HL: ABVD x4 + IFRT 30 Gy (level of evidence 1B).
- We recommend for advanced-stage HL: ABVD x6–8 +/- RT (level of evidence 1B).

### 10.5.1 Recommendations

- We recommend patients should receive HAART during chemotherapy (level of evidence 1A).
- We recommend to avoid PI/ritonavir-boosted regimens (level of evidence 1D).

### 10.7.1 Recommendation

- We recommend that fit patients with relapsed/refractory HL should receive salvage chemotherapy and, if the disease proves to be chemosensitive, consolidate the response with HDT/ASCR (level of evidence 1B).

### 10.8.1 Recommendation

- We recommend PCP, MAI and fungal infection prophylaxis (level of evidence 1D).

### 10.9.1 Recommendations

- We recommend assessment of response after treatment should be performed by FDG-PET scan and BM biopsy (level of evidence 1D).
- We recommend assessment during follow-up should be performed every 2–4 months during the first 2 years and every 3–6 months for 3 further years (level of evidence 1D).
- People living with HIV and Hodgkin lymphoma who require blood products should receive irradiated products in line with the national guidelines, as should patients who are candidates for stem-cell transplantation (GPP).

## 11 Multicentric Castleman's disease

### 11.2.1 Recommendations

- We suggest that histological confirmation requires immunocytochemical staining for HHV8 and IgM lambda (level of evidence 2B).
- We suggest that all patients should have their blood levels of HHV8 measured to support the diagnosis (level of evidence 2C).



### 11.12 Recommendations

- We suggest that histological confirmation requires immunocytochemical staining for HHV8 and IgM lambda (level of evidence 2B).
- We suggest that all patients should have their blood levels of HHV8 measured to support the diagnosis (level of evidence 2C).
- We suggest that the risk of lymphoma in patients diagnosed with MCD is high (level of evidence 2C).
- We suggest that cART does not prevent MCD (level of evidence 2D).
- We suggest that a rise in plasma HHV8 level can predict relapse (level of evidence 2D).
- We recommend that rituximab should be first-line treatment for MCD (level of evidence 1B).
- We recommend that chemotherapy should be added to rituximab for patients with aggressive disease (level of evidence 1C).
- We recommend re-treatment with rituximab-based therapy for relapsed MCD (level of evidence 1C).
- We suggest clinical monitoring for patients in remission should include measurement of blood HHV8 levels (level of evidence 2C).

### 11.13 Auditable outcomes

- *Proportion of patients with MCD treated with rituximab as first-line treatment*
- *Proportion of patients with aggressive MCD treated with rituximab and chemotherapy*
- *Proportion of patients with relapsed MCD re-treated with rituximab*

## 12 Non-AIDS-defining malignancies

### 12.2.4 Summary

- We suggest germ cell tumours of the testis should be treated in an identical manner regardless of HIV status (level of evidence 2C).
- We suggest men living with HIV who require chemotherapy for germ cell tumours should receive concomitant HAART and opportunistic infection prophylaxis (level of evidence 2C).
- We suggest surveillance for stage I disease is safe (level of evidence 2C).
- We suggest bleomycin can be avoided if necessary in the management of these patients (level of evidence 2D).

### 12.3.6 Summary

- We recommend HIV-positive patients should be encouraged to stop smoking cigarettes (level of evidence 1B).
- We suggest patients should be offered potentially curative surgery where appropriate (level of evidence 2C).
- We suggest patients should be screened for activating EGFR mutations and treated with EGFR TKIs by a team experienced in the use of HAART (level of evidence 2D).
- We suggest there is currently no role for screening for lung cancer in people living with HIV (GPP).

### 12.4.5 Summary

- We suggest that people living with HIV with HCC should be treated in a similar manner to their HIV-negative counterparts (level of evidence 2C).
- We suggest that liver transplantation should be considered for appropriate cases, as in the HIV-negative population (level of evidence 2D).
- We suggest that sorafenib is a treatment option in advanced, nonoperable HCC (level of evidence 2D).
- Noncirrhotic HBV coinfecting patients should be considered for HCC screening (GPP).
- We recommend HCC screening with liver ultrasound (level of evidence 1A) and suggest 6-monthly AFP (level of evidence 2C) be offered to all cirrhotic patients with HBV and HCV coinfections.

### 12.5.7 Summary

- We recommend that the management of people living with HIV with non-AIDS-defining malignancy should be in a centre with adequate experience and requires a joint MDT including both oncologists with experience of managing HIV-related malignancy and HIV physicians (level of evidence 1C).
- We recommend that patients with NADM should be offered the standard care given to HIV-negative patients (level of evidence 1C).
- We recommend that all potential interactions between HAART, opportunistic infection prophylaxis and cancer therapy should be considered (level of evidence 1C).

### 13 Opportunistic infection prophylaxis in HIV-associated malignancy

#### 13.7 Recommendations

- We recommend that all patients with AIDS-defining malignancies should start HAART (level of evidence 1B).
  - We suggest that all patients with non-AIDS-defining malignancies who are due to start chemotherapy or radiotherapy should be started on HAART unless contraindicated (level of evidence 2C).
  - We recommend that prophylaxis against *Pneumocystis jirovecii* pneumonia (PCP) should be started for those who have a CD4 cell count less than 200 cells/ $\mu$ L (level of evidence 1A) and should be considered at higher levels in all patients starting chemotherapy or radiotherapy (GPP).
  - We recommend prophylaxis against MAC for individuals with a CD4 cell count less than 50 cells/ $\mu$ L (level of evidence 1B) and in those whose treatment puts their CD4 count at risk of falling below this level.
  - We recommend that systemic azole antifungal prophylaxis should be used in all patients receiving chemotherapy or radiotherapy for HIV-associated malignancy (level of evidence 1D).
  - We do not recommend routine fluoroquinolone prophylaxis in low-risk patients and the use of cotrimoxazole to prevent PCP may provide some protection against bacterial infection for patients living with HIV (level of evidence 1C).
  - We recommend HSV prophylaxis in people living with HIV with a history of HSV infection who are starting chemotherapy to reduce the incidence and severity of reactivations (level of evidence 1D).
  - We recommend annual influenza vaccination (level of evidence 1B).
  - We recommend vaccination against pneumococcus and hepatitis B virus (level of evidence 1D).
  - We recommend that patients with antibodies against hepatitis B core antigen (HBcAb) should be treated with prophylactic antivirals in line with BHIVA hepatitis guidelines (level of evidence 1B).
-



### 3 Kaposi sarcoma (KS)

#### 3.1 Diagnosis, staging and prognosis

Kaposi sarcoma is still the most common tumour in people with HIV infection, is an AIDS-defining illness and is caused by the Kaposi sarcoma herpesvirus (KSHV). The diagnosis is usually based on the characteristic appearance of cutaneous or mucosal lesions and should be confirmed histologically since even experienced clinicians misdiagnose KS [1] (level of evidence 1C). Lesions are graded histopathologically into patch, plaque or nodular grade disease. Visceral disease is uncommon, affecting about 14% at diagnosis [2] and CT scans, bronchoscopy and endoscopy are not warranted in the absence of symptoms (level of evidence 2D).

The AIDS Clinical Trial Group (ACTG) staging system for AIDS-related KS was developed in the pre-HAART era to

predict survival and includes tumour-related criteria (T), host immunological status (I) and the presence of systemic illness (S) (see Table 3.1) [3,4]. The ACTG also established uniform criteria for response evaluation in AIDS KS (see Table 3.2) [3]. In the era of HAART, the prognostic value of this staging system has been questioned and one study suggested that only the T and S stages identify patients with poor survival [5], whilst another study from Nigeria found that I and S stages but not T stage were of prognostic significance [6]. However, a comprehensive evaluation of prognostic factors in 326 patients diagnosed with AIDS KS in the era of HAART, externally validated on 446 patients from the US HIV/AIDS Cancer Match Study, has established a prognostic scoring scheme [7] and more detailed immune subset analysis does not provide additional prognostic information [8]. Having KS as the first AIDS-defining

**Table 3.1** The modified AIDS Clinical Trials Group staging of KS [3,4]

TIS staging of KS	Good risk (all of the following)	Poor risk (any of the following)
(T) Tumour	Confined to skin, lymph nodes or minimal oral disease	Tumour-associated oedema or ulceration Extensive oral KS Gastrointestinal KS KS in other non-nodal viscera
(I) Immune status (S) Systemic illness	CD4 cell count >150 cells/ $\mu$ L Karnovsky performance status >70	CD4 cell count <150 cells/ $\mu$ L Karnovsky performance status <70 or other HIV-related illness

**Table 3.2** Response criteria for HIV-associated Kaposi sarcoma [3]

#### Complete response (CR)

The complete resolution of all KS with no new lesions, lasting for at least 4 weeks. A biopsy is required to confirm the absence of residual KS in flat lesions containing pigmentation. Endoscopies must be repeated to confirm the complete resolution of previously detected visceral disease

#### Clinical complete response (CCR)

Patients who have no detectable residual KS lesions for at least 4 weeks but whose response was not confirmed by biopsy and/or repeat endoscopy

#### Partial response (PR)

One or more of the following in the absence of (i) new cutaneous lesions, (ii) new visceral/oral lesions, (iii) increasing KS-associated oedema, (iv) a 25% or more increase in the product of the bidimensional diameters of any index lesion:

1. A 50% or greater decrease in the number of measurable lesions on the skin and/or in the mouth or viscera
2. A 50% or greater decrease in the size of the lesions as defined by one of the following three criteria:
  - (a) a 50% or more decrease in the sums of the products of the largest bidimensional diameters of the index lesions
  - (b) a complete flattening of at least 50% of the lesions
  - (c) where 75% or more of the nodular lesions become indurated plaques

#### Stable disease (SD)

Any response that does not meet the above criteria

#### Progressive disease (PD)

Any of the following:

1. A 25% or more increase in the product of the bidimensional diameters of any index lesion
2. The appearance of new lesions
3. Where 25% or more of previously flat lesions become raised
4. The appearance of new or increased KS-associated oedema

illness (-3 points) and increasing CD4 cell count (-1 for each complete 100 cells/ $\mu$ L in counts at KS diagnosis) improved prognosis, whereas age at KS  $\geq$ 50 years old (+2) and S1 stage (+3) conveyed a poorer prognosis. On the basis of this index it was suggested that patients with a poor risk prognostic index (score  $>$ 12) should be initially treated with HAART and systemic chemotherapy together, whilst those with a good risk (score  $<$ 5) should be treated initially with HAART alone, even if they have T1 disease. Over time, there has been a rise in the CD4 cell count at diagnosis of KS, and the impact of initiation of treatment may also change [9–12].

In addition to prognostic factors identified in the model, blood levels of Kaposi sarcoma herpesvirus (KSHV) DNA are a surrogate marker of tumour burden and are of prognostic significance. In 144 patients followed in the Swiss HIV Cohort study, detectable levels of KSHV DNA in the blood were an indicator of a poor prognosis [13]. Patients in Zimbabwe initiated on ART for advanced AIDS-KS, also had a poorer outcome when pretreatment plasma KSHV levels were high [14].

## 3.2 Management

### 3.2.1 Prevention

The introduction of HAART was associated with a substantial reduction in the incidence of KS in many large cohorts [15–21], although some of this decline in incidence appears to have preceded the introduction of HAART [22]. A population-based, record-linkage study of 472,378 individuals living with AIDS described a fall in the cumulative incidence of KS from 14.3% during 1980–1989, to 6.7% during 1990–1995, and a further fall to 1.8% during 1996–2006 [23]. Similarly, survival rates from KS have risen gradually during this period [24–26]. In contrast, KS continues to be a significant problem in Africa [27–32] although it is hoped that with increasing access to HAART, outcomes will improve [33–35]. The decline in incidence of KS has been shown to be attributable to HAART, and NNRTI-based regimens are as effective as PI-based regimens in preventing KS [16,36]. Moreover, the SMART study assigned 5472 patients to continuous or intermittent use of ART, guided by CD4 cell count, and it found that patients receiving continuous ART had lower rates of KS (0.3 per 1000 person-years *vs.* 1.9, hazard ratio 7.0), as well as lower rates of opportunistic infections and deaths [37]. The optimal time to start HAART for asymptomatic HIV infection is still unclear, and is being addressed in the Strategic Timing of AntiRetroviral Treatment (START) study, an ongoing multicentre international trial designed to assess the risks and benefits including prevention of KS,

of initiating HAART earlier than currently recommended [38].

Specific therapies against KSHV, the cause of KS, may also be helpful in the prevention of KS but published retrospective cohort studies are contradictory. A UK cohort study of 3688 people living with HIV showed that the risk of KS was reduced by ganciclovir and foscarnet exposure but not aciclovir [39]. However, data from a cohort of 935 MSM living with AIDS found that exposure to aciclovir, ganciclovir and foscarnet did not significantly reduce the risk of KS [40]. A small randomized controlled cross-over trial of oral vanganciclovir in 26 men reduced the frequency and quantity of KSHV replication, but this returned to baseline levels soon after stopping therapy [41]. HAART results in significant falls in the levels of oropharyngeal KSHV, whereas valaciclovir and famciclovir have only a modest effect that is not synergistic with HAART [42].

### 3.2.2 Local therapy

Local treatments are most useful for managing localized or symptomatic KS lesions or for cosmesis. However, local therapies are limited by their inability to treat large areas or to affect the development of lesions in untreated areas.

#### 3.2.2.1 Radiotherapy

During the pre-HAART era, radiotherapy had an important and established role in the management of low-volume cutaneous KS, including the cosmetic control of skin lesions, treatment of painful lesions on soles, genitalia, oral cavity and conjunctiva [43]. An early randomized study of radiation fractionation for cutaneous KS showed that both response rate and duration of local control were better with fractionated regimens (40 Gy in 20 fractions and 20 Gy in 10 fractions) compared with an 8-Gy single fraction, although toxicity and patient convenience were worse [44]. A second nonrandomized study of 57 patients found no significant difference in response rates between 16 Gy in 4 fractions and 8 Gy in a single fraction [45]. A retrospective study of 80 patients including some with endemic KS treated with a radiotherapy dose of 8 Gy reported an objective response rate of 74% [46]. In another study of 36 patients with KS of the feet, a schedule of 3 fractions/week at 3.5 Gy/fraction up to a total dose of 21 Gy, the response rate was 91% with a complete response rate of 80% [47]. A randomized trial compared two regimens: 24 Gy in 12 fractions and 20 Gy in 5 fractions with similar biologically equivalent doses, 28.8 and 28 Gy, respectively [48]. Eighty sites in 60 patients (10 of whom were on HAART) were randomized, though 13 patients died before receiving radiotherapy. A total of 65 sites in 47 patients were treated, 50 on the lower limbs, with a median area treated

of 714 cm<sup>2</sup>. Objective response rates, acute and late toxicities were similar in both arms, with a mean time to response of 3 months. An important large randomized study from Zimbabwe has evaluated treatments for AIDS-KS in 495 patients who were not treated with antiretroviral agents. This showed that radiotherapy did not improve either overall survival or quality of life compared to supportive care alone [49]. In conclusion, higher numbers of fractions of radiotherapy appear to offer only minor benefits and are more costly as well as being less convenient for patients.

*In vitro* models suggest a radiosensitizing effect of HIV, though it is not clear if this is of clinical relevance [50]. Radiotherapy side effects in patients with AIDS have been reported as more severe [43,51], although a recent review of head and neck cancer patients treated with high-dose radiotherapy or chemoradiotherapy did not show any significant increase in toxicity for HIV-positive compared to HIV-negative patients [52]. Modified fractionated schedules and close attention to skin care, including avoidance of friction and sparing use of moisturizers, may help.

The use of radiotherapy has declined since the introduction of HAART, although it may still be useful for KS at specific sites; for example, <sup>90</sup>Strontium brachytherapy is an effective and well-tolerated treatment for eyelid and conjunctival lesions [53].

### 3.2.2.2 Other local therapies

Retinoids bind nuclear hormone receptors, resulting in profound effects on cellular differentiation and programmed cell death and can inhibit KS cell lines *in vitro* [54]. Alitretinoin gel (0.1%) (9-*cis*-retinoic acid) is a topical, self-administered therapy approved in the US and some European countries for the treatment of KS. Two double-blind, randomized placebo-controlled trials involving a total of 402 individuals, evaluated 12 weeks of twice-daily alitretinoin gel [55,56]. The response rates in the active arm after 12 weeks were 37% [56] and 35% [55] compared to 7% and 18% in the placebo arms analysed by intention to treat. In both studies, over 80% of participants were receiving HAART and this did not influence the results. In another study of 114 patients, 27% of treated lesions responded compared to 11% of the controls [57]. The gel may cause dermal irritation and skin lightening at the application site. Responses are seen even in patients with low CD4 cell counts and typically occur 4–8 weeks after treatment. 9-*cis*-retinoic acid has also been administered orally (and is only licensed in the UK for chronic eczema). In a Phase II study of 57 patients (56 on HAART), the response rate was 19% although the contribution of the HAART is unclear [58].

Vinblastine is the most widely used intralesional agent for KS and responses of around 70% were reported in the

pre-HAART era [59,60]. Treated lesions usually fade and regress although typically do not resolve completely. A randomized study in 16 patients comparing intralesional vinblastine or sodium tetradecyl sulfate in the treatment of oral KS demonstrated partial responses in both groups with no significant differences [61]. Intralesional injections of biologic agents such as interferon- $\alpha$  have also shown activity, but are infrequently used now.

In one early study of 20 patients, complete responses were observed in 80% of lesions treated with cryotherapy, and the duration of the response was more than 6 weeks. In addition, greater than 50% cosmetic improvement of KS was reported in this pre-HAART era study [62]. Destructive (i.e., CO<sub>2</sub> laser) interventions, can have a role. An alternative experimental approach is photodynamic therapy, which is based upon activation by light of a photosensitizing drug that preferentially accumulates in tumour tissues such as KS [63]. A series of 25 patients with a total of 348 KS lesions received photofrin 48 hours prior to light activation. No patients were on HAART and 95% of the lesions responded to therapy (33% and 63% complete and partial responses, respectively) [64].

Topical halofuginone is an angiogenesis inhibitor that inhibits collagen type-1 and matrix metalloproteinases (MMPs). It was tested in a blinded intra-patient control study for KS, with serial biopsies taken from index lesions [65]. The study was stopped early due to slow accrual, and clinical benefit could not be assessed. To a large extent local therapies for KS have been superseded by the introduction of HAART.

Excisional surgery under local anaesthetic is a simple approach for small solitary or paucifocal lesions.

### 3.2.3 Systemic therapy

#### 3.2.3.1 HAART

There are no randomized trials comparing HAART with no HAART as all patients with KS should receive HAART. Many case reports and small series have described the regression of KS with HAART alone. HAART has been shown to prolong time to treatment failure after KS treatment with local or systemic therapy [66]. HAART has also been shown to prolong survival in patients who have been treated for KS with chemotherapy [67].

The beneficial effects of HAART on both the incidence and the outcomes of KS have been shown in several cohort studies [20,68–71]. The Swiss HIV Cohort Study reported step-wise falls in the relative risk of KS from the pre-HAART (1985–1996) to the early-HAART era (1997–2001), and continuing reduction in the late-HAART era (2002–2006) [72]. With the increasing roll out of HAART, these benefits have also started to be seen in Africa [33,36].

Initiation of HAART may precipitate a paradoxical worsening of symptoms, termed the immune reconstitution inflammatory syndrome (IRIS). Opportunistic infections are the most common manifestation, although sudden progression of existing KS or development of new lesions may also occur [73–76]. A systematic review identified 54 cohort studies of 13 103 patients starting HAART, of whom 1699 developed IRIS, 6.4% of whom had KS [77]. Conversely the frequency of IRIS KS in patients with KS who start HAART varies between different populations but is up to 29% in a recent publication from Chicago [76]. Risk factors for IRIS KS include a higher CD4 cell count, the presence of oedema and the use of protease inhibitors and nonnucleosides together [73]. The clinical management of IRIS KS is usually with systemic chemotherapy and this has been successful in a small series of patients [78] and several case reports [79–82].

### 3.2.3.2 Cytotoxic chemotherapy

Administration of systemic cytotoxic chemotherapy is warranted in patients with advanced, symptomatic or rapidly progressive KS. It has been suggested that patients with a poor prognostic risk index (score >12) should be initially treated with both HAART and systemic chemotherapy together whilst those with a good risk (score <5) should be treated initially with HAART alone, even if they have T1 disease [7]. A recent randomized study from South Africa compared the response rates and survival in AIDS-KS patients treated with HAART alone or with HAART and chemotherapy. At enrolment, 89% of the 112 HAART-naive patients had advanced T1 stage KS. Of note, both the chemotherapy (doxorubicin, bleomycin, vincristine) and the HAART regimen used in this trial (lamivudine, stavudine, nevirapine) are not current first-line standards of care in economically developed nations. Patients randomized to HAART with chemotherapy had significantly higher response rates and progression-free survival although no difference in overall survival [83]. The lack of a significant difference in overall survival may be because many people with AIDS-KS die of other causes associated with advanced immunosuppression including opportunistic infections. These results suggest that patients with T1 advanced stage KS, should receive chemotherapy along with HAART (level of evidence 1B).

In the pre-HAART era, several chemotherapeutic agents (bleomycin, vinblastine, vincristine and etoposide) were shown to have activity against KS in case series and small Phase II trials using different combinations and doses of these drugs [84–88]. However, liposomal anthracyclines and taxanes have become established as the backbone of current standard systemic cytotoxic therapy against KS.

### 3.2.3.3 Liposomal anthracyclines

Liposome encapsulation of anthracyclines constitutes a considerable advance in the chemotherapy of KS. The advantages of liposomal formulation include increased tumour uptake and hence favourable pharmacokinetics and toxicity profile. The trials of liposomal anthracyclines for HIV-associated KS were undertaken in the pre-HAART era but clinicians continue to regard them as the gold-standard first-line chemotherapy for KS. Previous manufacturing problems leading to interruptions in supply have been resolved. Both liposome encapsulated daunorubicin (DaunoXome 40 mg/m<sup>2</sup> every 2 weeks) and the pegylated liposomal doxorubicin, which is known variously as Caelyx, Doxil or PLD (20 mg/m<sup>2</sup> every 3 weeks) have been shown to have good antitumour activity. A meta-analysis of 2200 patients treated in nine randomized controlled trials, including two for KS patients, demonstrated that the toxicity profile compares favourably with that of conventional anthracyclines [89]. A report of 93 patients treated at a single centre has found no evidence of cardiotoxicity even at high cumulative dosages [90] and rarely significant alopecia. However, there remains considerable myelosuppression, and occasional emesis. In addition, infusion-related hypotension and hand/foot syndrome are novel side effects seen with these liposomal formulations.

Three sizeable, randomized controlled studies have compared liposomal anthracyclines with conventional combination chemotherapy regimens and all were conducted before the introduction of HAART. A Phase III randomized comparison of DaunoXome and ABV (doxorubicin, bleomycin, vincristine) demonstrated equivalent overall response rates (partial and complete responses), time to treatment failure and survival duration [91]. Two randomized Phase III trials compared pegylated liposomal doxorubicin (PLD) with conventional combination chemotherapy, ABV in one study and BV (bleomycin vincristine) in the other, as first-line therapy for KS in patients not on HAART. Both found response rates were higher in the PLD arms but responses were often not sustained [92,93] (see Table 3.3 for details). The three Phase III studies may not be directly comparable. In one small randomized study of 80 patients, KS patients were randomized 3:1 to PLD (20 mg/m<sup>2</sup>) or DaunoXome (40 mg/m<sup>2</sup>) every 2 weeks for up to six cycles. Partial responses, correlating with clinical benefit, were observed in 55% patients receiving PLD and in 32% receiving DaunoXome. However, this was not statistically significant and there is insufficient evidence to recommend a particular liposomal anthracycline [94].

Since the widespread introduction of HAART, the duration of responses to treatment for KS has increased [66] and no further randomized trials have compared liposomal anthracyclines with nonencapsulated, anthracycline-based

Table 3.3 Results of Phase III trials of liposomal anthracyclines for KS

Agent	Dose	Schedule	Assessable patients	Response rate (CR + PR)	Median response duration (months)	p-value	Ref.
DaunoXome	40 mg/m <sup>2</sup>	Every 2 weeks	116	25%	3.8	NS	[91]
ABV	10 mg/m <sup>2</sup> /15 U/1 mg	Every 2 weeks	111	28%	3.2		
Doxil/Caelyx/PLD	20 mg/m <sup>2</sup>	Every 2 weeks	133	46%	3.0	<0.001	[92]
ABV	20 mg/m <sup>2</sup> /10 mg/m <sup>2</sup> /1 mg	Every 2 weeks	125	25%	–		
Doxil/Caelyx/PLD	20 mg/m <sup>2</sup>	Every 3 weeks	121	59%	5.0	<0.001	[93]
BV	15 mg/m <sup>2</sup> /2 mg	Every 3 weeks	120	23%	–		
Doxil/Caelyx/PLD	20 mg/m <sup>2</sup>	Every 2 weeks	60	55%	5.0	NS	[94]
DaunoXome	40 mg/m <sup>2</sup>	Every 2 weeks	19	32%	–		
Doxil	20 mg/m <sup>2</sup>	Every 3 weeks	37	46%	12.2*	NS	[94]
Paclitaxel	100 mg/m <sup>2</sup>	Every 2 weeks	36	56%	17.5*		

\*53 out of the 73 patients (73%) were on HAART at baseline.

regimens. The safety and tolerability of these drugs in combination with HAART has been evaluated. In one study of 54 patients, 82% had a response within 8 weeks and the PLD-HAART combination was well tolerated with no evidence of suppression of CD4 cell counts [95]. In a cohort study of 50 patients treated with concomitant HAART and liposomal anthracycline chemotherapy for KS, there was no decline in CD4 cell count or rise in HIV viral load [96]. These findings suggest that standard opportunistic infection prophylaxis guidelines may be followed when treating patients with liposomal anthracycline chemotherapy for KS. Based on the response rates, median response durations and the toxicity profile, liposomal anthracyclines are considered first-line chemotherapy for advanced KS (level of evidence 1A).

### 3.2.3.4 Taxanes

Like vinca alkaloids, taxanes bind to the  $\beta$  subunit of  $\alpha/\beta$  tubulin and disrupt microtubules leading to mitotic arrest and subsequent cell death. Paclitaxel also promotes apoptosis by binding to Bcl-2 via the same mechanism [97]. In a number of phase II trials, paclitaxel was shown to have single-agent activity against AIDS-KS; furthermore, these studies included a number of patients who had previously received anthracyclines [98–102]. One Phase II study of paclitaxel (135 mg/m<sup>2</sup> every 3 weeks) for KS, enrolled 28 patients and reported a response rate of 71%. This included four (14%) patients who had received anthracyclines but no patients received HAART [99]. A second, larger study of 56 patients included 20 (36%) who received a protease inhibitor at some stage during the study and 40 (70%) who had received prior therapy for KS that included liposomal anthracyclines in 17 (30%). The overall objective response rate was 59% and the median response duration was 10.4 months [100].

A first-line study for advanced, symptomatic KS randomized 73 patients between paclitaxel 100 mg/m<sup>2</sup> every

2 weeks and PLD 20 mg/m<sup>2</sup> every 3 weeks; 73% patients received HAART (see Table 3.3) [103]. Treatment was associated with significant improvements in pain and swelling, for both arms. There was no significant difference between the arms in response rates, progression-free or overall survival at 2 years, and slightly higher rates of grade 3–4 toxicity for paclitaxel (84% *vs.* 66%,  $p = 0.07$ ). Progression-free survival for both arms in this study was higher than those reported in the pre-HAART era. Pharmacokinetic studies revealed higher paclitaxel levels in patients taking protease inhibitors, though this did not have any obvious clinical impact [104].

Two studies have addressed the role of paclitaxel as second-line chemotherapy. One open-label multicentre trial enrolled 107 individuals who had received prior chemotherapy for AIDS-KS. The previous therapy regimens included ABV in 52, liposomal daunorubicin in 49, and liposomal doxorubicin in 40 patients. Moreover, only 77% were receiving concomitant HAART (all protease inhibitor based) and 33% started this treatment at the same time as the taxane chemotherapy. The paclitaxel protocol used was 100 mg/m<sup>2</sup> fortnightly. The overall response rate was 56% with no significant difference in response rate when comparing patients on or not on HAART. Less surprising was the finding that patients on HAART had a significantly improved survival. The main side effect reported in these studies was neutropenia that generally resolved prior to the next chemotherapy cycle [101].

A second study enrolled 17 patients with anthracycline refractory AIDS-KS, defined as KS that had progressed during or within 6 months of completing liposomal anthracycline chemotherapy. All patients were receiving a stable HAART regimen to avoid confounding of results. The treatment schedule was again 100 mg/m<sup>2</sup> fortnightly. The objective response rate to paclitaxel was 71% (95% CI: 60–81), with 8 of 17 partial responses and 4 of 17 complete responses. There were no significant changes in CD4, CD8,



CD16/56 (natural killer cells) and CD19 (B cells) lymphocyte subset cell counts during and for up to 1 year following chemotherapy. Similarly, plasma HIV-1 viral loads did not change significantly during or after treatment suggesting that the combined use of paclitaxel and HAART reduces the risk of chemotherapy-related immunological decline and opportunistic infections [102]. In contrast, previous trials without concomitant HAART were worrying in this respect; Gill [100] reported 51 AIDS-defining opportunistic infections in the 56 patients treated with paclitaxel (10.5/100 patient months on paclitaxel), only 36% of whom received HAART, and Welles [99] reported 27 opportunistic infections (8.4/100 person months on paclitaxel) among her cohort of 28, none of whom received HAART. Thus the concomitant use of HAART and paclitaxel appears to be safe and not detrimental to immune function despite initial concerns over pharmacological interactions [104–106]. These findings suggest that standard opportunistic infection prophylaxis guidelines may be followed when treating patients with taxane chemotherapy for KS.

The higher rates of toxicity and the need for a 3-hour infusion make paclitaxel a less attractive first-line option than PLD [103]. The clinical experience in KS with docetaxel, another taxane, is much more limited though two small studies suggest that this agent can produce meaningful responses when used weekly [107], and in anthracycline pretreated individuals [108]. However, severe toxicities, including one death, have been reported in patients prescribed docetaxel with ritonavir-boosted protease inhibitors [109,110]. The mechanism for this enhanced toxicity is a pharmacokinetic interaction as docetaxel is metabolized by CYP3A4, which is inhibited by ritonavir. This pathway is less important in the metabolism of paclitaxel.

### 3.2.3.5 Immunotherapy

The biological response modifier interferon-alpha (IFN- $\alpha$ ) was approved for KS treatment before the availability of HAART and liposomal anthracyclines. The ACTG randomized 68 individuals to low- and intermediate-dose IFN- $\alpha$  (1 million and 10 million units daily) plus didanosine [111]. Response rates and durations were not statistically different though there were more toxicities in the higher dose group. In another randomized study, 108 patients were treated with IFN- $\alpha$  (1 million or 8 million units daily) with AZT [112]. The higher-dose regimen was associated with statistically higher responses and longer time to progression. In a retrospective study of patients with classic KS comparing PLD with low dose IFN- $\alpha$ , 12 patients received 20 mg/m<sup>2</sup> of PLD monthly, while six received 3 million units of IFN- $\alpha$  three times per week, with PLD being superior in terms of responses and toxicity [113].

Response to IFN- $\alpha$  frequently requires continued treatment for 6 months or more, as the time to response is typically more than 4 months. It should not be considered for progressive or visceral disease. Toxicity at higher doses including fever, chills, neutropenia and depression is common, and poor responses are observed in the setting of low CD4 cell counts. While it can be considered in those with residual KS who have appropriately reconstituted their immune systems with HAART, it is seldom used.

### 3.2.3.6 Other systemic therapies

With greater understanding of the biology of KS and the cellular pathways activated in these tumours, novel targets for treatment have been identified. In many clinical trials the effects of the experimental drug and of HAART are difficult to separate, often because of poor trial design.

Vascular endothelial growth factor-A (VEGF-A) is an important growth factor in KS and seems to be responsible for vascular permeability [114,115]. Bevacizumab, a humanized, monoclonal, anti-VEGF-A antibody has been used in a Phase I/II study in 17 patients with advanced disease, 13 of whom had had prior chemotherapy [116]. The overall response rate was 31% and median progression-free survival 8.3 months. Apart from a fall in IL-8, there were no other immune markers of response, and serum VEGF-A levels did not change.

Thalidomide also has significant anti-angiogenic activity and two Phase II studies enrolled a total of 37 AIDS-KS patients. Partial responses were recorded for 35% and 47% evaluable patients with toxicity including fatigue, neuropathy and depression [117,118]. The importance of the c-kit pathway has been evaluated in 30 patients with previously treated cutaneous KS who received oral imatinib; 10 (33.3%) achieved a partial response while six (20%) had stable disease. Treatment was relatively well tolerated, with nine patients completing 52 weeks of therapy [119]. Other agents tested include COL-3, a matrix metalloproteinase inhibitor (MMPI), which in a Phase II trial of 75 patients demonstrated partial responses in 41% [120]. However, in a Phase I/II trial, BMS-275291, a more specific oral nonpeptidic MMPI, was poorly tolerated and did not show any meaningful responses [121]. Similarly, interleukin 12 was administered to patients on HAART with KS and the response rate was 71% [122]. Valproic acid has properties of an HDAC inhibitor with some activity *in vitro*, but a pilot study in 18 patients did not show any promising efficacy [123]. PI3K/AKT/mTOR signalling is a common pathway downstream of many growth factor and cytokine receptors and is upregulated by KSHV encoded proteins. Rapamycin, an oral immunosuppressant used to prevent rejection in solid organ transplantation, has activity in AIDS-KS but has significant pharmacokinetic interactions with HAART [124].

Topoisomerase I and II enzymes play a critical role in KSHV DNA replication, and type I inhibitors such as irinotecan and topotecan, and type II poisons, such as etoposide [125,126] and doxorubicin have significant cytotoxic activity but with dose-limiting toxicities including myelosuppression. Topoisomerase II catalytic inhibitors such as novobiocin, in contrast, show marked inhibition of KSHV replication and minimal cytotoxicity and may be a promising therapeutic alternative [127].

A number of antiherpes virus agents have been studied in AIDS-related KS; none has demonstrated significant activity, although they have been shown to prevent KS in one cohort study [39]. KSHV stimulates expression of angiopoietin-2 in KS via upregulation of the Ras/Raf/MEK/ERK pathway. Selumetinib is an oral selective inhibitor of MEK1/2 with anticancer activity in a variety of tumour models [128] and is being tested in a Phase I/II study for AIDS-KS patients.

Where possible, patients should be considered for appropriate clinical trials.

### 3.3 Summary of recommendations

- We recommend that KS should be confirmed histologically (level of evidence 1C).
- We suggest that CT scans, bronchoscopy and endoscopy are not warranted in the absence of symptoms (level of evidence 2D).
- We recommend that HAART should be started in all patients diagnosed with KS (level of evidence 1B)
- We suggest local radiotherapy or intralesional vinblastine for symptomatic or cosmetic improvement in early stage T0 KS (level of evidence 2C)
- We recommend that patients with T1 advanced stage KS, should receive chemotherapy along with HAART (level of evidence 1B).
- We recommend that liposomal anthracyclines (either DaunoXome 40 mg/m<sup>2</sup> q14d or Caelyx 20 mg/m<sup>2</sup> q21d) are first-line chemotherapy for advanced KS (level of evidence 1A).
- We recommend paclitaxel chemotherapy (100 mg/m<sup>2</sup> q14d) for second-line treatment of anthracycline refractory KS (level of evidence 1C).
- All patients should be considered for clinical trial enrolment if eligible (GPP).

### 3.4 References

- 1 Amerson E, Buziba N, Wabinga H *et al.* Diagnosing Kaposi's Sarcoma (KS) in East Africa: How accurate are clinicians and pathologists? *Infect Agents Cancer* 2012; 7(Suppl 1): P6.
- 2 Pria AD, Hayward K, Bower M. Do we still need chemotherapy for AIDS-associated Kaposi's sarcoma? *Expert Rev Anticancer Ther* 2013; 13: 203–209.
- 3 Krown S, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. *J Clin Oncol* 1989; 7: 1201–1207.
- 4 Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. *J Clin Oncol* 1997; 15: 3085–3092.
- 5 Nasti G, Talamini R, Antinori A *et al.* AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. *J Clin Oncol* 2003; 21: 2876–2882.
- 6 Agaba P, Sule H, Ojoh R *et al.* Poor immune status and systemic disease are independently associated with mortality in AIDS-related Kaposi Sarcoma in Nigeria. *Infect Agents Cancer* 2012; 7(Suppl 1): P7.
- 7 Stebbing J, Sanitt A, Nelson M *et al.* A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. *Lancet* 2006; 367: 1495–1502.
- 8 Stebbing J, Sanitt A, Teague A *et al.* Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma. *J Clin Oncol* 2007; 25: 2230–2235.
- 9 Crum-Cianflone NF, Hullsiek KH, Ganesan A *et al.* Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic? *AIDS* 2010; 24: 2881–2883.
- 10 Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. *N Engl J Med* 2007; 357: 1352–1353.
- 11 Stebbing J, Powles T, Bower M. AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count. *AIDS* 2008; 22: 551–552.
- 12 Krown SE, Lee JY, Dittmer DP. More on HIV-associated Kaposi's sarcoma. *N Engl J Med* 2008; 358: 535–536; author reply 536.
- 13 El Amari EB, Toutous-Trellu L, Gayet-Ageron A *et al.* Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. *AIDS* 2008; 22: 1019–1028.
- 14 Borok M, Fiorillo S, Gudza I *et al.* Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. *Clin Infect Dis* 2010; 51: 342–349.
- 15 International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in

- human immunodeficiency virus-infected adults. *J Natl Cancer Inst* 2000; **92**: 1823–1830.
- 16 Portsmouth S, Stebbing J, Gill J *et al*. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. *AIDS* 2003; **17**: 17–22.
  - 17 Carrieri MP, Pradier C, Piselli P *et al*. Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. *Int J Cancer* 2003; **103**: 142–144.
  - 18 Mocroft A, Kirk O, Clumeck N *et al*. The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: the EuroSIDA Study. *Cancer* 2004; **100**: 2644–2654.
  - 19 Engels EA, Pfeiffer RM, Goedert JJ *et al*. Trends in cancer risk among people with AIDS in the United States 1980–2002. *AIDS* 2006; **20**: 1645–1654.
  - 20 Franceschi S, Maso LD, Rickenbach M *et al*. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *Br J Cancer* 2008; **99**: 800–804.
  - 21 Guiguet M, Boué F, Cadranel J *et al*. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS C04): a prospective cohort study. *Lancet Oncol* 2009; **10**: 1152–1159.
  - 22 Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987–1999. *J Acquir Immune Defic Syndr* 2002; **29**: 378–387.
  - 23 Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. *Cancer* 2011; **117**: 1089–1096.
  - 24 Lodi S, Guiguet M, Costagliola D *et al*. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. *J Natl Cancer Inst* 2010; **102**: 784–792.
  - 25 Pipkin S, Scheer S, Okeigwe I *et al*. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry. *AIDS* 2011; **25**: 463–471.
  - 26 Shiels MS, Pfeiffer RM, Gail MH *et al*. Cancer burden in the HIV-infected population in the United States. *J Natl Cancer Inst* 2011; **103**: 753–762.
  - 27 Sitas F, Carrara H, Beral V *et al*. Antibodies against human herpesvirus 8 in black South African patients with cancer. *N Engl J Med* 1999; **340**: 1863–1871.
  - 28 Bassett MT, Chokunonga E, Mauchaza B *et al*. Cancer in the African population of Harare, Zimbabwe, 1990–1992. *Int J Cancer* 1995; **63**: 29–36.
  - 29 Wabinga HR, Parkin DM, Wabwire-Mangen F, Namboozee S. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. *Br J Cancer* 2000; **82**: 1585–1592.
  - 30 Parkin DM, Sitas F, Chirenje M *et al*. Part I: Cancer in indigenous Africans—burden, distribution, and trends. *Lancet Oncol* 2008; **9**: 683–692.
  - 31 Mosam A, Carrara H, Shaik F *et al*. Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983–2006). *Int J STD AIDS* 2009; **20**: 553–556.
  - 32 Chokunonga E, Borok MZ, Chirenje ZM *et al*. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991–2010. *Int J Cancer* 2013; **133**: 721–729.
  - 33 Mosam A, Uldrick TS, Shaik F *et al*. An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi's sarcoma in KwaZulu-Natal, South Africa. *Int J STD AIDS* 2011; **22**: 671–673.
  - 34 Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. *Ann Rev Med* 2011; **62**: 157–170.
  - 35 Martin J, Wenger M, Busakhala N *et al*. Prospective evaluation of the impact of potent antiretroviral therapy on the incidence of Kaposi's Sarcoma in East Africa: findings from the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. *Infect Agents Cancer* 2012; **7**(Suppl 1): 06.
  - 36 Asiimwe F, Moore D, Were W *et al*. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda. *HIV Med* 2012; **13**: 166–171.
  - 37 Silverberg MJ, Neuhaus J, Bower M *et al*. Risk of cancers during interrupted antiretroviral therapy in the SMART study. *AIDS* 2007; **21**: 1957–1963.
  - 38 Babiker AG, Emery S, Fätkenheuer G *et al*. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. *Clin Trials* 2013; **10**(1 Suppl): S5–S36.
  - 39 Mocroft A, Youle M, Gazzard B *et al*. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. *AIDS* 1996; **10**: 1101–1105.
  - 40 Glesby MJ, Hoover DR, Weng S *et al*. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. *J Infect Dis* 1996; **173**: 1477–1480.
  - 41 Casper C, Krantz EM, Corey L *et al*. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. *J Infect Dis* 2008; **198**: 23–30.
  - 42 Cattamanchi A, Saracino M, Selke S *et al*. Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human



- herpesvirus-8 replication in HIV-1 seropositive men. *J Med Virol* 2011; **83**: 1696–1703.
- 43 Kirova YM, Belembaogo E, Frikha H *et al.* Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases. *Radiother Oncol* 1998; **46**: 19–22.
- 44 Stelzer K, Griffin T. A randomised prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. *Int J Radiat Oncol Biol Phys* 1993; **27**: 1057–1061.
- 45 Harrison M, Harrington KJ, Tomlinson DR, Stewart JS. Response and cosmetic outcome of two fractionation regimens for AIDS-related Kaposi's sarcoma. *Radiother Oncol* 1998; **46**: 23–28.
- 46 Kigula-Mugambe JB, Kavuma A. Epidemic and endemic Kaposi's sarcoma: a comparison of outcomes and survival after radiotherapy. *Radiother Oncol* 2005; **76**: 59–62.
- 47 Gressen EL, Rosenstock JG, Xie Y, Corn BW. Palliative treatment of epidemic Kaposi sarcoma of the feet. *Am J Clin Oncol* 1999; **22**: 286–290.
- 48 Singh NB, Lakier RH, Donde B. Hypofractionated radiation therapy in the treatment of epidemic Kaposi sarcoma—a prospective randomized trial. *Radiother Oncol* 2008; **88**: 211–216.
- 49 Olweny CL, Borok M, Gudza I *et al.* Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. *Int J Cancer* 2005; **113**: 632–639.
- 50 Sun Y, Huang Y-C, Xu Q-Z *et al.* HIV-1 Tat depresses DNA-PKCS expression and DNA repair, and sensitizes cells to ionizing radiation. *Int J Radiat Oncol Biol Phys* 2006; **65**: 842–850.
- 51 Watkins E, Findlay P, Gelmann E *et al.* Enhanced mucosal reactions in AIDS patients receiving oropharyngeal irradiation. *Int J Radiat Oncol Biol Phys* 1987; **13**: 1403–1408.
- 52 Sanfilippo NJ, Mitchell J, Grew D, DeLacure M. Toxicity of head-and-neck radiation therapy in human immunodeficiency virus-positive patients. *Int J Radiat Oncol Biol Phys* 2010; **77**: 1375–1379.
- 53 Evans MD, Yassa M, Podgorsak EB *et al.* Surface applicators for high dose rate brachytherapy in AIDS-related Kaposi's sarcoma. *Int J Radiat Oncol Biol Phys* 1997; **39**: 769–774.
- 54 Guo W-X, Gill PS, Antakly T. Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. *Cancer Research* 1995; **55**: 823–829.
- 55 Walmsley S, Northfelt DW, Melosky B *et al.* Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-*cis*-retinoic acid) gel. Panretin Gel North American Study Group. *J Acquir Immune Defic Syndr* 1999; **22**: 235–246.
- 56 Bodsworth NJ, Bloch M, Bower M *et al.* Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. *Am J Clin Dermatol* 2001; **2**: 77–87.
- 57 Duvic M, Friedman-Kien AE, Looney DJ *et al.* Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. *Arch Dermatol* 2000; **136**: 1461–1469.
- 58 Aboulaflia DM, Norris D, Henry D *et al.* 9-*cis*-Retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. *Arch Dermatol* 2003; **139**: 178–186.
- 59 Boudreaux AA, Smith LL, Cosby CD *et al.* Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection. *J Am Acad Dermatol* 1993; **28**: 61–65.
- 60 Moyle G, Youle M, Barton S. Intralesional vinblastine in the treatment of oral Kaposi's sarcoma. *Br J Clin Pract* 1993; **47**: 79–80.
- 61 Ramirez-Amador V, Esquivel-Pedraza L, Lozada-Nur F *et al.* Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. *Oral Oncol* 2002; **38**: 460–467.
- 62 Tappero JW, Berger TG, Kaplan LD *et al.* Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. *J Acquir Immune Defic Syndr* 1991; **4**: 839–846.
- 63 Hebeda KM, Huizing MT, Brouwer PA *et al.* Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma. *J Acquir Immune Defic Syndr Hum Retrovirol* 1995; **10**: 61–70.
- 64 Bernstein ZP, Wilson BD, Oseroff AR *et al.* Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. *AIDS* 1999; **13**: 1697–1704.
- 65 Koon HB, Fingleton B, Lee JY *et al.* Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. *J Acquir Immune Defic Syndr* 2011; **56**: 64–68.
- 66 Bower M, Fox P, Fife K *et al.* Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. *AIDS* 1999; **13**: 2105–2111.
- 67 Holkova B, Takeshita K, Cheng DM *et al.* Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. *J Clin Oncol* 2001; **19**: 3848–3851.
- 68 Dal Maso L, Polesel J, Serraino D *et al.* Pattern of cancer risk in persons with AIDS in Italy in the HAART era. *Br J Cancer* 2009; **100**: 840–847.

- 69 Seaberg EC, Wiley D, Martínez-Maza O *et al.* Cancer incidence in the multicenter AIDS cohort study before and during the HAART era. *Cancer* 2010; 116: 5507–5516.
- 70 Bower M, Weir J, Francis N *et al.* The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. *AIDS* 2009; 23: 1701–1706.
- 71 Petoumenos K, van Leuwen MT, Vajdic CM *et al.* Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). *HIV Med* 2013; 14: 77–84.
- 72 Franceschi S, Lise M, Clifford GM *et al.* Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. *Br J Cancer* 2010; 103: 416–422.
- 73 Bower M, Nelson M, Young AM *et al.* Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. *J Clin Oncol* 2005; 23: 5224–5228.
- 74 Jaffe HW, De Stavola BL, Carpenter LM *et al.* Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. *AIDS* 2011; 25: 1395–1403.
- 75 Letang E, Miro JM, Nhampossa T *et al.* Incidence and predictors of immune reconstitution inflammatory syndrome in a rural area of Mozambique. *PLoS ONE* 2011; 6: e16946.
- 76 Achenbach CJ, Harrington RD, Dhanireddy S *et al.* Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. *Clin Infect Dis* 2012; 54: 424–433.
- 77 Müller M, Wandel S, Colebunders R *et al.* Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. *Lancet Infect Dis* 2010; 10: 251–261.
- 78 Leidner RS, Aboulaflia DM. Recrudescence Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. *AIDS Patient Care STDS* 2005; 19: 635–644.
- 79 Connick E, Kane MA, White IE *et al.* Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. *Clin Infect Dis* 2004; 39: 1852–1855.
- 80 Feller L, Anagnostopoulos C, Wood NH *et al.* Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report. *J Periodontol* 2008; 79: 362–368.
- 81 Read PJ, Desai M, Lucas S *et al.* Immune reconstitution inflammatory syndrome (IRIS)-associated Kaposi sarcoma (KS) in the liver manifesting as acute obstructive hepatitis. *HIV Med* 2009; 10(Suppl 2): 163 [Abstr PE12.1/2].
- 82 Pal J, Shrivastav A, Pathak HS, Sarkar DK. Immune reconstitution inflammatory syndrome associated with acquired immunodeficiency syndrome-related gastrointestinal limited Kaposi's sarcoma presenting as acute intestinal obstruction: a case report. *J Med Case Reports* 2011; 5: 327.
- 83 Mosam A, Shaik F, Uldrick TS *et al.* A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naïve patients with HIV-associated Kaposi sarcoma in South Africa. *J Acquir Immune Defic Syndr* 2012; 60: 150–157.
- 84 Laubenstein LJ, Krigel RL, Odajnyk CM *et al.* Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. *J Clin Oncol* 1984; 2: 1115–1120.
- 85 Gill PS, Akil B, Colletti P *et al.* Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. *Am J Med* 1989; 87: 57–61.
- 86 Gill P, Rarick M, Bernstein-Singer M *et al.* Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. *Am J Clin Oncol* 1990; 13: 315–319.
- 87 Gill PS, Bernstein-Singer M, Espina BM *et al.* Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma. *AIDS* 1992; 6: 1477–1481.
- 88 Cadranell JL, Kammoun S, Chevret S *et al.* Results of chemotherapy in 30 AIDS patients with symptomatic pulmonary Kaposi's sarcoma. *Thorax* 1994; 49: 958–960.
- 89 Rafiyath SM, Rasul M, Lee B *et al.* Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. *Exp Hematol Oncol* 2012; 1: 10.
- 90 Young AM, Dhillon T, Bower M. Cardiotoxicity after liposomal anthracyclines. *Lancet Oncol* 2004; 5: 654.
- 91 Gill PS, Wernz J, Scadden DT *et al.* Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. *J Clin Oncol* 1996; 14: 2353–2364.
- 92 Northfelt DW, Dezube BJ, Thommes JA *et al.* Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. *J Clin Oncol* 1998; 16: 2445–2451.
- 93 Stewart S, Jablonowski H, Goebel FD *et al.* Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. *J Clin Oncol* 1998; 16: 683–691.

- 94 Cooley T, Henry D, Tonda M *et al.* A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. *Oncologist* 2007; 12: 114–123.
- 95 Lichterfeld M, Qurishi N, Hoffmann C *et al.* Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. *Infection* 2005; 33: 140–147.
- 96 Esdaile B, Davis M, Portsmouth S *et al.* The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma. *AIDS* 2002; 16: 2344–2347.
- 97 Ferlini C, Cicchillitti L, Raspaglio G *et al.* Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. *Cancer Research* 2009; 69: 6906–6914.
- 98 Saville MW, Lietzau J, Pluda JM *et al.* Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. *Lancet* 1995; 346: 26–28.
- 99 Welles L, Saville MW, Lietzau J *et al.* Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. *J Clin Oncol* 1998; 16: 1112–1121.
- 100 Gill PS, Tulpule A, Espina BM *et al.* Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. *J Clin Oncol* 1999; 17: 1876–1883.
- 101 Tulpule A, Groopman J, Saville MW *et al.* Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. *Cancer* 2002; 95: 147–154.
- 102 Stebbing J, Wildfire A, Portsmouth S *et al.* Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations. *Ann Oncol* 2003; 14: 1660–1666.
- 103 Cianfrocca M, Lee S, Von Roenn J *et al.* Randomized trial of paclitaxel *versus* pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. *Cancer* 2010; 116: 3969–3977.
- 104 Cianfrocca M, Lee S, Von Roenn J *et al.* Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. *Cancer Chemother Pharmacol* 2011; 68: 827–833.
- 105 Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. *AIDS* 1999; 13: 283–284.
- 106 Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. *Am J Clin Oncol* 2004; 27: 81–84.
- 107 Lim ST, Tupule A, Espina BM, Levine AM. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. *Cancer* 2005; 103: 417–421.
- 108 Autier J, Picard-Dahan C, Marinho E *et al.* Docetaxel in anthracycline-pretreated AIDS-related Kaposi's sarcoma: a retrospective study. *Br J Dermatol* 2005; 152: 1026–1029.
- 109 Mir O, Dessard-Diana B, Louet AL *et al.* Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. *Br J Clin Pharmacol* 2010; 69: 99–101.
- 110 Louergue P, Mir O, Allali J, Viard JP. Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma. *AIDS* 2008; 22: 1237–1239.
- 111 Krown SE, Li P, von Roenn JH *et al.* Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS Clinical Trials Group Study. *J Interferon Cytokine Res* 2002; 22: 295–303.
- 112 Shepherd FA, Beaulieu R, Gelmon K *et al.* Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. *J Clin Oncol* 1998; 16: 1736–1742.
- 113 Kreuter A, Rasokat H, Klouche M *et al.* Liposomal pegylated doxorubicin *versus* low-dose recombinant interferon alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. *Cancer Invest* 2005; 23: 653–659.
- 114 Masood R, Cai J, Zheng T *et al.* Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi's sarcoma. *Proc Natl Acad Sci USA* 1997; 94: 979–984.
- 115 Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the [beta]-arrestin-dependent endocytosis of VE-cadherin. *Nat Cell Biol* 2006; 8: 1223–1234.
- 116 Uldrick TS, Wyvill KM, Kumar P *et al.* Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. *J Clin Oncol* 2012; 30: 1476–1483.
- 117 Fife K, Howard MR, Gracie F *et al.* Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. *Int J STD AIDS* 1998; 9: 751–755.
- 118 Little RF, Wyvill KM, Pluda JM *et al.* Activity of thalidomide in AIDS-related Kaposi's sarcoma. *J Clin Oncol* 2000; 18: 2593–2602.
- 119 Koon HB, Honda K, Lee JY *et al.* Phase II AIDS Malignancy Consortium trial of imatinib in AIDS-associated Kaposi's sarcoma (KS). *J Acquir Immune Defic Syndr* 2011; 56: 64–68.

- 120 Dezube BJ, Krown SE, Lee JY *et al.* Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. *J Clin Oncol* 2006; **24**: 1389–1394.
- 121 Brinker BT, Krown SE, Lee JY *et al.* Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. *Cancer* 2008; **112**: 1083–1088.
- 122 Little RF, Pluda JM, Wyvill KM *et al.* Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. *Blood* 2006; **107**: 4650–4657.
- 123 Lechowicz M, Dittmer DP, Lee JY *et al.* Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. *Clin Infect Dis* 2009; **49**: 1946–1949.
- 124 Krown SE, Roy D, Lee JY *et al.* Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. *J Acquir Immune Defic Syndr* 2012; **59**: 447–454.
- 125 Evans SR, Krown SE, Testa MA *et al.* Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. *J Clin Oncol* 2002; **20**: 3236–3241.
- 126 Zhong DT, Shi CM, Chen Q *et al.* Etoposide, vincristine, doxorubicin and dexamethasone (EVAD) combination chemotherapy as second-line treatment for advanced AIDS-related Kaposi's sarcoma. *J Cancer Res Clin Oncol* 2012; **138**: 425–430.
- 127 González-Molleda L, Wang Y, Yuan Y. Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus. *Antimicrob Agents Chemother* 2012; **56**: 893–902.
- 128 Davies BR, Logie A, McKay JS *et al.* AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action *in vivo*, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. *Mol Cancer Ther* 2007; **6**: 2209–2219.

## 4 Systemic AIDS-related non-Hodgkin lymphoma (ARL)

### 4.1 Introduction

People living with HIV have an increased risk of developing non-Hodgkin lymphoma (NHL) [1–4]. The two commonest subtypes are diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma/leukaemia (BL), which are considered AIDS-defining illnesses (ADI). NHL is the second most common tumour in individuals with HIV and although studies show a decline in incidence since the introduction of HAART [5–8], AIDS-related lymphomas (ARLs) have increased as a percentage of first ADI [9,10]. The development of ARL has been shown to be related to older age, low CD4 cell count and no prior treatment with HAART [11]. Patients tend to present with advanced clinical stage, B symptoms and extranodal involvement, including bone marrow.

Before the introduction of HAART, the outlook for patients with ARL was poor, with the median survival for patients treated with chemotherapy being around 2–13 months. Median survival in the post-HAART era is beginning to approach that observed in the HIV-negative population and depends critically on histological subtype and stage of disease [12–20].

### 4.2 Diagnosis, staging and prognosis

The diagnosis of ARL should be based on a tissue biopsy rather than a cytological sample. In addition to the routine investigations advised as part of HIV clinical care, all patients require staging with clinical evaluation, blood tests, computerized tomography (CT) scanning and bone marrow aspiration and trephine (Table 4.1). <sup>18</sup>F-fluoro-2-deoxy-D-glucose positron emission tomography (<sup>18</sup>F-FDG PET) scanning at diagnosis improves the staging accuracy and the Imaging Subcommittee of the International Harmonisation Project in Lymphoma has produced guidelines strongly recommending a baseline pretreatment <sup>18</sup>F-FDG PET scan [21]. Cerebrospinal fluid (CSF) examination is recommended if there are clinical signs of central nervous system (CNS) disease, or paranasal sinus, breast, epidural or testicular involvement. Cytological assessment by cytospin and flow cytometry is recommended [22]. Indications for intrathecal prophylaxis will be outlined in BCSH guidelines and should be administered at time of first CSF examination in these patients. Patients with BL are at a particularly high-risk of developing CNS disease [23] and thus treatment should incorporate CNS-penetrating chemotherapy in

all patients with BL. Staging should be according to the Ann Arbor classification/Cotswolds modification system [24].

Prognostic factors for survival in the pre-HAART era were predominantly immunological (prior ADI and low CD4 cell count) [25,26]. Factors that are associated with survival in the post-HAART era are the International Prognostic Index (IPI) score (Tables 4.2–4.4) [17,27] and in some studies, the CD4 cell count at diagnosis, with a CD4 cell count less than 100 cells/ $\mu$ L predictive of a worse outcome [28]. In two studies performed by the AIDS-Malignancies Consortium (AMC) in the US, patients with a CD4 count of <50 cells/ $\mu$ L treated with either R-CHOP or R-EPOCH experienced a high rate of infection-related mortality (35–40%) [19,27]. Whether improved infection surveillance and prophylaxis or alternative approaches are warranted for

**Table 4.1** BHIVA recommendations for baseline investigations\* in DLBCL and BL

Haematology: FBC, blood film, ESR, blood group and screen, consider coagulation screen
Serum chemistry: renal and liver function, bone profile, LDH, urate, CRP, immunoglobulins, serum protein electrophoresis, $\beta_2$ microglobulin
Virology: HbsAg, HbsAb, HbcAb, anti HCV, VZV IgG, CMV IgG
Lumbar puncture: this is not a routine staging investigation. If performed because IT prophylaxis is indicated according to BCSH/local guidelines: CSF protein. CSF glucose, CSF cytology with flow cytometry should be performed
ECG
Chest X-ray
Bone marrow (BM) biopsy and aspirate
Neck-chest-abdomen-pelvis (NCAP) CT scan with contrast unless contra-indicated
<sup>18</sup> F-FDG PET-CT scan
Other investigations if clinically indicated (MRI, ECHO, MUGA)

\*Tests in addition to routine HIV clinical care investigations.

**Table 4.2** International prognostic index for aggressive non-Hodgkin lymphoma [30]

Score 1 for each factor present:
Age >60 years
Serum LDH > normal
Performance status >1
Stage III/IV
Extranodal site >1
Final IPI risk group
0 or 1, low risk;
2, low intermediate risk;
3, high intermediate risk;
4 or 5, high risk



**Table 4.3** Outcome of DLBCL according to the IPI score in HIV-negative patients treated with rituximab (adapted from [31])

Risk group	Number of adverse factors	Percentage of patients (%)	4-year PFS* (%)	4-year OS* (%)
Low risk	0–1	28	85	82
Intermediate–low	2	27	80	81
Intermediate–high	3	21	57	49
High-risk	4–5	24	51	59

Risk factors: age >60; LDH > ULN; stage III–IV; PS ECOG  $\geq$ 2; extranodal sites  $\geq$ 2.

\*Data on HIV-negative patients treated with R-CHOP.

#### Revised-IPI#

Risk group	Number of adverse factors	Percentage of patients (%)	4-year PFS (%)	4-year OS (%)
Very good	0	10	94	94
Good	1–2	45	80	79
Poor	3–5	45	53	55

Risk factors: age >60; LDH > ULN; stage III–IV; PS ECOG  $\geq$ 2; extranodal sites  $\geq$ 2.

#'Revised-IPI' includes the same prognostic factors as the IPI but differs in the distribution of risk-group according to the number of adverse prognostic factors.

**Table 4.4** Outcome of DLBCL according to IPI score in HIV-positive patients (adapted from [32])

IPI risk group (no. of patients)	Complete responses to chemotherapy (%)	3-year survival (%)
Low (42)	63	64
Low intermediate (35)	64	64
High intermediate (13)	28	50
High (11)	13	13

this subgroup remains unclear, as this has not been noted in other studies [29].

### 4.3 Recommendation

- We recommend that all patients have pathology and treatment plans reviewed by a specialist multidisciplinary team (MDT) and that management is co-ordinated closely with an HIV physician and a haemato-oncologist familiar with the treatment of such patients (level of evidence 1D).

### 4.4 Management

#### 4.4.1 First-line chemotherapy for DLBCL in HIV-infected individuals

Prior to the introduction of HAART, treatment with standard-dose chemotherapy induced high levels of toxicity. Improvements in chemotherapy response rates were generally offset by increased death due to opportunistic

infection [33,34]. The introduction of HAART has led to better control of HIV viral replication and improved immune function, and the incorporation of haematopoietic growth factors (G-CSF) into treatment protocols has allowed for the introduction of increasingly myelotoxic regimens. This has allowed conventional chemotherapy regimens in use in the HIV-negative setting, such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone), to be used as first-line treatment in HIV-positive patients and outcomes are now similar for those with and without HIV infection [15,16].

The infusional regimen, dose-adjusted (DA) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and hydroxydaunorubicin) has been favoured over CHOP chemotherapy in some US centres, due to superior response rates, survival and lower rates of infectious death observed when compared to historical data [18–20,35]. The DA-EPOCH regimen is based on *in vitro* studies demonstrating that prolonged exposure to low doses of chemotherapy agents can overcome tumour resistance as compared to brief exposure to high concentrations [36,37]. Dose adjustment to the neutrophil nadir minimizes haematological toxicity [38]. However, CHOP and EPOCH have not been compared in a randomized study. The outcome after the infusional chemotherapy regimen of cyclophosphamide, doxorubicin and etoposide (CDE), administered as a 96-hour continuous infusion, has also been reported in single and multicentre series [39–41], and although patients who received HAART did better, the outcome has not been compared directly to CHOP. These reports are consistent with those for DLBCL in HIV-negative patients where CHOP is considered the standard therapy for most patients treated in the UK, as no survival advantage has been demonstrated for any other chemotherapy regimen in a randomized study [42–44].

#### 4.4.1.1 Localized disease

Localized DLBCL usually refers to patients with stage I disease. However, some patients with stage II disease, where the disease can be incorporated into a single radiotherapy field, are sometimes referred to as having localized disease. A minority of HIV-infected patients (10–30%) present with localized disease [14,17,27], and for these patients either combined-modality treatment with 3 cycles of chemotherapy followed by radiotherapy or chemotherapy alone (4–8 cycles) are valid options. In the HIV-negative setting, there continues to be debate as to which approach is best, with some studies demonstrating the superiority of chemotherapy alone [45], whilst others showing a benefit for combined-modality treatment [46]. Although radiotherapy may decrease the risk of recurrence at the site of initial disease, it does not prevent distant recurrence [47]. These studies all differ in design, patient

characteristics, the type of chemotherapy and the number of cycles administered. Thus, the decision as to which approach to use will depend on the toxicity associated with irradiating a particular disease site and patient/physician choice.

#### 4.4.1.2 Disseminated disease

In the UK, the most commonly used chemotherapy combination in both the HIV-positive and -negative setting is CHOP-21. In disseminated disease, a minimum of 6 cycles are given or 2 cycles beyond documentation of a complete response (CR) (i.e., a maximum of 8 cycles). This is extrapolated from data generated in HIV-negative patients, in which studies have used either 6 or 8 cycles of chemotherapy, but with no direct comparison [48,49].

#### 4.4.2 Rituximab for DLBCL

The role of rituximab (R) in HIV-associated B-cell lymphomas has been controversial ever since a randomized Phase III study conducted by AMC in the US of CHOP *versus* R-CHOP, in patients with aggressive B-cell lymphoma was published [27]. This trial compared R-CHOP ( $n = 99$ ) with CHOP ( $n = 50$ ), using a standard rituximab dose of 375 mg/m<sup>2</sup> with each cycle of chemotherapy but also included maintenance rituximab every 3 months in those who responded to R-CHOP [39]. Although there was a trend to improved response rate with rituximab (58% *vs.* 47%,  $p = 0.15$ ), a significant reduction in progression of lymphoma on treatment, and in death due to lymphoma, unfortunately an increased death rate from infectious complications, particularly (9/15) in those with a CD4 cell count below 50 cells/ $\mu$ L, was observed. Six of 15 deaths occurred during the maintenance phase of rituximab, a strategy not used in aggressive NHL in HIV-negative patients and this subgroup analysis was *post hoc*, not pre-planned. However, this remains the only Phase III study addressing the role of rituximab in HIV-positive patients with DLBCL. An increased risk of life-threatening infection was also observed when the results of three Phase II studies were pooled, combining rituximab with the infusional CDE chemotherapy regimen in 74 patients with ARL [50]. However, subsequent Phase II studies of R-CHOP (without maintenance rituximab) from Europe did not show an increased risk of infectious deaths, instead showing that rituximab was beneficial [14,17].

The AMC went on to perform a randomized study of DA-EPOCH with either concurrent or sequential rituximab [19]. Concurrent administration was superior, with no increase in infectious deaths, but outcome in both groups was excellent, supporting the efficacy and tolerability of concurrent rituximab. A recent meta-analysis of prospec-

tive studies has confirmed the benefit in response rate and overall survival (OS) of the addition of rituximab to chemotherapy [20]. A pooled analysis of both AMC studies mentioned above suggested that R-EPOCH resulted in superior response rates and survival compared to R-CHOP [18], although these regimens have not been compared in any randomized study. Importantly, the R-EPOCH study was performed during a later time period (2002–2006) than the R-CHOP study (1998–2002), suggesting other variables, including supportive care and antiretroviral drug options, may have differed. Consistent with this, the patients treated with R-EPOCH routinely received concurrent antifungal and antibacterial prophylaxis, which was omitted from those treated earlier with R-CHOP.

The AMC have recently reported the results of a prospective, multicentre Phase II trial of R-CHOP, but with pegylated, liposomal doxorubicin in order to limit toxicity. Of note, HAART was continued during chemotherapy. The treatment was well tolerated without any deaths from infection, even in those with a low CD4 cell count, thus supporting the inclusion of rituximab in treatment regimens. However, the response rate was inferior to that reported in prior studies (overall response 76.5%, CR 47.5%) [51].

Thus, the addition of rituximab to chemotherapy is now recommended for DLBCL in HIV-positive patients. Although the use of rituximab is contentious in patients with a CD4 count <50 cells/ $\mu$ L [27], with appropriate antimicrobial prophylaxis (cotrimoxazole, fluconazole, aciclovir, azithromycin), pre-emptive G-CSF and prompt treatment of opportunistic infection, rituximab is recommended for all patients with DLBCL. The rate of overall response (CR and partial remission; PR) and CR to R-CHOP chemotherapy is reported to be around 66–87% and 58–77%, respectively [14,17,27,29]. In one study with long follow-up, the 8-year OS was 46% [52]. (See Table 4.5 for summary of R+ chemotherapy studies in HIV-positive patients.)

#### 4.4.3 Treatment for high-risk patients

As mentioned, the IPI score at diagnosis is prognostic of outcome, such that those patients with high-risk disease (IPI score 3–5) have a lower response rate and overall survival to standard chemotherapy [17,27]. In the HIV-negative setting, studies have investigated intensification of chemotherapy in this high-risk group, including high-dose therapy with autologous stem cell rescue. To date, results have been heterogeneous and no clear survival benefit demonstrated [53]. This question has not been addressed in prospective studies in HIV-positive patients. However, a recent multicentre, retrospective analysis

**Table 4.5** Summary of R+ chemotherapy studies in HIV-positive patients

Regimen	Phase	Patients (n)	ORR (CR+PR) (%)	CR/CRu (%)	Duration	OS	Reference
R-CHOP	III	99	65.7	57.6	PFS 45 weeks	139 weeks	[27]
R-EPOCH (Concurrent rituximab only)	II	51	88	73	2-year PFS 66%	2-year 70%	[19]
R-CHOP	II	81		69	8-year 59%	8-year 46%	[17,52]
R-CHOP	II	52	87	77	2-year PFS 69%	2-year 75%	[14]
R-CDE	II (3 studies pooled)	74	75	70	2-year EFS 52%	2-year 64%	[50]
R-EPOCH	II	33	94	91	5-year PFS 84%	5-year 68%	[35]

ORR: overall response rate; CR: complete response; PR: partial response; CRu: complete response unknown; OS: overall survival.

reviewed the outcome of patients with an IPI score 3–5 and made a comparison between those treated with R-CHOP ( $n = 35$ ) chemotherapy and the more intensive regimen, CODOX-M/IVAC+/-R ( $n = 15$ ). Overall, the outcome was favourable with 68% achieving a CR and a 2-year progression-free and overall survival of 68% and 70%, respectively. There was no significant difference in remission duration, progression free survival (PFS) or OS between the two treatment groups; however, there were significantly more infections and nonhaematological toxicities in the CODOX-M/IVAC+/-R group [29].

#### 4.4.4 The effect of adding HAART

A comparison of 363 patients treated pre and post the introduction of HAART has shown that overall survival has improved in the HAART era [54]. Although tumour regressions with immune reconstitution are rarely observed with lymphomas, optimizing the immune status of the patient has been shown to reduce opportunistic infections and is associated with superior response rates and survival. Results from Phase II studies and case-control series have reported higher response rates and improved survival with the addition of HAART to CHOP chemotherapy [55–59].

Opinions differ as to whether HAART should be continued during chemotherapy or not. Treatment centres in the US that use the DA-EPOCH regimen have previously suspended HAART because of concern regarding potential adverse pharmacokinetic and pharmacodynamic interactions with chemotherapy and the potential for increased toxicity [60]. In these studies, despite a high response rate, CD4 cell counts fell dramatically during chemotherapy and took months to recover to baseline levels despite the re-introduction of HAART on completion of chemotherapy. Although this strategy did not appear to adversely affect lymphoma outcomes or increase infectious complications, the treatment groups have not been large [19,35]. There is concern that the interruption of HAART in patients on therapy prior to lymphoma diagnosis might lead to the development of viral resistance. In Europe, it is

usual to continue HAART during chemotherapy, avoiding boosted protease inhibitors wherever possible as they are associated with greater toxicity and drug interactions [61]. A combined approach to care involving HIV physicians and haemato-oncologists ensures awareness that many antiretrovirals have overlapping toxicities with chemotherapeutic agents. The aim in selecting a HAART regimen is to derive the potential benefits of HIV virological suppression and the associated immune reconstitution whilst minimizing any potential toxicity. Again, this issue has not been examined in randomized studies.

#### 4.4.5 Recommendations for DLBCL

- We recommend that patients should be entered into clinical trials, if available (GPP).
- We recommend that first-line treatment of DLBCL in HIV-positive individuals includes chemotherapy regimens used in HIV-negative patients, such as CHOP or infusional therapies such as EPOCH. No randomized studies have been published in the era of ART and hence there is no optimal ‘gold-standard therapy’ (level of evidence 1B).
- We recommend that chemotherapy regimens should be combined with HAART therapy (level of evidence 1B).
- We recommend the concomitant administration of rituximab (level of evidence 1B). Patients with CD4 cell counts <50 cells/ $\mu$ L may require closer surveillance (GPP).

### 4.5 Burkitt lymphoma/leukaemia

Until recently, patients with HIV-associated BL have been treated similarly to HIV-positive patients with DLBCL. However, in a large retrospective study the survival of patients with BL was very poor when treated with CHOP or M-BACOD (methotrexate with leucovorin, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone), despite adjunctive HAART [54]. This was corroborated by the results of a Phase II prospective study



**Table 4.6** Risk stratification for treatment of BL (adapted from the IPI score)

<b>Low risk disease</b>	Normal LDH
Must have at least three of these factors	Stage I or II disease
	WHO performance score 0–1
	Number of extranodal sites $\leq 1$
<b>High-risk disease</b>	Raised LDH
Two or more of these factors	Stage III or IV disease
	WHO performance score 2–4
	Number of extranodal sites $> 1$

involving 74 patients with HIV-NHL and HIV-BL treated with rituximab and the CDE infusional regimen (R-CDE). In multivariate analysis, a diagnosis of HIV-BL was significantly associated with a worse outcome in comparison to HIV-NHL patients [50].

In the HIV-negative setting, BL is a highly curable malignancy if intensive chemotherapy regimens of short duration are combined with CNS-penetrating therapy [62–64]. In the UK, the most widely used regimen is CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, methotrexate/ifosfamide, etoposide, cytarabine) and the two MRC/NCRI studies (LY6 and LY10) have stratified patients into low-risk and high-risk (Table 4.6). In low-risk disease, patients receive 3 cycles of CODOX-M and those with high-risk disease receive 4 cycles of chemotherapy alternating between CODOX-M and IVAC. Grade 3/4 haematological toxicity is universal with this regimen with a high incidence of neutropenic fever and mucositis. The reported treatment-related death rate is around 8–14% [62,63]. In the LY6 study, the main toxicity was from the use of high-dose methotrexate at a dose of 6.7 g/m<sup>2</sup> [63] and thus in the LY10 study, the dose was reduced to 3 g/m<sup>2</sup> [62] without compromising outcomes. In the LY10 study, the 2-year PFS and OS for low-risk disease was 85% and 88%, respectively, and for high risk, 49% and 52%, respectively [62].

Two small retrospective studies and one prospective comparative study [65–67] have demonstrated the feasibility of administering more intensive chemotherapy regimens, such as CODOX-M/IVAC [65] and hyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine) to HIV-positive patients with BL [66]. These studies report a CR rate of 63–71% and a 2-year event-free survival of 60%, similar to that observed in HIV-negative patients treated with the same regimen, with no increase in toxicity [66,67]. A retrospective study investigated concerns regarding prolonged immunosuppression and loss of viral control following intensive chemotherapy. However, in 30 HIV-positive patients with BL treated with CODOX-M/IVAC, excellent immune recovery was demonstrated with viral loads undetectable in 88% and 87% of patients at 6 and 12 months

respectively following chemotherapy. In addition, the CD4 cell count was greater than 200 cells/ $\mu$ L in 58% and 80% of patients at 6 and 12 months, respectively [68]. These studies, although small, suggest that a uniform approach to treatment of BL should be used, regardless of HIV status.

In the HIV-negative setting, it is presumed that the addition of rituximab to intensive chemotherapy will improve outcomes and its use is becoming more widespread. However, there have not been, and are unlikely to be, randomized studies addressing this question. The feasibility of adding rituximab to CODOX-M/IVAC chemotherapy has been demonstrated in a retrospective study of 23 patients. There was no increase in toxicity and outcomes were favourable [69]. A Phase II NCRI prospective study of R-CODOX-M/IVAC in BL is currently open.

The addition of rituximab to the treatment of BL in HIV-positive patients also seems feasible. A prospective study of 36 patients with BL, treated with intensive chemotherapy and rituximab, included 19 with HIV infection. Although HIV-positive patients experienced more severe mucositis and a higher incidence of infection, their outcome was not significantly different to HIV-negative patients with a CR rate of 84% and a 2-year OS of 73% [70]. A prospective Phase II study from the AMC, reported in abstract form, treated patients with HIV-associated BL with a modified version of R-CODOX-M/IVAC to limit the toxicity. The 1-year OS was 82% at a median follow-up of 9 months and there were no treatment-related deaths [71]. A retrospective analysis of 80 patients with BL lymphoma treated with CODOX-M/IVAC with or without rituximab included 14 patients who were HIV-positive, 10 of whom received rituximab. The results demonstrated that there were fewer relapses in patients treated with rituximab but only a nonsignificant trend to improved survival. Importantly, the outcome for those with HIV infection was comparable to the HIV-negative patients [72]. A recently reported prospective study of rituximab combined with intensive chemotherapy in 118 patients with BL included 38 HIV-positive patients [73]. HIV status did not impact on outcome and 87% of HIV-positive patients achieved a CR. With a median follow-up of 2.5 years, the 4-year probabilities for disease-free and OS were 63% and 78%, respectively. Overall, 8% of patients died during chemotherapy and those with HIV-infection had a higher incidence of grade 3/4 mucositis and severe infections.

In order to overcome concerns of treatment toxicity in HIV-associated BL, the DA-EPOCH regimen plus rituximab is favoured in the US. With a follow-up of 28 months, a study presented only in abstract form reported an impressive CR rate and OS of 100% in patients treated with this regimen [74]. The studies performed in patients with BL are summarized in Table 4.7.

**Table 4.7** Summary of studies performed in HIV-related BL

Regimen	Phase	Patients (n)	ORR (CR+PR) (%)	CR/CRu (%)	Duration	OS	Reference
CODOX-M/IVAC	Retrospective	8	63	63	2-year EFS 60%		[65]
Hyper-CVAD	Retrospective	13	100	92		2-year 52%	[66]
PETHEMA-LAL3/97 study	Phase II	14	71	71	2-year DFS 60%	2-year 43%	[67]
CODOX-M/IVAC	Retrospective	30	70	57	3-year EFS 75%	3-year 52%	[68]
Rituximab plus German ALL type chemotherapy (B-ALL/B-NHL2002)	Phase II	19		84	2-year 87%	2-year 73%	[70]
Rituximab plus CODOX-M/IVAC	Retrospective	14*	93	93	3-year PFS 68%	3-year 68%	[72]
Rituximab plus German ALL type chemotherapy (B-ALL/B-NHL2002)	Phase II	38		82	4-year DFS 77%	4-year 63%	[73]
Rituximab plus DA-EPOCH	Phase II	8	100	100		28 month 100%	[74]

ORR: overall response rate; CR: complete response; PR: partial response; CRu: complete response unknown; DFS:disease-free survival; EFS: event-free survival; OS: overall survival

\*Four patients did not receive rituximab

#### 4.5.1 Recommendations for BL

- We recommend that first-line treatment of BL in HIV-infected individuals includes regimens such as CODOX-M/IVAC and DA-EPOCH. No comparative studies have been performed and hence there is no optimal 'gold-standard therapy' (level of evidence 1B).
- We recommend that chemotherapy regimens should be combined with HAART therapy (level of evidence 1B).
- We recommend the addition of rituximab (level of evidence 1C).

#### 4.6 Prevention of secondary CNS lymphoma

The incidence of CNS involvement has been suggested to be higher in ARL compared to the HIV-negative patients with NHL [23,75] and this may reflect the more advanced stage at presentation or adverse features. Although there is no reported increase in incidence of secondary CNS lymphoma in the HIV setting, there have been no specific studies that have addressed this in a randomized setting. However, the outcome of secondary CNS involvement by lymphoma is very poor [76], and therefore the administration of preventative treatment during first-line therapy to reduce the incidence CNS relapse is a commonly adopted strategy for those patients with NHL perceived at risk. There is much debate regarding identification of these patients and the optimal strategy to adopt. Many studies [27,33,41,55–57,60,77–82] have reported the use of CNS prophylaxis and treatment in individuals with ARL, although there is a paucity of prospective or randomized trials and these studies have allowed individual institutions to administer CSF prophylaxis according to local protocol or preference. Presently a manuscript addressing these issues is in preparation by the British Committee for Standards in Haematology (BCSH) and thus this will not be discussed in detail.

Immunochemotherapy has significantly improved outcome in the HIV-negative setting, and a number of reports suggest that the overall risk of CNS relapse has decreased with the addition of rituximab to CHOP chemotherapy [83–85] although this has not been detected in all reports [86]. This observation supports the hypothesis that CNS relapse is less likely to occur if there is improved control of systemic disease.

The identification of patients at risk of CNS relapse remains inconclusive [23]; however, data from immunocompetent individuals suggest that advanced stage, elevated serum LDH and extranodal disease [87] and involvement of specific anatomical sites such as: testes [88,89], paranasal sinuses [90], paraspinal disease, breast [91], renal [84], epidural space [92] and bone [93,94], predict a higher likelihood of CNS relapse.

Both intrathecal and intravenous methotrexate have been used to prevent CNS disease. There are insufficient data to identify whether HIV-positive patients have a higher risk of CNS relapse independent of other criteria and thus such patients should be given CNS prophylaxis according to the same criteria as HIV-negative patients. There is universal acceptance that all patients with Burkitt lymphoma should receive specific protocols that include CNS-directed therapy, which in the UK in most instances is R-CODOX-M/R-IVAC.

##### 4.6.1 Recommendations for IT prophylaxis

- We recommend that patients with DLBCL, considered to have a high risk of CNS relapse, should be given CNS prophylaxis (IT and/or IV methotrexate) according to the same criteria as HIV-negative patients (level of evidence 1C).
- We recommend that prophylactic intrathecal chemotherapy should be offered to all patients with Burkitt lymphoma (level of evidence 1B).

#### 4.7 Supportive care

Patients with a high tumour burden are at risk of developing tumour lysis syndrome (TLS). This can occur spontaneously or after commencement of chemotherapy (usually between 12 and 72 hours after). Patients thought to be at high risk of developing TLS include those with DLBCL who have an elevated LDH and bulky disease and those with BL with stage III/IV disease or an elevated LDH. These patients should receive aggressive treatment to prevent TLS, including adequate intravenous hydration and rasburicase. Those who do not meet the criteria for high-risk disease should also be adequately hydrated, although oral hydration and allopurinol may suffice [95].

The inclusion of prophylactic agents to reduce the incidence of infectious complications is common but details regarding this are discussed elsewhere. It is usual to give HIV-infected patients receiving chemotherapy prophylactic G-CSF to prevent or limit the duration of neutropenia.

#### 4.8 Treatment of relapsed/refractory AIDS-related lymphoma

Treatment of refractory or relapsed DLBCL in the pre-HAART era was disappointing with few clinically useful responses [96–98]. In the HIV-negative setting, patients are treated with a more intensive second-line chemotherapy regimen. For those who respond, studies have shown that consolidation with high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) is the optimal therapy for relapsed NHL [99]. Since the introduction of concomitant HAART therapy, with the associated improvement in the immune function and haematological reserve, and better supportive care, a number of studies have confirmed that this strategy is both feasible and effective in the HIV setting [100–108].

Even in the HIV-negative setting, there is no standard second-line chemotherapy regimen but most contain platinum agents. Commonly used regimens include DHAP (dexamethasone, high-dose cytarabine and cisplatin) and ICE (ifosfamide, cisplatin and etoposide). This is usually combined with rituximab, although the value of rituximab in those who relapse early after, or are refractory to, upfront treatment with rituximab is less clear. Response rates to these second-line chemotherapy regimens in HIV-negative patients are around 60% [109]. Similar results have been achieved in HIV-positive patients [100].

Two large, retrospective, multicentre studies performed by the European Group for Blood and Marrow Transplantation (EBMT) have confirmed the feasibility and efficacy of HDT and ASCT for HIV-positive patients that respond to second-line chemotherapy [110,111]. In one of these

studies a comparative analysis was performed between 53 HIV-positive lymphoma patients and a matched cohort (66% non-Hodgkin and 34% Hodgkin lymphoma) of 53 HIV-negative patients [110]. The incidence of relapse, OS and PFS were similar in both cohorts. A higher nonrelapse mortality within the first year after ASCT was observed in the HIV-positive group (8% *vs.* 2%), predominantly because of early bacterial infections, although this was not statistically significant and did not influence survival. In the other study performed by the EBMT, the outcome of 68 patients from 20 institutions (median age, 41 years; range, 29–62 years) transplanted after 1999, for relapsed NHL ( $n = 50$ ) or Hodgkin lymphoma ( $n = 18$ ) was reported [111]. At the time of ASCT, 16 patients were in first CR; 44 patients were in second CR and beyond, PR, or chemotherapy-sensitive relapse; and 8 patients had chemotherapy-resistant disease. At a median follow-up of 32 months (range 2–81 months), PFS was 56%. Patients not in CR or with refractory disease at ASCT had a worse PFS (RR: 2.4 and 4.8, respectively) as is frequently reported in the HIV-negative setting. Thus, in the HAART era, HIV patients with chemosensitive relapsed ARL should be considered for ASCT according to the same criteria adopted for HIV-lymphoma patients.

##### 4.8.1 Recommendations for patients with relapsed/refractory aggressive ARL

- We recommend that patients deemed fit for intensive chemotherapy should receive a second-line chemotherapy regimen (level of evidence 1C), which may contain platinum (level of evidence 2C).
- We recommend that those patients responding to second-line chemotherapy (CR or PR) should be considered for HDT with ASCT (level of evidence 1C).

#### 4.9 Response evaluation and follow-up

Specific response criteria for NHL in HIV-positive patients have not been described, but the International Working Group response criteria defined for the general population are generally used and are shown in Table 4.8 [21]. Response to treatment is assessed by clinical evaluation, CT scanning and bone marrow biopsy (if the CT scan shows CR and BM was involved at diagnosis). It is usual to assess response half way through treatment, i.e., after 3–4 cycles of R-CHOP chemotherapy or 2 cycles of R-CODOX-M/IVAC. However, the role of  $^{18}\text{F}$ -FDG PET scanning during therapy is less clear due to the high false-positive rate [112] and is thus currently not recommended. At the end of treatment, in addition to the mid-treatment investigation, an  $^{18}\text{F}$ -FDG PET scan is recommended as in the HIV-negative setting it has been shown to be superior to CT

**Table 4.8** Response assessment in patients with DLBCL

Response	Definition
Complete response (CR)	Complete clinical and radiological disappearance of disease PET negative
Partial response (PR)	≥50% decrease in diameter of up to 6 of the largest dominant masses PET positivity in a previously involved site
Stable disease (SD)	Failure to attain CR/PR or progressive disease (PD)
Relapsed or PD	Any new lesion or increase by ≥50% of a previously involved site

scanning in detecting residual disease with a very high negative predictive value [21]. These investigations should be performed at least 4–6 weeks after the last cycle of chemotherapy and 8–12 weeks after radiotherapy.

It should be noted that the role of <sup>18</sup>F-FDG PET scanning has been less well studied in HIV-positive patients and false-positive results due to HIV-related pathology are reported, resulting in a positive-predictive values of <10%. Nonetheless, the negative-predictive value is high [35]. Therefore, re-biopsy of residual FDG-avid lesions post-therapy should always be considered. Those with persistent disease should be considered for salvage therapy, and those who have achieved a CR, observed.

The decision to offer consolidation radiotherapy should be made at presentation (i.e., to bulk disease or bony lesions) and not to residual FDG-avid lesions in those treated with curative intent, as PET-positive lesions may represent more widespread disease. RT may be offered to those with PET-positive lesion(s) and who are ineligible for salvage chemotherapy.

There are scant data regarding long-term follow-up of survivors of lymphoma treatment in the HIV setting. However, it is well described in the HIV-negative setting that prior anthracyclines (e.g., doxorubicin) are associated with cardiomyopathy and heart failure. Although it is unclear if the incidence is higher in the HIV setting, patients with other cardiovascular risk factors (e.g., blood pressure, lipids, family history) may deserve greater surveillance.

Chemotherapy for lymphoma is associated with an increased risk of myelodysplasia and acute myeloid leukaemia arising some 2–7 years later, often with cytogenetic abnormalities of chromosomes 5, 7 or 12. Chemotherapy is also associated with an increased risk of second solid tumours, although previous radiotherapy is the greater risk factor. Other potential issues include endocrine and metabolic complications.

Follow-up varies between centres but generally patients with aggressive histologies are seen every 3 months in the

first year, 4–6 monthly for the second and third and thereafter 6 monthly until 5 years post treatment. Patients are then often discharged to primary care (having received an ‘end-of-treatment summary’) although data regarding long-term side effects in patients with HIV who have received treatment for lymphoma are scant. In light of this some patients continue to be monitored on an annual basis.

#### 4.10 References

- Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. *Lancet* 1991; **337**: 805–809.
- Biggar RJ, Rosenberg PS, Cote T. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. *Int J Cancer* 1996; **68**: 754–758.
- Cote TR, Biggar RJ, Rosenberg PS *et al.* Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. *Int J Cancer* 1997; **73**: 645–650.
- Engels EA, Biggar RJ, Hall HI *et al.* Cancer risk in people infected with human immunodeficiency virus in the United States. *Int J Cancer* 2008; **123**: 187–194.
- Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. *J Natl Cancer Inst* 2000; **92**: 1823–1830.
- Stebbing J, Gazzard B, Mandalia S *et al.* Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. *J Clin Oncol* 2004; **22**: 2177–2183.
- Engels EA, Pfeiffer RM, Goedert JJ *et al.* Trends in cancer risk among people with AIDS in the United States 1980–2002. *AIDS* 2006; **20**: 1645–1654.
- Besson C, Goubar A, Gabarre J *et al.* Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. *Blood* 2001; **98**: 2339–2344.
- Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. *Int J Cancer* 1999; **83**: 481–485.
- Mocroft A, Katlama C, Johnson AM *et al.* AIDS across Europe, 1994–98: the EuroSIDA study. *Lancet* 2000; **356**: 291–296.
- Matthews GV, Bower M, Mandalia S *et al.* Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. *Blood* 2000; **96**: 2730–2734.
- Thirlwell C, Sarker D, Stebbing J, Bower M. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. *Clin Lymph* 2003; **4**: 86–92.



- 13 Stebbing J, Marvin V, Bower M. The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma. *Cancer Treat Rev* 2004; **30**: 249–253.
- 14 Boue F, Gabarre J, Gisselbrecht C *et al*. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. *J Clin Oncol* 2006; **24**: 4123–4128.
- 15 Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. *Leuk Lymphoma* 2006; **47**: 1822–1829.
- 16 Navarro JT, Lloveras N, Ribera JM *et al*. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. *Haematologica* 2005; **90**: 704–706.
- 17 Ribera JM, Oriol A, Morgades M *et al*. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. *B J Haematol* 2008; **140**: 411–419.
- 18 Barta SK, Lee JY, Kaplan LD *et al*. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. *Cancer* 2011; **118**: 3977–3983.
- 19 Sparano JA, Lee JY, Kaplan LD *et al*. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. *Blood* 2010; **115**: 3008–3016.
- 20 Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. *Am J Hematol* 2012; **87**: 330–333.
- 21 Cheson BD, Pfistner B, Juweid ME *et al*. Revised response criteria for malignant lymphoma. *J Clin Oncol* 2007; **25**: 579–586.
- 22 Benevolo G, Stacchini A, Spina M *et al*. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. *Blood* 2012; **120**: 3222–3228.
- 23 Sarker D, Thirlwell C, Nelson M *et al*. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. *AIDS* 2003; **17**: 861–865.
- 24 Lister TA, Crowther D, Sutcliffe SB *et al*. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. *J Clin Oncol* 1989; **7**: 1630–1636.
- 25 Straus DJ, Huang J, Testa MA *et al*. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142—low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. *J Clin Oncol* 1998; **16**: 3601–3606.
- 26 Levine AM, Sullivan-Halley J, Pike MC *et al*. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. *Cancer* 1991; **68**: 2466–2472.
- 27 Kaplan LD, Lee JY, Ambinder RF *et al*. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. *Blood* 2005; **106**: 1538–1543.
- 28 Bower M, Gazzard B, Mandalia S *et al*. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. *Ann Intern Med* 2005; **143**: 265–273.
- 29 Kassam S, Bower M, Lee SM *et al*. A retrospective, multicenter analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma. *Leuk Lymphoma* 2013; **54**: 1921–1927.
- 30 A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. *N Engl J Med* 1993; **329**: 987–994.
- 31 Sehn LH, Berry B, Chhanabhai M *et al*. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood* 2007; **109**: 1857–1861.
- 32 Lim ST, Karim R, Tulpule A *et al*. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. *J Clin Oncol* 2005; **23**: 8477–8482.
- 33 Kaplan LD, Straus DJ, Testa MA *et al*. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. *N Engl J Med* 1997; **336**: 1641–1648.
- 34 Mounier N, Spina M, Gabarre J *et al*. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. *Blood* 2006; **107**: 3832–3840.
- 35 Dunleavy K, Little RF, Pittaluga S *et al*. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. *Blood* 2010; **115**: 3017–3024.
- 36 Lai GM, Chen YN, Mickley LA *et al*. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. *Int J Cancer* 1991; **49**: 696–703.

- 37 Gutierrez M, Chabner BA, Pearson D *et al.* Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. *J Clin Oncol* 2000; **18**: 3633–3642.
- 38 Wilson WH, Grossbard ML, Pittaluga S *et al.* Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. *Blood* 2002; **99**: 2685–2693.
- 39 Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. *J Clin Oncol* 1993; **11**: 1071–1079.
- 40 Sparano JA, Wiernik PH, Hu X *et al.* Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. *J Clin Oncol* 1996; **14**: 3026–3035.
- 41 Sparano JA, Lee S, Chen MG *et al.* Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). *J Clin Oncol* 2004; **22**: 1491–1500.
- 42 Fisher RI, Gaynor ER, Dahlberg S *et al.* Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. *N Engl J Med* 1993; **328**: 1002–1006.
- 43 Linch DC, Vaughan Hudson B, Hancock BW *et al.* A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. *Br J Cancer* 1996; **74**: 318–322.
- 44 Messori A, Vaiani M, Trippoli S *et al.* Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. *Br J Cancer* 2001; **84**: 303–307.
- 45 Miller TP, LeBlanc M, Spier C. CHOP alone compared to CHOP plus radiotherapy for early aggressive non-Hodgkin's lymphoma: update of the SouthWest Oncology Group (SWOG) randomized trial. *Blood* 2001; **98**: 714a.
- 46 Horning SJ, Weller E, Kim K *et al.* Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. *J Clin Oncol* 2004; **22**: 3032–3038.
- 47 Bonnet C, Fillet G, Mounier N *et al.* CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2007; **25**: 787–792.
- 48 Coiffier B, Lepage E, Briere J *et al.* CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002; **346**: 235–242.
- 49 Pfreundschuh M, Trumper L, Osterborg A *et al.* CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet Oncol* 2006; **7**: 379–391.
- 50 Spina M, Jaeger U, Sparano JA *et al.* Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. *Blood* 2005; **105**: 1891–1897.
- 51 Levine AM, Noy A, Lee JY *et al.* Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. *J Clin Oncol* 2013; **31**: 58–64.
- 52 Ribera JM, Morgades M, Gonzalez-Barca E *et al.* Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP. *Br J Haematol* 2012; **157**: 637–639.
- 53 Strehl J, Mey U, Glasmacher A *et al.* High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. *Haematologica* 2003; **88**: 1304–1315.
- 54 Lim ST, Karim R, Nathwani BN *et al.* AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. *J Clin Oncol* 2005; **23**: 4430–4438.
- 55 Antinori A, Cingolani A, Alba L *et al.* Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. *AIDS* 2001; **15**: 1483–1491.
- 56 Navarro JT, Ribera JM, Oriol A *et al.* Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. *B J Haematol* 2001; **112**: 909–915.
- 57 Vaccher E, Spina M, di Gennaro G *et al.* Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. *Cancer* 2001; **91**: 155–163.
- 58 Hoffmann C, Wolf E, Fatkenheuer G *et al.* Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. *AIDS* 2003; **17**: 1521–1529.

- 59 Weiss R, Mitrou P, Arasteh K *et al.* Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival—results of the German Multicenter Trial. *Cancer* 2006; **106**: 1560–1568.
- 60 Ratner L, Lee J, Tang S *et al.* Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. *J Clin Oncol* 2001; **19**: 2171–2178.
- 61 Bower M, McCall-Peat N, Ryan N *et al.* Protease inhibitors potentiate chemotherapy-induced neutropenia. *Blood* 2004; **104**: 2943–2946.
- 62 Mead GM, Barrans SL, Qian W *et al.* A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). *Blood* 2008; **112**: 2248–2260.
- 63 Mead GM, Sydes MR, Walewski J *et al.* An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. *Ann Oncol* 2002; **13**: 1264–1274.
- 64 Magrath I, Adde M, Shad A *et al.* Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. *J Clin Oncol* 1996; **14**: 925–934.
- 65 Wang ES, Straus DJ, Teruya-Feldstein J *et al.* Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. *Cancer* 2003; **98**: 1196–1205.
- 66 Cortes J, Thomas D, Rios A *et al.* Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. *Cancer* 2002; **94**: 1492–1499.
- 67 Oriol A, Ribera JM, Esteve J *et al.* Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. *Haematologica* 2003; **88**: 445–453.
- 68 Montoto S, Wilson J, Shaw K *et al.* Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. *AIDS* 2010; **24**: 851–856.
- 69 Mohamedbhai SG, Sibson K, Marafioti T *et al.* Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. *Br J Haematol* 2011; **152**: 175–181.
- 70 Oriol A, Ribera JM, Bergua J *et al.* High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. *Cancer* 2008; **113**: 117–125.
- 71 Noy A, Kaplan L, Lee J. Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma(BL): Preliminary results of a prospective multicenter phase ii trial of the AIDS Malignancy Consortium (AMC). *Blood* 2009; **114**: Abstract 3673.
- 72 Barnes JA, Lacasce AS, Feng Y *et al.* Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. *Ann Oncol* 2011; **22**: 1859–1864.
- 73 Ribera JM, Garcia O, Grande C *et al.* Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). *Cancer* 2013; **119**:1660–1668.
- 74 Dunleavy K, Little RF, Pittaliga S *et al.* A prospective study of dose-adjusted (DA) EPOCH with rituximab in adults with newly diagnosed Burkitt lymphoma: a regimen with high efficacy and low toxicity. *10th International Conference on Malignant Lymphoma*. Lugano, Switzerland. June 2008 [Abstract 009].
- 75 Desai J, Mitnick RJ, Henry DH *et al.* Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma. *Cancer* 1999; **86**: 1840–1847.
- 76 Doolittle ND, Abrey LE, Shenkier TN *et al.* Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. *Blood* 2008; **111**: 1085–1093.
- 77 Sawka CA, Shepherd FA, Brandwein J *et al.* Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program. *Leuk Lymphoma* 1992; **8**: 213–220.
- 78 Bower M, Brock C, Gulliford T *et al.* A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma. *Cancer Chemother Pharmacol* 1996; **38**: 106–109.
- 79 Bower M, Stern S, Fife K *et al.* Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma. *Eur J Cancer* 2000; **36**: 363–367.
- 80 Levine AM, Tulpule A, Espina B *et al.* Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related

- non-Hodgkin's lymphoma: results of therapy and correlates of response. *J Clin Oncol* 2004; 22: 2662–2670.
- 81 Spina M, Carbone A, Vaccher E *et al.* Outcome in patients with non-Hodgkin lymphoma and with or without human immunodeficiency virus infection. *Clin Infect Dis* 2004; 38: 142–144.
- 82 Lascaux AS, Hemery F, Goujard C *et al.* Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas. *AIDS Res Human Retroviruses* 2005; 21: 214–220.
- 83 Boehme V, Schmitz N, Zeynalova S *et al.* CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). *Blood* 2009; 113: 3896–3902.
- 84 Villa D, Connors JM, Shenkier TN *et al.* Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. *Ann Oncol* 2010; 21: 1046–1052.
- 85 Mitrovic Z, Bast M, Bierman PJ *et al.* The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. *Br J Haematol* 2012; 157: 401–403.
- 86 Feugier P, Virion JM, Tilly H *et al.* Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. *Ann Oncol* 2004; 15: 129–133.
- 87 van Besien K, Ha CS, Murphy S *et al.* Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. *Blood* 1998; 91: 1178–1184.
- 88 Fonseca R, Habermann TM, Colgan JP *et al.* Testicular lymphoma is associated with a high incidence of extranodal recurrence. *Cancer* 2000; 88: 154–161.
- 89 Zucca E, Conconi A, Mughal TI *et al.* Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. *J Clin Oncol* 2003; 21: 20–27.
- 90 Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. *Hematol Oncol* 1990; 8: 141–145.
- 91 Gholam D, Bibeau F, El Weshi A *et al.* Primary breast lymphoma. *Leuk Lymphoma* 2003; 44: 1173–1178.
- 92 MacKintosh FR, Colby TV, Podolsky WJ *et al.* Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. *Cancer* 1982; 49: 586–595.
- 93 Cetto GL, Iannucci A, Tummarello D *et al.* Involvement of the central nervous system in non-Hodgkin's lymphoma. *Tumori* 1981; 67: 39–44.
- 94 Keldsen N, Michalski W, Bentzen SM *et al.* Risk factors for central nervous system involvement in non-Hodgkins-lymphoma—a multivariate analysis. *Acta Oncol* 1996; 35: 703–708.
- 95 Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. *Br J Haematol* 2010; 149: 578–586.
- 96 Tirelli U, Errante D, Spina M *et al.* Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. *Cancer* 1996; 77: 2127–2131.
- 97 Levine AM, Tulpule A, Tessman D *et al.* Mitoguzone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. *J Clin Oncol* 1997; 15: 1094–1103.
- 98 Spina M, Vaccher E, Juzbasic S *et al.* Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. *Cancer* 2001; 92: 200–206.
- 99 Philip T, Guglielmi C, Hagenbeek A *et al.* Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med* 1995; 333: 1540–1545.
- 100 Bi J, Espina BM, Tulpule A *et al.* High-dose cytosine-arabioside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. *J Acquir Immune Defic Syndr* 2001; 28: 416–421.
- 101 Gabarre J, Leblond V, Sutton L *et al.* Autologous bone marrow transplantation in relapsed HIV-related non-Hodgkin's lymphoma. *Bone Marrow Transplant* 1996; 18: 1195–1197.
- 102 Gabarre J, Azar N, Autran B *et al.* High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. *Lancet* 2000; 355: 1071–1072.
- 103 Molina A, Zaia J, Krishnan A. Treatment of human immunodeficiency virus-related lymphoma with haematopoietic stem cell transplantation. *Blood Rev* 2003; 17: 249–258.
- 104 Serrano D, Carrion R, Balsalobre P *et al.* HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. *Exp Hematol* 2005; 33: 487–494.
- 105 Hoffmann C, Repp R, Schoch R *et al.* Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma. *Eur J Med Res* 2006; 11: 73–76.



- 106 Krishnan A, Molina A, Zaia J *et al.* Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. *Blood* 2005; **105**: 874–878.
- 107 Gabarre J, Marcelin AG, Azar N *et al.* High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. *Haematologica* 2004; **89**: 1100–1108.
- 108 Re A, Cattaneo C, Michieli M *et al.* High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. *J Clin Oncol* 2003; **21**: 4423–4427.
- 109 Gisselbrecht C, Glass B, Mounier N *et al.* Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol* 2010; **28**: 4184–4190.
- 110 Diez-Martin JL, Balsalobre P, Re A *et al.* Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. *Blood* 2009; **113**: 6011–6014.
- 111 Balsalobre P, Diez-Martin JL, Re A *et al.* Autologous stem-cell transplantation in patients with HIV-related lymphoma. *J Clin Oncol* 2009; **27**: 2192–2198.
- 112 Moskowitz CH, Schoder H, Teruya-Feldstein J *et al.* Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. *J Clin Oncol* 2010; **28**: 1896–1903.

## 5 Primary central nervous system lymphoma (PCNSL)

### 5.1 Introduction

Primary central nervous system lymphoma (PCNSL) is defined as a non-Hodgkin lymphoma (NHL) confined to the cranio-spinal axis without systemic involvement. It occurs more frequently in patients with both congenital and acquired immunodeficiency. In HIV it is generally seen in patients with severe and prolonged immunosuppression. It can affect any part of the brain, leptomeninges, cranial nerves, eyes or spinal cord [1]. AIDS-related PCNSL occurs with a similar distribution across transmission risk groups and all ages, and is characteristically high-grade diffuse large B-cell or immunoblastic NHL [2]. Shortly after the introduction of highly active antiretroviral therapy (HAART), a decline in the incidence of PCNSL was recognized and a meta-analysis of 48 000 individuals confirmed this significant decrease (relative risk 0.42, 99% CI: 0.24–0.75) [3]. A subsequent study has shown that the incidence of PCL is lower in the HAART era (1.2 cases per 1000 patient-years, 95% CI: 0.8–1.9) than in the pre-HAART era (3.0 cases per 1000 patient-years, 95% CI: 2.1–4.0;  $p < 0.001$ ), and overall survival is longer (median survival 32 days, range 5–315 days *vs.* 48 days, range 15–1136 days; log rank  $p = 0.03$ ) [4].

### 5.2 Diagnosis, staging and prognosis

Patients rarely present with B symptoms such as fever, weight loss, or night sweats that are commonly associated with other forms of NHL. PCNSL typically presents with a focal mass lesion in more than 50% of cases. In 248 immunocompetent patients, 43% had neuropsychiatric signs, 33% had increased intracranial pressure, 14% had seizures, and 4% had ocular symptoms at the time of presentation [3]. The presentation of PCNSL in people living with HIV may be with subacute focal neurological signs [4].

Examination includes full medical, neurological and neuropsychological assessment. Investigations including serum LDH, CSF analysis only when lumbar puncture can be safely performed, radiology (MRI brain, CT CAP), will help to support the diagnosis of PCNSL. Stereotactic brain biopsy is the only confirmatory test and this may be guided by gadolinium-enhanced MRI scan. The presence of Epstein-Barr virus (EBV) in tumour cells is a universal feature of HIV-associated PCNSL but is not found in other PCNSLs [5,6]. In patients with HIV, computed tomography

(CT) scans of PCNSL may show ring enhancement in as many as half the cases, whilst in immunocompetent patients with PCNSL the enhancement is almost always homogeneous [7,8]. Most commonly, PCNSL presents as diffuse and multifocal supratentorial brain masses. As a peculiarity of PCNSL, involvement of the vitreous, retina and optic nerves may be found in about 10–15% of patients at presentation [9]. Lymphomatous infiltration of the leptomeninges or ependymal surfaces and radicular or plexus invasion may occur as well [10]. By systemic staging, occult systemic lymphoma may be detected in up to 8% of patients initially presenting with brain lymphoma. Therefore, bone marrow biopsy, CT scan of chest and abdomen, testicular ultrasound and careful physical examination to detect occult systemic lymphoma is recommended [11]. The diagnostic algorithm for the management of cerebral mass lesions in HIV-seropositive patients includes a 2-week trial of antitoxoplasmosis therapy (sulfadiazine 1 g four times a day, pyrimethamine 75 mg once daily). Magnetic resonance imaging is the most sensitive radiological procedure: the densely cellular tumour appears as single (65%) or multiple lesions on nonenhanced T1-weighted images, hyperintense tumour and oedema on T2 or FLAIR images and densely enhancing masses after administration of gadolinium. Fifty per cent or more of the lesions are in contact with the meninges, and meningeal enhancement appears in 10–20% [12].

### 5.3 Treatment of HIV-associated primary cerebral lymphoma

The treatment of HIV-associated primary cerebral lymphoma is poor with median survival rarely reported at greater than 9 months. Primarily the reasons for this are due to the advanced stage disease at the time of presentation with low CD4 cell counts (typically below 100 cells/ $\mu$ L) and poor performance status. Compared to immune competent patients the age of presentation tends to be younger, with worse performance status and higher LDH. Often the patients present with multifocal disease.

In the HIV population the incidence of PCNSL has fallen dramatically since the introduction of HAART [13,14]. In immune competent individuals, the treatment of choice is chemotherapy, with the antimetabolites methotrexate and cytarabine forming the backbone of the majority of PCNSL regimens and is the current regimen of choice for *de novo* immune competent patients [15] with PCNSL. However, in

the HIV population this is rarely feasible due to poor performance status and concerns over toxicity with the combination of two chemotherapeutic agents. Therefore single modality use of intravenous methotrexate is the most utilized treatment yielding median overall survival of 8–9 months in most small series of patients [16,17]. In these situations, it is recommended to utilize growth factors such as G-CSF to prevent enhanced haematological toxicity in this population. In patients with well-controlled HIV viral load and good performance status, and in the absence of comorbidities, ideally the treatment of choice would be combination therapy with a methotrexate and AraC combination. In those cases where treatment is tolerated and chemosensitive disease demonstrated, consolidation of an autologous stem transplant may be considered. Because of the association with EBV and HIV-related PCNSL, investigators have tried to develop antiviral-based regimens including nucleoside analogues such as AZT and ganciclovir [18]. However, although ORR rates of 56% were reported, outcome measures remain disappointing with OS reported of 4 months [17], which is inferior to single-agent methotrexate. In the future, further knowledge of the biological basis of EBV and its association with PCNSL may facilitate novel targeted approaches. The use of HAART is mandatory, and has been demonstrated in three small series to be correlated with enhanced OS [17,19,20]. Part of its effect may be to induce restoration of an immune response to EBV. Therefore it is recommended to initiate HAART in all newly diagnosed patients with HIV PCNSL. Newer antiviral agents with minimal drug–drug interaction may facilitate the ability to administer standard or intensive chemotherapy agents. Radiotherapy is a useful palliative treatment modality for control of symptoms or should be considered as an alternative first-line treatment modality in those patients where the risks of toxicity from high-dose intravenous agents are considered unacceptable [21].

#### 5.4 Recommendations

- We recommend that all patients with PCNSL should be started on HAART if not already on it (level of evidence 1C).
- We recommend that patients with an adequate performance status should be treated, if possible, with high-dose methotrexate-containing chemotherapy regimen (level of evidence 1D).
- We recommend that whole brain radiotherapy is a useful palliative treatment modality for control of symptoms or should be considered as an alternative first-line treatment modality in those patients where the risks of toxicity from high-dose intravenous agents are considered unacceptable (level of evidence 1C).

#### 5.5 References

- 1 Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. *Leuk Lymphoma* 2008; 49(Suppl 1): 43–51.
- 2 Kasamon YL, Ambinder RF. AIDS-related primary central nervous system lymphoma. *Hematol Oncol Clin North Am* 2005; 19: 665–687.
- 3 Bataille B, Delwail V, Menet E *et al.* Primary intracerebral malignant lymphoma: report of 248 cases. *J Neurosurg* 2000; 92: 261–266.
- 4 Baumgartner JE, Rachlin JR, Beckstead JH *et al.* Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. *J Neurosurg* 1990; 73: 206–211.
- 5 MacMahon EM, Glass JD, Hayward SD *et al.* Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. *Lancet* 1991; 338: 969–973.
- 6 Cinque P, Brytting M, Vago L *et al.* Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. *Lancet* 1993; 342: 398–401.
- 7 Fine HA, Mayer RJ. Primary central nervous system lymphoma. *Ann Intern Med* 1993; 119: 1093–1104.
- 8 Fine H, Loeffler J. Primary central nervous system lymphoma. In: Canellos G, Lister T, Skiar J, (eds). *The Lymphomas*. Philadelphia, WB Saunders; 1998: 481–494.
- 9 Jahnke K, Hummel M, Korfel A *et al.* Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. *J Clin Oncol* 2006; 24: 4754–4757.
- 10 Pels H, Schlegel U. Primary central nervous system lymphoma. *Curr Treat Options Neurol* 2006; 8: 346–357.
- 11 Abrey LE, Ben-Porat L, Panageas KS *et al.* Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. *J Clin Oncol* 2006; 24: 5711–5715.
- 12 Kuker W, Nagele T, Korfel A *et al.* Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. *J Neuro-oncol* 2005; 72: 169–177.
- 13 Bower M, Powles T, Nelson M *et al.* Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. *J Natl Cancer Inst* 2006; 98: 1088–1091.
- 14 Sabin CA. HIV viremia and the development of AIDS-related lymphoma in patients treated with highly active antiretroviral therapy. *J Infect Dis* 2009; 200: 8–10.
- 15 Ferreri AJ, Marturano E. Primary CNS lymphoma. *Best Pract Res Clin Haematol* 2012; 25: 119–130.

- 16 Jacomet C, Girard PM, Lebrette MG *et al.* Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. *AIDS* 1997; **11**: 1725–1730.
- 17 Bayraktar S, Bayraktar UD, Ramos JC *et al.* Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. *J Neuro-oncol* 2011; **101**: 257–265.
- 18 Raez L, Cabral L, Cai JP *et al.* Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. *AIDS Res Human Retroviruses* 1999; **15**: 713–719.
- 19 Hoffmann C, Tabrizian S, Wolf E *et al.* Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. *AIDS* 2001; **15**: 2119–2127.
- 20 Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. *AIDS* 2003; **17**: 178–1793.
- 21 British Neuro-Oncology Society. Guidelines on the diagnosis and management of primary CNS and intra-ocular lymphoma (PCNSL). June 2011. Available at <http://www.bnos.org.uk> (accessed December 2013).

## 6 Primary effusion lymphoma (PEL)

### 6.1 Introduction

Primary effusion lymphoma (PEL) is an unusual rare form (approximately 3%) of HIV-associated non-Hodgkin lymphoma. Patients with PEL are usually HIV-positive men and the presentation is unique in that growth in a liquid phase is observed in serous body cavities such as the pleura, peritoneum and pericardial cavities without identifiable tumour masses or lymphadenopathy. The precise diagnosis rests on demonstrating the presence of human herpes virus 8 (HHV8) in the malignant cells, which is characterized by a distinct morphological appearance and the absence of typical mature pan B and T cell immunohistochemical markers. The prognosis of HIV-related PEL remains poor with a median survival reported in one large series of 6.2 months [1].

### 6.2 Pathogenesis

The pathogenesis of PEL is linked to the presence of HHV8, which promotes tumorigenesis by enhanced proliferation and impaired apoptosis in cells with latent gene HHV8 expression. There are three latent gene products: latency-associated nuclear antigen-1 (LANA-1), viral cyclin (v-Cyc), and viral FLICE inhibitory protein (vFLIP). LANA-1 functions to tether the viral genome to the infected host cell's genome [2] and also promotes cell survival by, and transformation of, infected cells by interaction with the tumour suppressor gene P53 and retinoblastoma gene [3,4]. v-Cyc is a viral homologue of cyclin D and binds to cyclin dependent kinase 6 (cdk-6), which results in resistance to CDK inhibitors, progression through the cell cycle and uncontrollable proliferation [5]. Further proactivation of NF- $\kappa$ B pathways by vFLIP and inhibition of apoptosis by blocking Fas-mediated caspase activation contributes to cellular transformation [6]. Another herpes virus, EBV, plays an unclear role in PEL pathogenesis. Studies of EBV gene expression indicate a restricted latency pattern of expression with minimal transforming genes evident, suggesting a supportive role of EBV in cellular transformation [7].

### 6.3 Presentation

Patients commonly present with dyspnoea as a result of pleural or pericardial involvement or abdominal distension from peritoneal involvement. Due to poor survival with

conventional therapy, frequent causes of death are related to progressive disease, opportunistic infection or other HIV-related complications.

### 6.4 Diagnosis

The diagnosis should be suspected in patients with the unique presentation of PEL and cytological analysis of the involved effusion fluid. The definitive diagnosis rests upon the morphological, immune phenotype and virological content of the affected tumour cells. Morphologically the cells are large, have round-to-irregular nuclei and conspicuous nucleoli, and may have the appearance of immunoblasts, plasmablasts and/or anaplastic forms [8]. Detection of evidence of viral infection is a *sine qua non* to make the diagnosis, and although serological evidence of infection informs of previous infection, immunohistochemical staining for LANA-1 expression is the standard for detecting HHV8 in tumour samples. Quantitative measurements of HHV8 viral load are available but no studies have yet demonstrated correlation of viral mass with prognosis or response to therapy. The immunophenotype of PEL cells displays a 'null' lymphocyte phenotype with expression of CD45 but absence of characteristic B cell markers (CD19, CD20, CD79a) and T cell markers (CD3, CD4, CD8). The cells express activation markers (CD30, CD38, CD71, HLA DR) and plasma cell markers (CD138) [8]. The cells are of B cell origin as evidenced by the presence of immunoglobulin gene rearrangements and somatic hypermutation [9]. Cytogenetic evaluation has revealed complex karyotypes but no recurrent chromosomal abnormalities [10]. The differential diagnosis from that of another NHL subtype associated with a lymphomatous effusion is the clinical appearance without solid LN masses and the requirement for HHV8 evidence and typical immunophenotype, which should leave little room for error.

### 6.5 Prognosis and management

Due to the low incidence of the disease, randomized clinical trials are not feasible and as such, there is no clear standard of care established to treat PEL. Since the widespread use of highly active antiretroviral therapy the morbidity and mortality associated with HIV infection has declined and, in particular, treatment results for HIV-associated lymphoma have improved. Unfortunately the results for HIV-associated PEL remain disappointing and no specific treatment regimen is currently recommended

for PEL. There have been sporadic case reports of HAART-induced responses alone [11] and the use of HAART in any treatment regimen is recommended. In a single institution study [12], which included 11 cases of PEL, treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) resulted in an overall response rate of 42% and median survival of 6 months despite standard concomitant HAART. In a further study by Boulanger [1] of 28 patients with PEL, prognostic factors identified at the time of diagnosis by multivariate analysis identified two factors indicative of poor clinical outcome: poor performance status; and the absence of HAART before PEL diagnosis. Only rare cases of CHOP-induced remission have been reported in patients simultaneously treated with HAART [13,14]. The induction of NF- $\kappa$ B in PEL cell lines has led to the investigation of proteasome inhibition in NF- $\kappa$ B-driven haematological malignancies. Bortezomib has recently been approved for the use in multiple myeloma and would seem an attractive therapy for PEL because of its intrinsic biology. Further antiviral approaches have been tried and in one patient the combination of interferon-alpha and AZT has been used with success [15]. Current clinical trials by the NCI utilize a combination approach with antivirals, bortezomib and systemic chemotherapy. Further approaches include targeting latency phase genes such as LANA-1 using siRNAs to silence viral regulatory proteins and augmentation of host immunity against HHV8.

## 6.6 Recommendations

- We suggest that first-line treatment of PEL in HIV-infected individuals includes CHOP-like regimens. No comparative studies have been performed and there is no optimal gold-standard therapy (level of evidence 2C).
- Patients, where possible, should be entered into clinical trials that are testing novel targeted approaches (GPP).
- We recommend that chemotherapy regimens should be combined with HAART (level of evidence 1C).

## 6.7 References

- 1 Boulanger E, Gerard L, Gabarre J *et al*. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. *J Clin Oncol* 2005; 23: 4372–4380.
- 2 Cotter MA 2nd, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. *Virology* 1999; 264: 254–264.
- 3 Friborg J Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. *Nature* 1999; 402: 889–894.
- 4 Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. *Nat Med* 2000; 6: 1121–1127.
- 5 Swanton C, Mann DJ, Fleckenstein B *et al*. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. *Nature* 1997; 390: 184–187.
- 6 Matta H, Chaudhary PM. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). *Proc Natl Acad Sci U S A* 2004; 101: 9399–9404.
- 7 Horenstein MG, Nador RG, Chadburn A *et al*. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. *Blood* 1997; 90: 1186–1191.
- 8 Nador RG, Cesarman E, Chadburn A *et al*. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. *Blood* 1996; 88: 645–656.
- 9 Karcher DS, Alkan S. Human herpesvirus-8-associated body cavity-based lymphoma in human immunodeficiency virus-infected patients: a unique B-cell neoplasm. *Human Pathol* 1997; 28: 801–808.
- 10 Boulanger E, Agbalika F, Maarek O *et al*. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. *Haematol J* 2001; 2: 172–179.
- 11 Oksenhendler E, Clauvel JP, Jouvesshomme S *et al*. Complete remission of a primary effusion lymphoma with antiretroviral therapy. *Am J Hematol* 1998; 57: 266.
- 12 Simonelli C, Spina M, Cinelli R *et al*. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. *J Clin Oncol* 2003; 21: 3948–3954.
- 13 Valencia ME, Martinez P, Moreno V *et al*. AIDS-related body cavity-based lymphomas, herpesvirus-8 and HIV infection: a study of seven cases. *AIDS* 1999; 13: 2603–2605.
- 14 Ascoli V, Signoretti S, Onetti-Muda A *et al*. Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. *J Pathol* 2001; 193: 200–209.
- 15 Toomey NL, Deyev VV, Wood C *et al*. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. *Oncogene* 2001; 20: 7029–7040.



## 7 Plasmablastic lymphoma

### 7.1 Introduction

Plasmablastic lymphoma accounts for 2.6% of all HIV-related lymphomas [1]. In the original report, 15 of the 16 cases were HIV infected and had involvement of the oral cavity [2]. The disease can also occur in the non-HIV population, particularly in those with immunosuppression. There are three recognized subtypes of plasmablastic lymphoma. The first is the usually found in the oral mucosa and contains a monomorphic population of plasmablasts with minimal plasmacytic differentiation. The second type tends to have more plasmacytic differentiation and is usually extraoral. The third type is plasmablastic lymphoma associated with Castleman's disease and is typically nodal or splenic. In the WHO classification [3], the tumour is a subtype of diffuse large B cell lymphoma (DLBCL). The majority of patients with PBL are men, particularly in the HIV population, with a mean age of presentation of 39 years.

### 7.2 Morphology

These tumours need to be distinguished from the immunoblastic variant of DLBCL and body and extracavity variants of primary effusion lymphoma (PEL), Burkitt lymphoma (BL) with plasmacytoid differentiation, and extramedullary plasmablastic secondary multiple myeloma. Advances in immunophenotyping have facilitated these distinctions based on the low or absent expression of leukocyte common antigen (CD45) or the B cell markers CD20, CD79a, and PAX5. The plasma cell markers VS38c, CD38, multiple myeloma oncogene-1 (mum-1) and CD138 (syndecan-1) are almost always expressed [4]. The tumour cells are nearly always Epstein-Barr virus positive and this may be demonstrated in their three latent forms by the use of fluorescent or chromogenic *in situ* hybridization and may be useful in distinguishing it from plasmablastic multiple myeloma.

### 7.3 Pathogenesis

Based on immunohistochemical, molecular and genetic studies, PBL is thought to derive from post-germinal centre terminally differentiated activated B cells. These cells have undergone class switching and somatic hypermutation. A recent study has demonstrated chromosomal rearrangements involving the cMyC oncogene and the immunoglobulin gene [5].

### 7.4 Clinical presentation

The disease is unique for its predilection for arising in the oral cavity of HIV-positive individuals. Extraoral involvement may occur, with the most commonly affected sites being the gastrointestinal tract, lymph nodes and skin. Many (60%) patients present with advanced disease. In a series of 131 cases, affected patients had a median CD4 cell count of 173 cells/ $\mu$ L with presentation on average 5 years after the initial diagnosis of HIV. Interestingly most patients (>95%) presented with either stage I or IV disease.

### 7.5 Treatment

In the pre-HAART era prognosis was poor with a median survival of only 5 months. The use of HAART has improved overall survival for patients and is recommended. The use of chemotherapy is important in the initial therapy of PBL and patients who do not receive chemotherapy have a dismal prognosis with median survival of only 3 months [6]. CHOP-like treatments have been the standard of care but due to the disappointing long-term survival rates, more intensive regimens have been suggested, such as hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) or CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, cytarabine). However, a recent review has not shown these higher-intensity regimens to confer an overall survival advantage [7]. Despite a good overall response rate to chemotherapy in the region of 70–80%, the median overall survival is 14 months with a 5-year overall survival of 31% [4]. PBL has a similar profile to that of nongermlinal centre DLBCL and therefore targeting biological pathways such as NF- $\kappa$ B may have benefit. A case reported in a patient started on HAART and bortezomib displayed a rapid response after 4 cycles of therapy but unfortunately the case was complicated by fatal sepsis [8]. A further case reported skin regression while on bortezomib; however, the patient then relapsed early [9]. Early case reports are encouraging and may further yield better results when combined with chemotherapy in the future.

### 7.6 Recommendation

- We recommend that patients should receive HAART with systemic anthracycline-containing chemotherapy as first-line therapy (level of evidence 1C).

## 7.7 References

- 1 Folk GS, Abbondanzo SL, Childers EL, Foss RD. Plasmablastic lymphoma: a clinicopathologic correlation. *Ann Diagn Pathol* 2006; **10**: 8–12.
- 2 Delecluse HJ, Anagnostopoulos I, Dallenbach F *et al.* Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. *Blood* 1997; **89**: 1413–1420.
- 3 Fritz A, Percy C, Jack A *et al.* (eds). International Classification of Diseases for Oncology (ICD-O). 3<sup>rd</sup> edn. WHO, Geneva; 2000.
- 4 Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. *Am J Hematol* 2008; **83**: 804–809.
- 5 Valera A, Balague O, Colomo L *et al.* IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. *Am J Surg Pathol* 2010; **34**: 1686–1694.
- 6 Castillo JJ, Winer ES, Stachurski D *et al.* Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. *Leuk Lymphoma* 2010; **51**: 2047–2053.
- 7 Castillo JJ, Winer ES, Stachurski D *et al.* Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. *Oncologist* 2010; **15**: 293–299.
- 8 Bose P, Thompson C, Gandhi D *et al.* AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. *Eur J Haematol* 2009; **82**: 490–492.
- 9 Bibas M, Grisetti S, Alba L *et al.* Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. *J Clin Oncol* 2010; **28**: e704–708.

## 8 Cervical intraepithelial neoplasia (CIN) and cervical cancer

### 8.1 Introduction

In the UK, cervical cancer is the most common cancer in women aged below 35, and the 11<sup>th</sup> most common in women overall. Worldwide, however, cervical cancer is the second most common cancer in women. In 2009, there were 2747 new diagnoses of cervical cancer in the UK, and in 2008, there were 759 recorded deaths from this disease; around 7% of deaths were in women below the age of 35 [1]. Death rates from cervical cancer in the UK fell markedly by around 70% between 1979 and 2008; much of this reduction is attributable to cervical screening.

Almost all cases of invasive cancer are associated with infection with oncogenic types of human papilloma virus (HPV), particularly HPV 16 and 18 [2]. Invasive cancer is preceded by cervical intraepithelial neoplasia (CIN), which can be detected by cervical screening; around 75% of cases of cancer are potentially preventable by screening [1]. Cervical cancer is around twice as common in women who smoke [1]. Women who smoke should be encouraged to stop smoking; effective interventions include simple opportunistic advice, individual behavioural counselling or group behaviour therapy, telephone counselling, provision of self-help materials and pharmacotherapy with nicotine replacement, varenicline and bupropion [3].

The incidence of some HIV-associated cancers, including Kaposi sarcoma and non-Hodgkin lymphoma, has fallen markedly in populations who have been treated with antiretroviral therapy. In contrast, the incidence of cervical cancer has not changed significantly. There are a number of possible explanations for this observation. Firstly, the differences in rates of decline of these cancers may reflect fundamental differences in their biology and association with different viral infections (HHV8, EBV and HPV). Secondly, the increase in incidence of cervical cancer associated with HIV is much lower than the increased risk of lymphoma or Kaposi sarcoma, so that any changes in incidence of cervical cancer in the HAART era may be less evident. Finally, survival bias may mask an effect, i.e., the absence of a rise in incidence in an ageing population may in fact be evidence of an effect of antiretroviral therapy [4,5].

### 8.2 Screening for cervical cancer and pre-cancer

The UK cervical cancer screening programme has specific recommendations for screening and management of women with HIV infection [6], which are summarized in *Key recommendations* below.

Women with HIV infection are more likely to have infection with HPV 16 or 18 than women who are HIV negative [7,8]. Women with HIV infection also have a higher prevalence [9,10] and incidence [10,11] of CIN than HIV-negative women. There is some evidence that HIV-positive women are at increased risk of false-negative cytology [12], although other studies have shown that cytology performed at 2-yearly intervals is sufficiently sensitive for cervical surveillance in women with HIV [13].

### 8.3 The effect of HAART on the natural history of CIN

In contrast to the relative lack of an effect of ART on the incidence of invasive cervical cancer, there is evidence from multiple cohort studies that ART is associated with a reduction in the incidence of CIN [4,5,14–19], although this finding is not universal [20–23]. Furthermore, the incidence of CIN is increased in women with lower CD4 cell counts, while higher CD4 cell counts are associated with a reduction in incidence and progression of CIN, and an increase in regression of disease [4,5,17,19]. The clinical significance of these findings is unclear. Whilst it is plausible that earlier initiation of ART may be associated with increased regression and a decreased incidence of CIN, at present the quality of the evidence does not permit a clear recommendation for earlier treatment in women with CIN to be made.

### 8.4 Diagnosis and management of CIN

Women with HIV and abnormal cytology should be managed according to the UK national guidelines [6]. Similarly women with HIV and histologically proven CIN 2/3 lesions should be treated and followed up according to the UK national guidelines [6]. These do not mandate a specific treatment modality for CIN 2/3 although various types of excision techniques are most commonly used. In women with HIV infection, persistence and recurrence of CIN 2/3 after treatment are more common than in HIV-negative women [24–30]. Risk factors for treatment failure in HIV-positive women include CD4 cell count <200 cells/ $\mu$ L [24–26,28,31,32], higher HIV viral load [27,31], and non-use of HAART [24,26]. Compromised margins on the excisional specimen are seen frequently in women with HIV and are also a risk factor for treatment failure [24,26,27,31–33]. Few studies have looked at the relationship of surgical procedure to treatment failure in women with HIV infection, but one study found use of LLETZ (RR: 3.38, 95% CI:

1.55–7.39) compared to cold knife cone to be a risk factor [31]. No specific information is available for late adverse obstetric outcomes in women with HIV treated for CIN.

### 8.5 Diagnosis, staging, management and prognosis of cervical cancer

Women with HIV and invasive cervical cancer should be managed in the same manner as HIV-negative women according to UK national guidelines [34]. Diagnosis is based on histopathological examination of cervical biopsies, and clinical staging uses the FIGO criteria. Radiological assessment of patients with cervical carcinoma is an essential part of the staging process. In general, MRI is used for clinical staging unless there are contraindications to MRI, and PET or PET-CT may be used additionally for the detection of metastatic lymphadenopathy.

In general, surgery is used as treatment for FIGO IA1, IA2 and IB1 disease, whereas concurrent chemoradiotherapy with platinum-based chemotherapy is recommended for treatment of IB2, IIA, IIB, IIIA and IVA disease. There are very few published clinical data on women with HIV and cervical cancer, and essentially all of this is reported from the developing world. Women with HIV infection and cervical cancer present at a younger age than HIV-negative women [35,36], whereas data are conflicting on whether women with HIV present with more advanced disease [35,36]. Only one series where women were treated with chemoradiotherapy is reported from the HAART era [36]. That series showed that 90% of HIV-negative women completed radiotherapy compared to 80% of HIV-positive women, and that 75% of HIV-negative women completed  $\geq 4$  weeks of platinum-based therapy compared to 53% of HIV-positive women. However, completion rates of chemotherapy were not related to receiving HAART or not, but were associated with higher CD4 cell counts (median 416 vs. 311 cells/ $\mu$ L) [36].

### 8.6 Key recommendations

- We recommend that all women newly diagnosed with HIV should have cervical surveillance performed by, or in conjunction with, the medical team managing their HIV infection (level of evidence 1B). An initial colposcopy and annual cytology should be performed if resources permit (level of evidence 2C).
- We recommend that subsequent colposcopy for cytological abnormality should follow UK national guidelines, and the age range screened should be the same as for HIV-negative women (level of evidence 1B).
- We suggest that CIN 2/3 (HSIL) should be managed according to UK national guidelines. Lesions less severe than CIN 2 should probably not be treated according to

CIN 2/3 recommendations, as these low-grade lesions represent persistent HPV infection of the cervix rather than pre-malignancy (level of evidence 2B). Women with HIV and CIN 2/3 treated by excisional procedures have a significantly higher treatment failure rate than HIV-negative women. A number of studies show such relapse is less frequent in the presence of HAART or higher CD4 cell counts or undetectable viral load. Multidisciplinary management of such women is thus recommended (GPP).

- We recommend that women with HIV who have invasive cervical cancer should be managed in the same way as HIV-negative women according to UK national guidelines, again within a multidisciplinary team framework (level of evidence 1B).

### 8.7 References

- 1 Public Health England. NHS Cervical Cancer Screening Programme. Available at: <http://www.cancerscreening.nhs.uk/cervical/cervical-cancer-mortality.html> (accessed December 2013).
- 2 Walboomers JM, Jacobs MV, Manos MM *et al*. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999; **189**: 12–19.
- 3 National Institute for Health and Care Excellence. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. PH10. Available at: <http://www.nice.org.uk/PH10> (accessed December 2013).
- 4 Minkoff H, Zhong Y, Burk RD *et al*. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. *J Infect Dis* 2010; **201**: 681–690.
- 5 Adler DH, Kakinami L, Modisenyane T *et al*. Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. *AIDS* 2012; **26**: 1645–1652.
- 6 Public Health England. Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme. NHSCSP 20 (2nd edition). May 2010. Available at: <http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.html> (accessed December 2013).
- 7 Minkoff H, Feldman J, DeHovitz J, Landesman S, Burke R. A longitudinal study of HPV carriage in HIV infected and HIV uninfected women. *Am J Obstet Gynecol* 1988; **178**: 982–986.
- 8 Palefsky JM, Minkoff H, Kalish LA *et al*. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. *J Natl Cancer Inst* 1999; **91**: 226–236.

- 9 Wright TC, Koulas J, Schnoll F *et al.* Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors and validity of papanicolaou smears. *Obstet Gynecol* 1994; **84**: 591–597.
- 10 Six C, Heard I, Bergeron C *et al.* Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and HIV-negative women. *AIDS* 1998; **12**: 1047–1056.
- 11 Ellerbrock TV, Chiasson MA, Bush TJ *et al.* Incidence of cervical squamous intraepithelial lesions in HIV infected women. *JAMA* 2000; **283**: 1031–1037.
- 12 Maiman M, Fruchter RG, Sedlis A *et al.* Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. *Gynecol Oncol* 1998; **68**: 233–239.
- 13 Kitchener H, Nelson L, Adams J *et al.*, on behalf of the MACH-1 Group. Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. *Int J Cancer* 2007; **121**: 2484–2491.
- 14 Heard I, Schmitz V, Costagliola D, Orth G, Kazatchine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. *AIDS* 1998; **12**: 1459–1464.
- 15 Minkoff H, Ahdieh L, Massad LS *et al.* The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. *AIDS* 2001; **15**: 2157–2164.
- 16 Heard I, Tassie JM, Kazatchine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. *AIDS* 2002; **16**: 1799–1802.
- 17 Schuman P, Ohmit SE, Klein RS *et al.* Longitudinal study of cervical squamous intraepithelial lesions in Human Immunodeficiency Virus (HIV)-seropositive and at-risk HIV-seronegative women. *J Infect Dis* 2003; **188**: 128–136.
- 18 Ahdieh-Grant L, Li R, Levine AM *et al.* Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. *J Nat Cancer Inst* 2004; **96**: 1070–1076.
- 19 Omar T, Schwartz S, Hanrahan C *et al.* Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. *AIDS* 2011; **25**: 87–94.
- 20 Orlando G, Fasolo MM, Schiavini M, Signori R, Cargnel A. Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients. *AIDS* 2009; **13**: 424–425.
- 21 Lillo FB, Ferrari D, Veglia F *et al.* Human Papillomavirus infection and associated cervical disease in Human Immunodeficiency Virus-infected women: effect of highly active therapy. *J Infect Dis* 2001; **184**: 547–551.
- 22 Moore AL, Sabin CA, Madge S, Mocroft A, Reid W, Johnson MA. Highly active antiretroviral therapy and cervical intraepithelial neoplasia. *AIDS* 2002; **16**: 927–929.
- 23 Paramsothy P, Jamieson DJ, Heilig CM *et al.* The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. *Obstet Gynecol* 2009; **113**: 26–31.
- 24 Robinson WR, Hamilton CA, Michaels SH, Kissinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. *Am J Obstet Gynecol* 2001; **184**: 538–543.
- 25 Tate DR, Anderson RJ. Recrudescence of cervical dysplasia among women who are infected with the human immunodeficiency virus: a case-control analysis. *Am J Obstet Gynecol* 2002; **186**: 880–882.
- 26 Heard I, Potard V, Foulot H, Chapron C, Costagliola D, Kazatchkine MD. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. *J Acquir Immune Defic Syndr* 2005; **39**: 412–418.
- 27 Gilles C, Manigart Y, Konopnicki D, Barlow P, Rozenberg S. Management and outcome of cervical intraepithelial neoplasia lesions: a study of matched cases according to HIV status. *Gynecol Oncol* 2005; **96**: 112–118.
- 28 Massad LS, Fazzari MJ, Anastos K *et al.* Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. *J Lower Genit Tract Dis* 2007; **11**: 90–97.
- 29 Russomano F, Reis A, Camargo, MJ, Grinsztejn B, Tristao, MA. Recurrence of cervical intraepithelial neoplasia grades 2 or 3 in HIV-infected women treated by large loop excision of the transformation zone (LLETZ). *Sao Paulo Med J* 2008; **126**: 17–22.
- 30 Cetjin HE, Malapati R, Chaparala S. A comparison of loop electrosurgical excision procedures between human immunodeficiency virus-seropositive and seronegative women. *Low Genit Tract Dis* 2011; **15**: 37–41.
- 31 Reimers LL, Sotardi S, Daniel D *et al.* Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. *Gynecol Oncol* 2010; **119**: 92–97.
- 32 Kabir F, van Gelderen C, McIntyre J, Michelow P, Turton D, Adam Y. Cervical intra-epithelial neoplasia in HIV-positive women after excision of the transformation zone – does the grade change? *S Afr Med J* 2012; **102**: 757–760.
- 33 Lima MI, Tafuri A, Araújo AC, de Miranda Lima L, Melo VH. Cervical intraepithelial neoplasia recurrence after conization in HIV-positive and HIV-negative women. *Int J Gynecol Obstet* 2009; **104**: 100–104.

- 34 Scottish Intercollegiate Guidelines Network. Management of cervical cancer: a national clinical guideline. January 2008. Available at: <http://www.sign.ac.uk/pdf/sign99.pdf> (accessed December 2013).
- 35 Lomolisa P, Smith T, Guidozi F. Human immunodeficiency virus infection and invasive cervical cancer in South Africa. *Gynecol Oncol* 2000; **77**: 460–463.
- 36 Simonds HM, Wright JD, du Toit N, Neugut AI, Jacobson JS. Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa. *Cancer* **118**: 2971–2979.



## 9 Anal cancer

### 9.1 Introduction

The updated published UK guidelines for the management of sexual and reproductive health (SRH) of people living with HIV infection, produced jointly by BHIVA, BASHH and FFPRHC, includes advice on anal cancer in HIV infection (available online at [www.bhiva.org](http://www.bhiva.org)). The key points and recommendations are included below [1].

#### 9.1.1 Key recommendations of BHIVA, BASHH and FFPRHC 2008 guidelines on anal cancer in HIV

All major HIV units should develop clinical guidelines for the management of suspected anal cancer and pre-cancer. All major HIV units should develop either local clinical expertise or referral pathways for suspected anal cancer and pre-cancer. The role of annual anal cytology and anoscopy is not yet proven; however, patients should be encouraged to check and report any lumps noticed in the anal canal.

#### 9.1.2 Key recommendations of NICE 2004 guidelines on anal cancer

In addition, the management of anal cancer is included in the updated *Guidance on Cancer Services Improving Outcomes in Colorectal Cancers* published by NICE (National Institute for Health and Clinical Excellence) [2]. The recommendations make no reference to HIV but are included below.

Anal cancer is a rare disease and specific expertise is important to optimize outcomes for patients. All patients with anal cancer, including those who have undergone local excision, should therefore be referred to multidisciplinary anal cancer teams that can provide specialist management.

Patients for whom curative treatment is likely to be appropriate should have a computed tomography (CT) scan of the abdomen and pelvis or pelvic magnetic resonance imaging (MRI).

**Primary treatment:** Concurrent chemoradiotherapy, using mitomycin C, 5-fluorouracil and radiation, is appropriate for most patients. Other forms of

treatment, such as surgical excision, may be considered by anal cancer multidisciplinary teams (MDTs), but surgery is usually reserved for salvage. There are still some areas of uncertainty about optimum treatment, and eligible patients should be encouraged to participate in trials.

**Management of relapse:** All patients with suspected or confirmed relapse should be discussed by the anal cancer MDT. Those with confirmed loco-regional recurrence should undergo cross-sectional imaging and all treatment options, including surgery, should be considered by the MDT. Palliative radiotherapy, chemotherapy and palliative care should be discussed with patients who have metastatic disease or who are not sufficiently fit to undergo potentially curative treatment.

#### 9.1.3 Epidemiology

The incidence of anal cancer in people living with HIV is up to 40 times higher compared with the general population [3] and it occurs at a much younger age [4–7]. The highest risk is in HIV-positive men who have sex with men (MSM) who have an incidence of 70–100 per 100 000 person years (PY) compared with 35 per 100 000 PY in HIV-negative MSM [8]. Recent studies confirmed the high incidence in HIV-positive MSM, other HIV-positive men and in HIV-positive women [9,10]. Importantly, the incidence of anal cancer appears to have risen with the widespread use of HAART [7,9,11–17] and this may relate to the longer survival of people living with HIV allowing time for the progression from HPV infection through the phases of anal dysplasia to invasive anal cancer.

It is believed that the pathogenesis of invasive anal cancer resembles that of cervical cancer with human papilloma virus (HPV) infection leading to anal intraepithelial neoplasia (AIN) and ensuing progression from low- to high-grade dysplasia and subsequently, invasive cancer [4,18–20]. This pathogenetic model suggests a role for anal screening by a combination of cytology and high-resolution anoscopy followed by local ablative therapy of AIN. However, as noted in the 2008 BHIVA, BASHH and FFPRHC guidelines, the role of anal screening is not yet proven [1,20,21]. Whilst some centres have instituted screening pilots [22,23], the cost-effectiveness analyses have produced both positive and negative results [24–29].

## 9.2 Diagnosis

The presentation of anal cancer can vary from rectal bleeding and anal pain to features of incontinence if the anal sphincters are affected, with some patients being asymptomatic [4]. Many comparative series have shown that people living with HIV who develop anal cancer are younger than HIV-negative individuals with anal cancer [5,30–36]. However, most comparisons suggest that there is no difference in tumour stage at presentation [5,30–39]. Since the prognosis of early stage anal cancer is better and late presentation may occur if anal symptoms are erroneously attributed to warts and haemorrhoids, we recommend the examination under anaesthetic (EUA) of the anal canal and rectum with biopsy in all suspected cases (level of evidence 1D).

## 9.3 Staging

We recommend that staging for anal cancer following EUA and biopsy includes computerized tomography (CT) of the chest, abdomen and pelvis and MRI of the pelvis in order to assess regional lymph nodes and tumour extension [2] (level of evidence 1B). The American Joint Committee on Cancer (AJCC) TNM (tumour, node and metastasis) staging is used for anal cancer (Table 9.1) [40]. The stages are also grouped as 0–IV as shown below. Positron emission tomography (PET) imaging with <sup>18</sup>F-fluorodeoxyglucose may have a greater accuracy in identifying inguinal nodal involvement by anal cancer and has been used in HIV-positive patients with anal cancer but is not currently recommended as routine staging because experience is limited and false-positive rates are higher in people living with HIV [41–46]. Where doubt exists, lymph-node sampling under radiological control is the optimal approach. Although squamous cell carcinoma antigen (SCC) is a tumour marker expressed by anal cancers, its use in the diagnosis and follow-up of anal cancer is yet to be established [45].

## Stage grouping

The TNM descriptions can be grouped together into a set of stages, from Stage 0 to Stage IV as shown below:

**Stage 0:** Tis, N0, M0: Stage 0: carcinoma *in situ*

**Stage I:** T1, N0, M0: tumour <2 cm in size

**Stage II:** T2 or 3, N0, M0: tumour >2 cm in size

**Stage IIIA:** (T1–3, N1, M0) or (T4, N0, M0): any size and either has spread to the lymph nodes around the rectum (N1), or has grown into nearby organs (T4), such as the vagina or the bladder, without spreading to nearby lymph nodes

**Stage IIIB:** (T4, N1, M0), or (any T, N2–3, M0): the cancer has grown into nearby organs, such as the vagina or the bladder, and has also spread to lymph nodes around the rectum, or has spread to lymph nodes in the groin, with or without spread to lymph nodes around the rectum

**Stage IV:** Any T, any N, M1: spread to distant organs or tissues

## 9.4 Management

The management of anal cancer in HIV patients requires a multidisciplinary team (MDT) approach involving oncologists, HIV physicians, surgeons, radiologists, histopathologists and palliative care specialists. In line with the 2004 NICE guidelines, we recommend that the management of HIV patients with anal cancer is in specialized centres where there is MDT experience in order to ensure optimal outcomes [2] (level of evidence 1C). We suggest that centres caring for these patients should be able to provide high-resolution anoscopy services (level of evidence 2D).

**Table 9.1** TNM staging for anal cancer

Primary tumour (T)	Regional lymph nodes (N)	Distant metastasis (M)
Tx Primary tumour cannot be assessed	Nx Regional lymph nodes cannot be assessed	Mx Distant metastasis cannot be assessed
T0 No evidence of primary tumour	N0 No regional lymph node metastasis	M0 No distant metastasis
Tis Carcinoma <i>in situ</i>	N1 Metastasis in perirectal lymph node(s)	M1 Distant metastasis
T1 Tumour 2 cm or less	N2 Metastasis in unilateral iliac or inguinal lymph node(s)	
T2 Tumour >2 cm but <5 cm in greatest dimension	N3 Metastasis in perirectal and inguinal lymph nodes, bilateral internal iliac or inguinal lymph nodes	
T3 Tumour >5 cm in greatest dimension		
T4 Tumour of any size invading adjacent organs e.g., vagina, bladder		

#### 9.4.1 First-line treatment for anal cancer

The first line of treatment for anal cancer is concurrent chemoradiotherapy (CRT), which has been shown to achieve local control and sphincter preservation. Randomized controlled studies have established the superiority of CRT with 5-fluorouracil and mitomycin C and no other CRT regimen has been shown to be superior [47–51] (level of evidence 1A). There is consensus now that this CRT regimen can be safely used for HIV patients and that outcomes are similar [30–35,37–39,52–54]. CRT generally has involved 5-fluorouracil and mitomycin C chemotherapy and concomitant radical radiotherapy to the pelvis (38–51 Gy in 20–30 fractions), with most patients receiving a perineal boost (10–18 Gy). Intensity-modulated radiation therapy (IMRT) has recently been used to achieve high doses of radiation with minimal impact to surrounding tissue so as to reduce the toxicity. This has been evaluated in anal cancer patients including HIV patients with decreased dermatological and gastrointestinal toxicity with good tolerance, and may become the standard of care in CRT for anal cancer [55–58].

#### 9.4.2 Benefit of adding antiretrovirals to anal cancer treatment

The most common grade 3–4 toxicities of CRT are haematological, gastrointestinal and skin and some series have found that these are more common in patients with lower CD4 cell counts [59–61] although this is not a universal finding [39,52]. Whilst HAART has not reduced the incidence of anal cancer, the toxicity of CRT with HAART in more recent series appears to have diminished somewhat [33,35,39,52,62–64]. Moreover, there has been a significant improvement in the overall survival from anal cancer diagnosis since the introduction of HAART; the 5-year overall survival has risen from 38% in the pre-HAART era to 68% in modern times [52]. In addition, CRT is associated with a significant and prolonged decline in CD4 cell count even when concomitant HAART is prescribed [52,63]. On account of the apparent reduction in treatment-related toxicity and the decline in CD4 cell count, we recommend that all people living with HIV who are to be treated with CRT should start HAART (level of evidence 1C) and opportunistic infection prophylaxis (level of evidence 1D).

#### 9.4.3 Best treatment of relapse of anal cancer

All patients with confirmed or suspected recurrence should be discussed in the MDT meeting. In the general population, 22–25% of patients with anal cancer develop persisting residual primary disease or loco-regional recurrence following CRT [47,65]. Both residual primary disease and

local recurrence after CRT are usually managed by salvage surgery, involving abdominoperineal excision of rectum and anal canal (APR) with a pedicle flap to assist perineal healing and the formation of a colostomy [66]. An APR may involve reconstruction surgery in conjunction with plastic surgeons for a muscle flap. The morbidity of APR can be considerable and prolonged, with delayed wound healing or dehiscence of the perineal wound [67]. Survival at 5 years following salvage surgery varies greatly between series, ranging from 29% to 61% [66,68–71]. Salvage surgery may be appropriate for people living with HIV who experience loco-regional disease persistence or relapse following CRT (level of evidence 2D), although experience in this population is limited [67]. In one series of salvage surgery, HIV-seropositive status was not associated with poorer outcome [68] although delayed healing was reported in another series [72].

Patients with metastatic disease or local relapse following salvage surgery may be considered for palliative chemotherapy; however, responses are rarely complete and usually of short duration [45], so best supportive care may be more appropriate (level of evidence 2D).

#### 9.4.4 Best response evaluation and follow-up in anal cancer

Response to CRT should be assessed at 6–8 weeks after completion of CRT. Clinical evaluation, MRI imaging of the pelvis and EUA is usually performed. Earlier evaluation may underestimate response rates and indeed in the ACT II trial (which excluded people living with HIV), 29% of patients who had not achieved a complete response (CR) at 11 weeks after CRT subsequently achieved CR at 26 weeks [73]. Hence residual disease should be confirmed histologically. Follow-up protocols for the general population suggest clinical evaluation and review every 3–6 months for 2 years and every 6–12 months up to 5 years [45]. We suggest a similar approach in people living with HIV (level of evidence 2D) and advocate surveillance for AIN by high-resolution anoscopy (HRA) (level of evidence 2D).

### 9.5 Summary of guidance

- We recommend the examination under anaesthetic (EUA) of the anal canal and rectum with biopsy in all suspected cases (level of evidence 1D).
- We recommend that staging for anal cancer following EUA and biopsy includes computerized tomography (CT) of the chest, abdomen and pelvis and MRI of the pelvis in order to assess regional lymph nodes and tumour extension [2] (level of evidence 1B).
- We recommend that the management of HIV patients with anal cancer is in specialized centres where there is

MDT experience in order to ensure optimal outcomes [2] (level of evidence 1C).

- We suggest that centres caring for these patients should be able to provide high-resolution anoscopy (HRA) services (level of evidence 2D).
- We recommend CRT with 5-fluorouracil and mitomycin C (level of evidence 1A).
- We recommend that all people living with HIV who are to be treated with CRT should start HAART (level of evidence 1C) and opportunistic infection prophylaxis (level of evidence 1D).
- We suggest that salvage surgery may be appropriate for people living with HIV who experience loco-regional disease persistence or relapse following CRT (level of evidence 2D).
- We suggest that best supportive care may be more appropriate for patients with metastatic disease or local relapse following salvage surgery (level of evidence 2D). We suggest a similar approach in people living with HIV (level of evidence 2D) and advocate surveillance for AIN by HRA (level of evidence 2D).

## 9.6 References

- 1 Fakoya A, Lamba H, Mackie N *et al*. British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. *HIV Med* 2008; **9**: 681–720.
- 2 National Institute for Clinical Care and Excellence. Improving Outcomes in Colorectal Cancers. Cancer service guidance CSGCC. June 2004. Available at: <http://www.nice.org.uk/CSGCC> (accessed December 2013).
- 3 Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 1940–1989. *Am J Epidemiol* 1994; **139**: 772–780.
- 4 Clark MA, Hartley A, Geh JI. Cancer of the anal canal. *Lancet Oncol* 2004; **5**: 149–157.
- 5 Kim JH, Sarani B, Orkin BA *et al*. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. *Dis Colon Rectum* 2001; **44**: 1496–1502.
- 6 Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. *J Clin Oncol* 2008; **26**: 474–479.
- 7 Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. *Ann Intern Med* 2010; **153**: 452–460.
- 8 Kreuter A, Potthoff A, Brockmeyer NH *et al*. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. *Br J Dermatol* 2010; **162**: 1269–1277.
- 9 Piketty C, Selinger-Leneman H, Bouvier AM *et al*. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French Hospital Database on HIV. *J Clin Oncol* 2012; **30**: 4360–4366.
- 10 Silverberg MJ, Lau B, Justice AC *et al*. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. *Clin Infect Dis* 2012; **54**: 1026–1034.
- 11 Bower M, Powles T, Newsom-Davis T *et al*. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? *J Acquir Immune Defic Syndr* 2004; **37**: 1563–1565.
- 12 Clifford GM, Polesel J, Rickenbach M *et al*. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. *J Natl Cancer Inst* 2005; **97**: 425–432.
- 13 Diamond C, Taylor TH, Aboumrad T *et al*. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. *Sex Transm Dis* 2005; **32**: 314–320.
- 14 Engels EA, Pfeiffer RM, Goedert JJ *et al*. Trends in cancer risk among people with AIDS in the United States 1980–2002. *AIDS* 2006; **20**: 1645–1654.
- 15 Piketty C, Selinger-Leneman H, Grabar S *et al*. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. *AIDS* 2008; **22**: 1203–1211.
- 16 Franceschi S, Lise M, Clifford GM *et al*. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. *Br J Cancer* 2010; **103**: 416–422.
- 17 Crum-Cianflone NF, Hullsiek KH, Marconi VC *et al*. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. *AIDS* 2010; **24**: 535–543.
- 18 Beckmann AM, Daling JR, Sherman KJ *et al*. Human papillomavirus infection and anal cancer. *Int J Cancer* 1989; **43**: 1042–1049.
- 19 Palefsky JM. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. *J Acquir Immune Defic Syndr* 1999; **21**(Suppl 1): S42–48.
- 20 Machalek DA, Poynten M, Jin F *et al*. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. *Lancet Oncol* 2012; **13**: 487–500.
- 21 Health Quality Ontario. Anal dysplasia screening: an evidence-based analysis. *Ont Health Technol Assess Ser* 2007; **7**: 1–43.
- 22 Mathews C, Caperna J, Cachay ER, Cosman B. Early impact and performance characteristics of an established anal dysplasia screening program: program evaluation considerations. *Open AIDS J* 2007; **1**: 11–20.

- 23 Scott H, Khoury J, Moore BA, Weissman S. Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic. *Sex Transm Dis* 2008; **35**: 197–202.
- 24 Goldie SJ, Kuntz KM, Weinstein MC *et al*. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. *JAMA* 1999; **281**: 1822–1829.
- 25 Goldie SJ, Kuntz KM, Weinstein MC *et al*. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. *Am J Med* 2000; **108**: 634–641.
- 26 Karnon J, Jones R, Czoski-Murray C, Smith KJ. Cost-utility analysis of screening high-risk groups for anal cancer. [Erratum appears in *J Public Health (Oxf)* 2009; **31**:194]. *J Public Health (Oxf)* 2008; **30**: 293–304.
- 27 Czoski-Murray C, Karnon J, Jones R *et al*. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. *Health Technol Assess* 2010; **14**: iii–iv, ix–x, 1–101.
- 28 Lam JM, Hoch JS, Tinmouth J *et al*. Cost-effectiveness of screening for anal precancers in HIV-positive men (Structured abstract). *AIDS* 2011; **25**: 635–642.
- 29 Lazenby GB, Unal ER, Andrews AL, Simpson K. A cost-effectiveness analysis of anal cancer screening in HIV-positive women. *J Lower Genital Tract Dis* 2012; **16**: 275–280.
- 30 De Nardi P, Merlini F, Staudacher C. Outcome of anal carcinoma in HIV positive vs HIV negative patients. *Dis Colon Rectum* 2010; **53**: 626.
- 31 Fraunholz I, Rabeneck D, Gerstein J *et al*. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? *Radiother Oncol* 2011; **98**: 99–104.
- 32 Hammad N, Heilbrun LK, Gupta S *et al*. Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience. *Am J Clin Oncol* 2011; **34**: 135–139.
- 33 Hogg ME, Popowich DA, Wang EC *et al*. HIV and anal cancer outcomes: a single institution's experience. *Dis Colon Rectum* 2009; **52**: 891–897.
- 34 Linam JM, Chand RR, Broudy VC *et al*. Evaluation of the impact of HIV serostatus, tobacco smoking and CD4 counts on epidermoid anal cancer survival. *Int J STD AIDS* 2012; **23**: 77–82.
- 35 Oehler-Janne C, Huguet F, Provencher S *et al*. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. *J Clin Oncol* 2008; **26**: 2550–2557.
- 36 Munoz-Bongrand N, Poghosyan T, Zohar S *et al*. Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study. *Dis Colon Rectum* 2011; **54**: 729–735.
- 37 Abramowitz L, Mathieu N, Roudot-Thoraval F *et al*. Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. *Aliment Pharmacol Ther* 2009; **30**: 414–421.
- 38 Myerson RJ, Outlaw ED, Chang A *et al*. Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. *Int J Radiat Oncol Biol Phys* 2009; **75**: 428–435.
- 39 Seo Y, Kinsella MT, Reynolds HL *et al*. Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. *Int J Radiat Oncol Biol Phys* 2009; **75**: 143–149.
- 40 Edge S, Byrd D, Compton C *et al*. AJCC Cancer Staging Manual. 7th edn. New York: American Joint Committee on Cancer; 2010.
- 41 Cotter SE, Grigsby PW, Siegel BA *et al*. FDG-PET/CT in the evaluation of anal carcinoma. *Int J Radiat Oncol Biol Phys* 2006; **65**: 720–725.
- 42 Nguyen BD, Ram PC, Roarke MC. F-18 FDG PET/CT imaging of anal canal squamous cell carcinoma. *Clin Nuclear Med* 2007; **32**: 234–236.
- 43 Grigsby PW. FDG-PET/CT: new horizons in anal cancer. *Gastroenterol Clin Biol* 2009; **33**: 456–458.
- 44 Mistrangelo M, Pelosi E, Bello M *et al*. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer. *Int J Radiat Oncol Biol Phys* 2010; **77**: 73–78.
- 45 Glynne-Jones R, Northover JM, Cervantes A. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; **21**(Suppl 5): v87–92.
- 46 Sveistrup J, Loft A, Berthelsen AK *et al*. Positron emission tomography/computed tomography in the staging and treatment of anal cancer. *Int J Radiat Oncol Biol Phys* 2012; **83**: 134–141.
- 47 Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. *Lancet* 1996; **348**: 1049–1054.
- 48 Bartelink H, Roelofsens F, Eschwege F *et al*. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomised trial of the European Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol* 1997; **15**: 2040–2049.
- 49 Ben-Josef E, Moughan J, Ajani JA *et al*. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy



- Oncology Group trials 87-04 and 98-11. *J Clin Oncol* 2010; 28: 5061–5066.
- 50 Peiffert D, Tournier-Rangard L, Gerard JP *et al*. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. *J Clin Oncol* 2012; 30: 1941–1948.
  - 51 Chin JY, Hong TS, Ryan DP. Mitomycin in anal cancer: still the standard of care. *J Clin Oncol* 2012; 30: 4297–4301.
  - 52 Alfa-Wali M, Allen-Mersh T, Antoniou A *et al*. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. *Ann Oncol* 2012; 23: 141–147.
  - 53 Mistrangelo M, Conte ID, Cassoni P *et al*. Anal cancer: differences between HIV+ and HIV- patients. *Colorectal Dis* 2011; 13: 20.
  - 54 Takahashi T, Braghiroli MI, Souza CE *et al*. Concurrent chemoradiation as definitive treatment in anal squamous cell carcinoma – Efficacy and safety in HIV+ patients under HAART. *Eur J Cancer* 2011; 47: S448.
  - 55 Salama JK, Mell LK, Schomas DA *et al*. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. [Erratum appears in *J Clin Oncol* 2008; 26: 694]. *J Clin Oncol* 2007; 25: 4581–4586.
  - 56 DeFoe SG, Beriwal S, Jones H *et al*. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma—clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. *Clin Oncol (R Coll Radiol)* 2012; 24: 424–431.
  - 57 Azria D, Vieillot S, Lemanski C *et al*. Clinical outcome of patients treated with IMRT for locally advanced anal canal cancer. *Int J Radiat Oncol Biol Phys* 2011; 81: S377.
  - 58 Kachnic LA, Tsai HK, Coen JJ *et al*. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. *Int J Radiat Oncol Biol Phys* 2012; 82: 153–158.
  - 59 Hoffman R, Welton ML, Klencke B *et al*. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. *Int J Radiat Oncol Biol Phys* 1999; 44: 127–131.
  - 60 Peddada AV, Smith DE, Rao AR *et al*. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. *Int J Radiat Oncol Biol Phys* 1997; 37: 1101–1105.
  - 61 Place RJ, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. *Dis Colon Rectum* 2001; 44: 506–512.
  - 62 Blazy A, Hennequin C, Gornet JM *et al*. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. *Dis Colon Rectum* 2005; 48: 1176–1181.
  - 63 Wexler A, Berson AM, Goldstone SE *et al*. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. *Dis Colon Rectum* 2008; 51: 73–81.
  - 64 Fraunholz I, Weiss C, Eberlein K *et al*. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. *Int J Radiat Oncol Biol Phys* 2010; 76: 1425–1432.
  - 65 Ajani JA, Winter KA, Gunderson LL *et al*. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA* 2008; 299: 1914–1921.
  - 66 Pocard M, Tiret E, Nugent K *et al*. Results of salvage abdominoperineal resection for anal cancer after radiotherapy. *Dis Colon Rectum* 1998; 41: 1488–1493.
  - 67 Burkholder H, Bailey H, Snyder M, Pidala M. Salvage abdominoperineal resection after failed chemoradiation for squamous-cell carcinoma of the anus. *Dis Colon Rectum* 2010; 53: 526–527.
  - 68 Eeson G, Foo M, Harrow S *et al*. Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment. *Am J Surg* 2011; 201: 628–633.
  - 69 Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. *BMJ* 2002; 324: 813.
  - 70 Akbari RP, Paty PB, Guillem JG *et al*. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. *Dis Colon Rectum* 2004; 47: 1136–1144.
  - 71 Sunesen KG, Buntzen S, Tei T *et al*. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. *Ann Surg Oncol* 2009; 16: 68–77.
  - 72 Cunin L, Alfa-Wali M, Turner J *et al*. Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals. *Ann Surg Oncol* 2013; Nov 18. [Epub ahead of print].
  - 73 Glynn-Jones R, James R, Meadows H *et al*. ACT II Study Group. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. *J Clin Oncol* 2012; 30: Abstract 4004.



## 10 Hodgkin Lymphoma (HL)

### 10.1 Introduction

Hodgkin lymphoma (HL) is one of the commonest tumours amongst the non-AIDS-defining malignancies (non-ADM) [1,2] with a 10- to 20-fold increased incidence in HIV patients in comparison with the HIV-negative population [1,3–6]. Conflicting results have been reported regarding the incidence of HL after the advent of highly active antiretroviral therapy (HAART): some authors have reported a slight increase in HL incidence [6], whereas others have not detected any difference in the incidence of HL in the pre-HAART and post-HAART eras [7,8].

HL in HIV patients tends to present more frequently in advanced stage at diagnosis, with extranodal involvement, especially bone marrow infiltration, and with a higher proportion of patients with B symptoms and poor performance status than in the general population [9–12]. From a histological point of view, HL in HIV patients is characterized by a predominance of the mixed cellularity (MC) and lymphocyte depleted (LD) subtypes, as opposed to nodular sclerosis (NS) [5,9–11,13,14], and by a higher percentage of EBV positivity [9,11].

The prognosis of HIV-HL in the pre-HAART era was considerably worse than in HIV-negative patients, with complete remission (CR) rates ranging from 44% to 65% [9,13,15,16], and median overall survival (OS) of about 18 months [9,15,16]. However, the outcome of HIV patients with HL has dramatically improved after the introduction of HAART; the CR rate, OS and disease-free survival (DFS) approach those seen in the general population [17–19].

### 10.2 Diagnosis, staging, prognostic factors

The diagnosis of HL, as that of any other lymphoid malignancy, should be based on a tissue sample biopsy, rather than on a cytological sample. Samples should be stained for CD20, CD3, CD15, CD30, BCL-2 and LMP-1 proteins.

Following the confirmation of diagnosis, patients should undergo a series of investigations (which include blood tests, whole body FDG-PET/CT scan and unilateral bone marrow biopsy) to assess the extension of the disease (see Table 10.1). Whereas a bone marrow biopsy is not necessary in all HIV-negative patients with HL, the higher proportion of bone marrow involvement in the HIV population [9,15] makes it mandatory. The above-mentioned investigations allow staging of the disease according to the Ann Arbor classification/Cotswolds modification [20] (see Table 10.2).

A prognostic score, which predicts both freedom from progression (FFP) and OS, has been defined for HIV-negative patients with advanced HL at diagnosis [21] (see Table 10.3). The applicability of the International Prognostic Score (IPS) in HIV patients was reported in a series of patients treated with Stanford V chemotherapy, in which the IPS was the only variable predictive for OS in the multivariate analysis. The IPS also predicted for FFP and CR rate [22]. Other prognostic markers that have been reported to have an impact on the outcome of HIV-HL patients include some predictive factors related to characteristics of the lymphoma, such as age, stage and responsiveness to therapy [12,23] and others associated with the

**Table 10.1** Baseline investigations in HIV-associated HL

Haematology: FBC, reticulocyte count, ESR, blood group & screen
Serum chemistry: U&E, albumin, calcium, phosphate, liver function, LDH, $\beta_2$ microglobulin, urate, CRP
Virology: HbsAg, HbsAb, HepB core, anti HCV IgG, CMV IgG
ECG
Unilateral bone marrow (BM) biopsy and aspirate
Whole body FDG-PET/CT scan
Other investigations if clinically indicated (MRI, MUGA, ECHO)

**Table 10.2** Ann Arbor classification/Cotswolds modification for staging HIV-associated HL

Stage I	Involvement of a single lymph node group or lymphoid structure
Stage II	Involvement of two or more lymph node groups on the same side of the diaphragm
Stage III	Involvement of lymph node groups on both sides of the diaphragm
Stage IV	Involvement of extranodal site(s) beyond those designated 'E'
X:	Bulky disease: >10 cm or >1/3 widening of the mediastinum at T5–6
E:	Extranodal extension contiguous or proximal to known nodal site of disease or single isolated site of extranodal disease
A/B:	Absence/presence of B symptoms (weight loss >10%, fever, drenching night sweats)

**Table 10.3** International prognostic score (IPS) Hasenclever Index for Hodgkin lymphoma (each element scores 1 and total score is sum of adverse element scores)

Male sex
Age >45 years
Stage IV
Albumin level <4 g/dL
Hb <10.5 g/dL
Lymphocyte count <8% or <0.6 x 10 <sup>9</sup> /L
Leukocyte count $\geq 15 \times 10^9$ /L

**Table 10.4** Risk factors defining treatment groups

Treatment group	EORTC/GELA	GHSG
Limited stage ('Early')	CS I-II without risk factors (supra-diaphragmatic)	CS I-II without risk factors
Intermediate stage ('Early unfavourable')	CS I-II with $\geq 1$ risk factors (supra-diaphragmatic)	CS I, CS IIA with $\geq 1$ risk factor; CS IIB with risk factors C/D but no A/B
Advanced stage	CS III-IV	CS IIB with risk factors A/B; CS III-IV
Risk factors	EORTC/GELA	GHSG
	(A) large mediastinal mass	(A) large mediastinal mass
	(B) age $\geq 50$ years	(B) extranodal disease
	(C) elevated ESR	(C) elevated ESR
	(D) $\geq 4$ nodal areas	(D) $\geq 3$ nodal areas

EORTC/GELA, European Organization for Research and Treatment of Cancer/Group d'Etude des Lymphomes de l'adult; GHSG, German Hodgkin Study Group.

HIV infection and/or its treatment [12,16,23–25]. Histological subtypes have been associated with prognosis in the HIV population in some studies [24] but not in others [23].

### 10.3 Do antiretrovirals reduce the risk of HL?

Despite the reduction in the incidence of ADMs since the advent of HAART, several large cohort studies have shown no fall in incidence rates of HL pre- and post-HAART [26–28], with some studies even showing increased incidence rates of HL immediately post HAART initiation [29]. The relationship between the incidence of HL and CD4 cell counts is complex. HL occurs most commonly at CD4 cell counts below 200 cells/ $\mu$ L [17,30]. However, there is ongoing risk of developing HL while on HAART despite an adequate CD4 cell count [26–28,30,31]. Furthermore, HL incidence rates are actually higher in the first few months after starting HAART [30–32]. Several cohort studies have also shown that drops in the CD4 cell count or CD4:CD8 ratio in the year prior to HL diagnosis may herald the advent of disease [27,28]. In contrast, viral load has not been shown to relate to incidence rates [26,30,31].

### 10.4 What is the best treatment for HL?

No randomized studies have addressed the question of the best chemotherapy regimen for patients with HL and HIV infection. The available data, especially in the pre-HAART era, are derived mainly from nonrandomized studies or case series. There has been a growing tendency, since the advent of HAART, to treat patients with HIV and lymphoma with the same chemotherapy protocols used in the general population. Hence the recommendations on the treatment of HIV-HL are based on data extrapolated from studies performed in immunocompetent patients. Nevertheless, a significant difference in the management of HIV-positive patients with HL is that risk-adapted strategies are

**Table 10.5** CR/CRu, EFS, DFS and OS in patients treated with ABVD according to their serological status [17]

End-point	HIV-negative (n = 131)	HIV-positive (n = 93)
CR/CRu	79%	74%
5-year EFS	66%	59%
5-year DFS	85%	87%
5-year OS	88%	81%

CR/CRu, complete response/complete response uncertain; EFS, event-free survival; DFS, disease-free survival; OS, overall survival.

less commonly used. This is due to the smaller proportion of patients with good-risk disease in HIV-positive patients and the perceived higher risk because of HIV infection.

ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) remains, in most parts of the world, the standard chemotherapy regimen for patients with HL. The number of cycles and the addition of radiotherapy (RT) depend on the stage and risk factors of the disease (see Tables 10.4 and 10.5). Thus, in patients with early favourable stage HL, a short course of chemotherapy followed by involved-field (IF) RT is considered standard [33]. Recently, the German Hodgkin Study Group (GHSG) demonstrated in the randomized HD10 trial that ABVD x2 + 20 Gy IF-RT results in a comparable freedom from treatment-failure (FFTF) and overall survival (OS) to ABVD x4 + 30 Gy, and with less toxicity [34]. The results of the RAPID trial, only presented in abstract form, suggest that in patients with early-stage HL (defined as stage IA–IIA without bulky mediastinal disease, although bulky disease in other areas was allowed) with a negative FDG-PET after 3 cycles of ABVD, the addition of RT does not improve the outcome [35].

A recently published study reported on a small subgroup of HIV seropositive patients with early favourable stage HL who were treated according to a prospective stage- and

risk-adapted strategy. Patients with early favourable stage HL received ABVD x2–4 + 30 Gy IFRT. The complete remission (CR)/CR uncertain (CRu) rate was 96%, with a 2-year progression-free survival (PFS) of 100% and a 2-year OS of 96% [36]. Of note, four of 23 patients in this group were ‘over-treated’ (either by receiving BEACOPP instead of ABVD or by receiving more cycles than the protocol mandated). The treatment-related mortality (TRM) in this good-risk group was 4%.

With regards to the management of early unfavourable/advanced stage patients in the general population, the introduction of more intensive chemotherapies that result in higher response rates with significantly more toxicity, such as Stanford V (mechlorethamine, doxorubicin, vinblastine, prednisone, vincristine, bleomycin and etoposide), BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) and escalated BEACOPP, has led to some controversy over the treatment of these patients. The German HD11 study for patients with early unfavourable HL demonstrated that ABVD x4 + 30 Gy resulted in a similar outcome, with less toxicity, than BEACOPP x4 + 30 Gy [37]. The UK NCRN trial randomized patients with advanced-stage HL to ABVD *versus* Stanford V and demonstrated no significant differences in terms of PFS and OS [38]. An Italian randomized study compared ABVD x6–8 with BEACOPP (4 escalated + 4 baseline) in patients with advanced-stage HL or high-risk (according to Hasenclever score) early-stage HL and showed that whereas BEACOPP resulted in a superior freedom from progression than ABVD (85% *vs.* 73%, respectively, at 7 years,  $p = 0.004$ ), this was not translated into a superior OS (7-year OS: 89% *vs.* 84%) as patients who failed ABVD could be rescued with second-line chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue (HDT-ASCR) [39]. Another randomized study, only presented in abstract form, confirms these results [40], as does a recent meta-analysis [41]. In most of the studies of advanced-stage HL, RT is given to residual masses or sites of bulky disease at diagnosis. Ongoing studies are assessing the role of FDG-PET to enable omission of the RT.

One large published series describing HIV patients treated with ABVD in the HAART era included 62 patients with advanced-stage HL and reported a CR rate of 87% with a 5-year event-free survival (EFS) and 5-year OS of 71% and 76%, respectively [42]. A recent study compared the outcome of patients with HL treated with ABVD according to their serological status and demonstrated comparable results in terms of CR/CRu, EFS, disease-free survival (DFS) and OS for patients with and without HIV infection (Table 10.2) [17]. The analysis revealed no significant difference in response rate, EFS, DFS or OS

between 93 HIV seropositive patients and 131 seronegative patients with HL, supporting the treatment of HIV-positive patients with HL with the same schedules as in HIV-negative patients. In this study, one of 93 HIV-positive patients died of neutropenic sepsis with a further patient dying of an opportunistic infection 1 year after finishing chemotherapy.

There have not been studies comparing ABVD with more intensive regimens in the setting of HIV infection, but several Phase II studies have reported on the efficacy and toxicity of intensive regimens in this population. Spina *et al.* published results on 59 patients treated with the Stanford V chemotherapy regimen with G-CSF support and concomitant HAART. One-third of the patients could not complete the 12-week treatment plan and 31% required a dose reduction, with considerable myelotoxicity and nonhaematological toxicity. CR was achieved in 81% of the patients and after a median follow-up of only 17 months, the 3-year DFS was 68% and 3-year OS 51% [43]. A multicentre pilot study reported the use of the intensive BEACOPP chemotherapy in HIV-positive patients with HL. Twelve patients were included in this study, which started in the pre-HAART era. Toxicity was considerable, with 4 of 12 discontinuing treatment, due to OI (two patients) and prolonged neutropenia (two patients). Grade 3–4 neutropenia was seen in 75% of patients, with six episodes of grade 3–4 infection. Of note, only two patients received HAART during chemotherapy, three patients received zidovudine monotherapy and G-CSF was optional, given in only 54% of the cycles; all these factors most likely contributing to the very significant toxicity reported in this study [44]. In contrast, in the above-mentioned stage-adapted study, 94% of patients received HAART during chemotherapy and G-CSF was recommended in all those receiving BEACOPP. Patients with early unfavourable HL (13% of the study population) received BEACOPP x4 or ABVD x4 + 30 Gy IF-RT, whereas those with advanced stage received BEACOPP x6–8. The CR/CRu rate was 100% and 86% for the early-unfavourable and the advanced-stage groups, respectively, and the 2-year PFS was 88% for both groups. Treatment-related mortality was 0% in the early-unfavourable group and 6% in the advanced-stage group [36].

#### 10.4.1 Recommendations

- We recommend for early-favourable HL: ABVD x2–4 + IFRT 20–30 Gy (level of evidence 1B).
- We recommend for early-unfavourable HL: ABVD x4 + IFRT 30 Gy (level of evidence 1B).
- We recommend for advanced-stage HL: ABVD x6–8 +/- RT (level of evidence 1B).

### 10.5 What is the benefit of adding ARVs to chemotherapy in HL?

Prior to HAART, the prognosis of HIV-HL was significantly worse than that of the HIV-negative population with reduced CR rates ranging from 44 to 65% [45–47] and median OS of about 18 months. Since HAART, the outcomes for patients with HIV-HL have dramatically improved with CR rates of 70–80% and EFS that are similar to the HIV-negative population [17,19]. Moreover, in recent studies, 5-year OS rates approach that of the HIV-negative population [17–19]. Higher CD4 cell counts, HL stage appropriate therapy and HAART are key factors that correlate with these improved outcomes [48].

Although HAART and ABVD can be safely co-administered [17–19], patients remain at increased risk for treatment-related toxicities [19]. Similarly, drug–drug interactions between chemotherapy and specific types of HAART may drive adverse outcomes [19,49–52]. Clinically important adverse events such as additive vinblastine-mediated neurotoxicity and neutropenia in the presence of ritonavir have been described [49,50]. Some of these adverse events, such as increased neutropenia, can cause delays in the chemotherapy schedule thereby compromising CR rates [50].

#### 10.5.1 Recommendations

- We recommend patients should receive HAART during chemotherapy (level of evidence 1A).
- We recommend to avoid PI/ritonavir-boosted regimens (level of evidence 1D).

### 10.6 What is the benefit of adding rituximab to chemotherapy in HL?

Once again the addition of rituximab to ABVD chemotherapy has been explored mostly in the setting of immunocompetent patients, with no studies in people living with HIV. Rituximab has demonstrated single-agent activity in HL, in spite of the fact that only 20–30% of classical HL expresses CD20. The depletion of reactive B-lymphocytes from the inflammatory background and the killing of clonotypic circulating B-cells have been hypothesized to explain rituximab activity in classical HL. A few Phase II studies in HIV-negative patients have demonstrated the safety of the combination of rituximab with ABVD and its efficacy (CR/CRu rates: 81–93%; 3–5 year EFS: 83% and 5-year OS: 96%). These results are still very preliminary and several randomized studies are comparing chemotherapy (ABVD or BEACOPP) with and without rituximab.

### 10.7 What is the best treatment in second line for HL?

The standard strategy in good performance status immunocompetent patients with relapsed/refractory HL consists of inducing a response with salvage chemotherapy and consolidating it with high-dose therapy with autologous stem cell rescue (HDT/ASCR). This is based on two old randomized studies demonstrating the superiority of HDT/ASCR over only chemotherapy [53,54]. However, no randomized studies have compared different salvage regimens, and a number of Phase II studies support the use of different regimens, with no evidence of superiority of one over the others. The most commonly used regimens are ESHAP, DHAP, MINE, IGEV, GEM-P.

No series has been published specifically on the treatment of relapsed/refractory HL in HIV patients. Thus recommendations are based on small studies of HDT/ASCR. As in the general population, the salvage protocols used vary and include ABVD, MOPP, CMOPP-ABV, MOPP/ABV, COPP-ABV, BEACOPP, vinorelbine, ESHAP, MINE, ifosfamide-VP16, ifosfamide-VP16-mitoxantrone and RT [25,55–57].

Several retrospective and prospective small pilot studies have demonstrated the feasibility of HDT/ASCR in patients with HIV and lymphoma [56,58], leading to the design of multicentre prospective studies aiming at confirming these results. Thus, the AIDS Malignancy Consortium Study 020 included 27 HIV patients with relapsed lymphoma, of whom 20 (5 with HL) received HDT/ASCR with dose-reduced busulfan-cyclophosphamide as the conditioning regimen [59]. There were only six episodes of febrile neutropenia and one treatment-related death due to veno-occlusive disease. CMV infection was demonstrated in four patients. Another prospective study by the Italian Cooperative Group on AIDS and Tumours (GICAT) recruited 50 patients [58]. Only 27 (including eight HL) patients actually received HDT/ASCR with no treatment-related deaths or associated infections. Four-year PFS and OS for the entire population was 49% and 50%, respectively, whereas it was 76% and 75% for those who actually received HDT/ASCR. A large retrospective registry matched-cohort study has demonstrated that the outcomes of patients with HIV infection who receive HDT/ASCR for relapsed/refractory lymphoma are comparable to those seen in HIV-negative patients [60]. At 30 months, the PFS and OS for HIV-positive patients were 61% and 61.5%, respectively, whereas the corresponding figures for the control population were 56% and 70%, respectively ( $p = \text{NS}$  both for PFS and for OS).

The management options for relapsed HL in patients who are unfit for high-dose chemotherapy are limited, but

one option used in HIV-negative individuals is the immunoconjugate brentuximab.

#### 10.7.1 Recommendation

- We recommend that fit patients with relapsed/refractory HL should receive salvage chemotherapy and, if the disease proves to be chemosensitive, consolidate the response with HDT/ASCR (level of evidence 1B).

### 10.8 What is the benefit of adding opportunistic infection prophylaxis in HL?

While there is no direct evidence to support opportunistic prophylaxis specifically in HL, prophylaxis is nevertheless recommended for PCP, MAI and fungal infections as in other HIV-related lymphomas [61].

#### 10.8.1 Recommendation

- We recommend PCP, MAI and fungal infection prophylaxis (level of evidence 1D).

### 10.9 What is the best response evaluation and follow-up in HL?

No specific response criteria for HL in patients living with HIV have been described, so the response criteria defined for the general population should be used [62,63]. These guidelines were initially developed for patients with non-Hodgkin lymphoma (NHL) and were subsequently reviewed and modified to include HL, amongst other modifications. One of the important modifications is the recommendation for FDG-PET scanning both at baseline and for the assessment of response in HL. Interpretation of FDG-PET in patients with HIV infection should be made with caution as increased FDG uptake is detected in those with unsuppressed HIV viral loads [64,65]. However, in the absence of specific data on the applicability of FDG-PET scanning in HIV-positive patients with HL, the same investigations and response criteria used in HIV-negative patients should be followed. Thus, assessment after treatment should include an FDG-PET scan and a BM biopsy if the BM was involved at diagnosis. These investigations should be performed at least 4–6 weeks after the last cycle of chemotherapy.

Regarding follow-up, several (empirically defined) schedules have been recommended for patients in CR, from 2 to 4 months for the first 2 years and from 3 to 6 months for the subsequent 3 years [33,66]. Investigations at follow-up should include medical history, physical examination and blood tests. No further surveillance investigations are recommended for patients in CR [67]. Patients who have received RT should have thyroid function tests

checked regularly and female patients treated with Mantle RT should have surveillance mammography [33,66].

#### 10.9.1 Recommendations

- We recommend assessment of response after treatment should be performed by FDG-PET scan and BM biopsy (level of evidence 1D).
- We recommend assessment during follow-up should be performed every 2–4 months during the first 2 years and every 3–6 months for 3 further years (level of evidence 1D).
- People living with HIV and Hodgkin lymphoma who require blood products should receive irradiated products in line with the national guidelines, as should patients who are candidates for stem-cell transplantation (GPP).

### 10.10 References

- 1 Grulich A, Li Y, McDonald A *et al.* Rates of non-AIDS defining cancers in people with HIV infection before and after AIDS diagnosis. *AIDS* 2002; **16**: 1155–1161.
- 2 Burgi A, Brodine S, Wegner S *et al.* Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. *Cancer* 2005; **104**: 1505–1511.
- 3 Petrukevitch A, Del Amo J, Phillips AN *et al.* Risk of cancer in patients with HIV disease. London African HIV/AIDS Study Group. *Int J STD AIDS* 1999; **10**: 38–42.
- 4 Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. *JAMA* 2001; **285**: 1736–1745.
- 5 Dal Maso L, Franceschi S, Polesel J *et al.* Risk of cancer in persons with AIDS in Italy, 1985–1998. *Br J Cancer* 2003; **89**: 94–100.
- 6 Herida M, Mary-Krause M, Kaphan R *et al.* Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. *J Clin Oncol* 2003; **21**: 3447–3453.
- 7 International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. *J Natl Cancer Inst* 2000; **92**: 1823–1830.
- 8 Bedimo R, Chen RY, Accortt NA *et al.* Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989–2002. *Clin Infect Dis* 2004; **39**: 1380–1384.
- 9 Tirelli U, Errante D, Dolcetti R *et al.* Hodgkin's disease and HIV infection: clinicopathologic and virologic features of 114 patients from the Italian cooperative group on AIDS and tumors. *J Clin Oncol* 1995; **13**: 1758–1767.



- 10 Re A, Casari S, Cattaneo C *et al.* Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. *Cancer* 2001; **92**: 2739–2745.
- 11 Glaser SL, Clarke CA, Gulley ML *et al.* Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998. *Cancer* 2003; **98**: 300–309.
- 12 Hoffmann C, Chow KU, Wolf E *et al.* Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. *Br J Haematol* 2004; **125**: 455–462.
- 13 Errante D, Zagonel V, Vaccher E *et al.* Hodgkin's disease in patients with HIV infection and in the general population: comparison of clinicopathological features and survival. *Ann Oncol* 1994; **5**(Suppl 2): 37–40.
- 14 Rapezzi D, Ugolini D, Ferraris AM *et al.* Histological subtypes of Hodgkin's disease in the setting of HIV infection. *Ann Hematol* 2001; **80**: 340–344.
- 15 Rubio R. Hodgkin's disease associated with HIV: a clinical study of 46 cases. *Cancer* 1994; **73**: 2400–2407.
- 16 Gerard L, Galicier L, Boulanger E *et al.* Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. *AIDS* 2003; **17**: 81–87.
- 17 Montoto S, Shaw K, Okosun J *et al.* HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. *J Clin Oncol* 2012; **30**: 4111–4116.
- 18 Hentrich M, Berger M, Hoffmann C *et al.* HIV-associated Hodgkin's lymphoma (HIV-HL): results of a prospective multicenter trial. *J Clin Oncol* 2010; **28**(Suppl 15): Abstract 8035.
- 19 Jacobson CA, Abramson JS. HIV-associated Hodgkin's lymphoma: prognosis and therapy in the era of cART. *Adv Hematol* 2012; **2012**: 507257.
- 20 Lister TA, Crowther D, Sutcliffe SB *et al.* Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. *J Clin Oncol* 1989; **7**: 1630–1636.
- 21 Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. *N Engl J Med* 1998; **339**: 1506–1514.
- 22 Spina M, Re A, Vaccher E *et al.* High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen. *Ann Oncol* 2003; **14**: 655–656.
- 23 Hentrich M, Maretta L, Chow KU *et al.* Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. *Ann Oncol* 2006; **17**: 914–919.
- 24 Ribera JM, Navarro JT, Oriol A *et al.* Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. *AIDS* 2002; **16**: 1973–1976.
- 25 Errante D, Gabarre J, Ridolfo AL *et al.* Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. *Ann Oncol* 1999; **10**: 189–195.
- 26 Bohlius J, Schmidlin K, Costagliola D *et al.* Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. *Antivir Ther* 2009; **14**: 1065–1074.
- 27 Clifford GM, Rickenbach M, Lise M *et al.* Hodgkin lymphoma in the Swiss HIV Cohort Study. *Blood* 2009; **113**: 5737–5742.
- 28 Dauby N, De Wit S, Delforge M *et al.* Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. *J Int AIDS Soc* 2011; **14**: 16.
- 29 Franzetti M, Adorni F, Vergani B *et al.* Incidence trends and outcome of non-aids-defining malignancies (NADM) in a cohort of HIV-infected patients during the period 1985–2008. *Infection* 2011; **39**: S30.
- 30 Lanoy E, Rosenberg PS, Fily F *et al.* HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. *Blood* 2011; **118**: 44–49.
- 31 Lanoy E, Rosenberg PS, Fily F *et al.* Risk of HIV-associated Hodgkin lymphoma during the first months after initiation of combination antiretroviral therapy. *Infect Agents Cancer* 2010; **5**(Suppl 1): A71.
- 32 Mwakigonja AR, Kaaya EE, Mgaya EM. Malignant lymphomas (ML) and HIV infection in Tanzania. *J Exp Clin Cancer Res* 2008; **27**: 9.
- 33 Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2011; **22**(Suppl 6): vi55–58.
- 34 Engert A, Plutschow A, Eich HT *et al.* Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. *N Engl J Med* 2010; **363**: 640–652.
- 35 Radford J, Barrington S, Counsell N *et al.* Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. *54<sup>th</sup> ASH Annual Meeting and Exposition*. Atlanta, GA, December 2012 [Abstract 547].
- 36 Hentrich M, Berger M, Wyen C *et al.* Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. *J Clin Oncol* 2012; **30**: 4117–4123.
- 37 Eich HT, Diehl V, Gorgen H *et al.* Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients



- with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. *J Clin Oncol* 2010; 28: 4199–4206.
- 38 Hoskin PJ, Lowry L, Horwich A *et al.* Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. *J Clin Oncol* 2009; 27: 5390–5396.
  - 39 Viviani S, Zinzani PL, Rambaldi A *et al.* ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. *N Engl J Med* 2011; 365: 203–212.
  - 40 Carde PP, Karrasch M, Fortpied C *et al.* ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. *ASCO Annual Meeting*. Chicago, IL, June 2012 [Abstract 8002].
  - 41 Bauer K, Skoetz N, Monsef I *et al.* Comparison of chemotherapy including escalated BEACOPP *versus* chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. *Cochrane Database Syst Rev* 2011; 8: CD007941.
  - 42 Xicoy B, Ribera J-M, Miralles P *et al.* Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. *Haematologica* 2007; 92: 191–198.
  - 43 Spina M, Gabarre J, Rossi G *et al.* Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. *Blood* 2002; 100: 1984–1988.
  - 44 Hartmann P, Rehwald U, Salzberger B *et al.* BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. *Ann Oncol* 2003; 14: 1562–1569.
  - 45 Shah BK, Subramaniam S, Peace D, Garcia C. HIV-associated primary bone marrow Hodgkin's lymphoma: a distinct entity? *J Clin Oncol* 2010; 28: e459–460.
  - 46 Tsimberidou AM, Sarris AH, Medeiros LJ *et al.* Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. *Leuk Lymphoma* 2001; 41: 535–544.
  - 47 Hessol NA, Pipkin S, Schwarcz S *et al.* The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. *Am J Epidemiol* 2007; 165: 1143–1153.
  - 48 Berenguer J, Miralles P, Ribera JM *et al.* Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2008; 47: 422–428.
  - 49 Cheung MC, Hicks LK, Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. *Clin Lymphoma Myeloma Leuk* 2010; 10: E22–25.
  - 50 Cingolani A, Torti L, Pinnetti C *et al.* Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. *AIDS* 2010; 24: 2408–2412.
  - 51 Mounier N, Katlama C, Costagliola D *et al.* Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. *Crit Rev Oncol Hematol* 2009; 72: 10–20.
  - 52 Rubinstein PG, Braik T, Jain S *et al.* Ritonavir based highly active retroviral therapy (HAART) correlates with early neurotoxicity when combined with ABVD treated HIV associated Hodgkin lymphoma but not non-Hodgkin lymphoma. A retrospective study. *Blood (ASH Annual Meeting Abstracts)* 2010; 116: Abstract 2807.
  - 53 Linch DC, Winfield D, Goldstone AH *et al.* Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. *Lancet* 1993; 341: 1051–1054.
  - 54 Schmitz N, Pfistner B, Sextro M *et al.* Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet* 2002; 359: 2065–2071.
  - 55 Gabarre J, Marcelin AG, Azar N *et al.* High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. *Haematologica* 2004; 89: 1100–1108.
  - 56 Serrano D, Carrion R, Balsalobre P *et al.* HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. *Exp Hematol* 2005; 33: 487–494.
  - 57 Krishnan A, Molina A, Zaia J *et al.* Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. *Blood* 2005; 105: 874–878.
  - 58 Re A, Cattaneo C, Michieli M *et al.* High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. *J Clin Oncol* 2003; 21: 4423–4427.
  - 59 Spitzer TR, Ambinder RF, Lee JY *et al.* Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. *Biol Blood Marrow Transplant* 2008; 14: 59–66.
  - 60 Diez-Martin JL, Balsalobre P, Re A *et al.* Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. *Blood* 2009; 113: 6011–6014.

- 61 Goedert JJ, Bower M. Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection. *Curr Opin Oncol* 2012; 24: 531–536.
- 62 Cheson BD, Horning SJ, Coiffier B *et al.* Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. *J Clin Oncol* 1999; 17: 1244–1253.
- 63 Cheson BD, Pfistner B, Juweid ME *et al.* Revised response criteria for malignant lymphoma. *J Clin Oncol* 2007; 25: 579–586.
- 64 Brust D, Polis M, Davey R *et al.* Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. *AIDS* 2006; 20: 495–503.
- 65 Goshen E, Davidson T, Avigdor A *et al.* PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. *Clin Nucl Med* 2008; 33: 610–614.
- 66 Brusamolino E, Bacigalupo A, Barosi G *et al.* Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. *Haematologica* 2009; 94: 550–565.
- 67 Guadagnolo BA, Punglia RS, Kuntz KM *et al.* Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. *J Clin Oncol* 2006; 24: 4116–4122.

## 11 Multicentric Castleman's disease

### 11.1 Introduction

The first description of Castleman's disease appeared as a case record of the Massachusetts General Hospital in the *New England Journal of Medicine* in 1954 [1]. Benjamin Castleman, pathologist at Massachusetts General Hospital, subsequently described 13 cases of asymptomatic localized mediastinal masses demonstrating lymph node hyperplasia resembling thymoma in 1956 [2]. Multicentric Castleman's disease (MCD) is a relatively rare lymphoproliferative disorder that classically presents with fevers, anaemia and multifocal lymphadenopathy, and is now most commonly diagnosed in individuals infected with HIV type 1.

Castleman's disease is classified into localized (LCD) and multicentric (MCD) forms. The localized form usually presents in young adults with isolated masses in the mediastinum (60–75%) or neck (20%) or less commonly with intra-abdominal masses (10%). Systemic symptoms are rare with localized Castleman's disease. In contrast, MCD is associated with multi-organ systemic features, and follows a more aggressive course. Histologically, symptomatic MCD is predominantly due to the plasma cell variant (as opposed to the asymptomatic hyaline vascular variant) characterized by large plasmablasts in the mantle zone [3].

MCD occurs in the fourth or fifth decade of life in HIV-negative people but at younger ages in those who are HIV-positive. MCD has been also been reported with HIV-2 [4] and in a non-HIV-infected paediatric patient [5]. MCD presents with generalized malaise, night sweats, rigors, fever, anorexia and weight loss. On examination, patients have widespread lymphadenopathy, often accompanied by one or more of hepatosplenomegaly, ascites, oedema and pulmonary and pericardial effusions. Laboratory investigations may reveal thrombocytopenia, anaemia, hypoalbuminaemia and hypergammaglobulinaemia. Haemophagocytic lymphohistiocytosis may also be present and confirmed by bone marrow examination [6]. Patients may also present with pancytopenia, renal or respiratory failure. Other less common complications include polyneuropathy and leptomeningeal and central nervous system (CNS) infiltration with central pontine myelinolysis [7] as well as myasthenia gravis [8]. The polyneuropathy is a chronic, inflammatory demyelinating neuropathy and may be present as part of the rare POEMS syndrome (Crow-Fukase disease) [9]. Primary effusion lymphoma (PEL), also driven by HHV8, can develop in the presence of MCD [10], demonstrating an association between these conditions,

although a definite clonal relationship has not been demonstrated. A study by Chadburn *et al.* [11] indicated that, although both PEL and MCD originate from HHV8-infected pre-terminally differentiated B cells, HIV-positive MCD arises from extrafollicular B cells, whereas PELs originate from cells that have traversed the germinal centre.

MCD is a relapsing and remitting disease and the definition of an 'attack' has recently been proposed as a combination of fever and a raised serum C-reactive protein plus three of the following symptoms: peripheral lymphadenopathy, splenomegaly, oedema, pleural effusion, ascites, cough, nasal obstruction, xerostomia, rash, central neurological symptoms, jaundice or autoimmune haemolytic anaemia [12].

There is an association between MCD and AIDS-associated Kaposi sarcoma (KS) [13]. In 1994, Chang and Moore isolated a new human gamma-2 herpesvirus from AIDS-KS lesions using differential representational analysis [14]. This virus, known as human herpesvirus 8 (HHV8) or Kaposi sarcoma herpesvirus (KSHV), was later found to be present in all cases of HIV-associated MCD [15].

The role of combination antiretroviral therapy (cART) and CD4 level in preventing the emergence of MCD, in treatment or in preventing relapse remains unclear. Powles *et al.* [16] showed that the risk of MCD was related to a nadir CD4 cell count greater than 200 cells/ $\mu$ L, older age, no previous cART and a non-Caucasian background. In one small series, seven of eight patients who were receiving cART at the time of presentation of MCD, had a median CD4 cell count of 385 (140–950) cells/ $\mu$ L [17]. Therefore MCD can present in the context of a well-preserved immune system.

Westrop *et al.* [18] suggested that the 2–4-fold higher incidence of MCD in patients of African ancestry presenting with HHV8-related malignancies might be due to the three-times higher frequency of the A299G single nucleotide polymorphism.

### 11.2 Diagnosis

The first step towards making the diagnosis of MCD in HIV infection is to consider it in those with suggestive symptoms, despite well-controlled HIV. CT scans of the neck, chest, abdomen and pelvis are useful to demonstrate lymphadenopathy, organomegaly and to direct tissue sampling [19]. The diagnosis of MCD can only be established definitively by lymph node biopsy. The characteristic features

of HIV-associated MCD are a characteristic 'onion-skin' appearance and interfollicular plasmablasts that express the HHV8 latent nuclear antigen (LANA). These plasmablasts also express high levels of  $\lambda$  light-chain restricted immunoglobulin M (IgM), but are polyclonal and do not contain somatic mutations in their IgV genes, suggesting that they arise from naïve B lymphocytes [20]. Occasionally these plasmablasts join together to form clusters or 'microlymphomas' and may progress to monoclonal plasmablastic lymphomas [3]. HHV8 is also present in the malignant cells of these plasmablastic lymphomas [20,21].

HHV8 encodes a viral homologue of interleukin-6 (vIL-6) as a lytic virokin. Only 10–15% of HHV8-positive plasmablasts in MCD express vIL6; however, the human IL-6 receptor is expressed by all HHV8-positive plasmablasts. It is hypothesized that activation of the IL-6 signaling pathway by HHV8 vIL-6 may transform naïve B cells into plasmablasts and lead to the lymphoproliferative diseases associated with this virus, including MCD. Detection of HHV8 by PCR in lymph nodes may represent latent infection but may be absent in a minority (1/10) patients with MCD [22]. The presence of HHV8 IL-6 in lymph nodes of patients with MCD and no risk factors for HIV was associated with poor survival and lack of HHV8 IL-6, with low risk for subsequent lymphoma [23]. Bacon *et al.* [24] examined bone marrow aspirates and biopsies from 13 cases of MCD (11 of the 13 were HIV positive) and 66 control cases and suggested that the presence of HHV8+ plasmablasts within lymphoid follicles and/or the interstitium of the bone marrow are helpful features for the early diagnosis of MCD.

Laboratory studies should include testing for HHV8 DNA in plasma or from peripheral blood mononuclear cells by real-time polymerase chain reaction (PCR). Preliminary studies suggest that plasma HHV8 viral load may be a usable tumour marker in HIV-associated MCD, helping in the diagnosis of MCD and in monitoring of responses to treatment and in the diagnosis of relapses [2,25]. Chilton *et al.* [26] demonstrated that HHV8 levels may become detectable up to 6 months before the onset of symptoms. Fish and Paul [27] showed that while HHV8 viral loads were significantly higher in MCD than KS, the usefulness of this observation was limited by some degree of overlap. A low HHV8 viral load (<2000 copies/mL) may be useful in excluding a diagnosis of MCD. Sayer *et al.* [28] reported that a cut-off of >1000 copies of HHV8/mL helped to discriminate between MCD and other diagnoses such as KS and lymphoma with a specificity of 94.7% and a negative-predictive value of 97.3%. Polizzotto *et al.* [29] demonstrated that in 21 patients experiencing 34 flares of inflammatory symptoms, e.g. fevers, elevated levels of HHV8 were associated with low haemoglobin, sodium and

albumin, and splenic enlargement. Stebbing *et al.* [30], showed that in 52 individuals with MCD, relapses were strongly associated with rising levels of HHV8 which predicted an attack (hazard ratio 2.9, 95% CI: 1.3–6.7).

### 11.2.1 Recommendations

- We suggest that histological confirmation requires immunocytochemical staining for HHV8 and IgM lambda (level of evidence 2B).
- We suggest that all patients should have their blood levels of HHV8 measured to support the diagnosis (level of evidence 2C).

### 11.3 Staging

Following diagnosis, patients should have a CT of neck, chest, abdomen and pelvis. It is unclear whether a bone marrow biopsy to exclude microlymphoma should be required where HLH is suspected. The role of functional imaging such as fluorodeoxyglucose positron emission tomography (FDG-PET) scans is uncertain although a small study [31], indicated that in individuals with active MCD, FDG-PET scans more frequently detected abnormal uptake than CT.

### 11.4 Prognosis

HIV-associated MCD is relatively uncommon and only recently recognized, so the incidence and prognosis are not well established. The precise effect of cART on incidence and prognosis is similarly unclear. Not only is MCD itself potentially fatal as a result of organ failure but it is also associated with an increased incidence of non-Hodgkin lymphoma (NHL). In a prospective study of 60 HIV-infected individuals with MCD, 14 patients developed HHV8-associated NHL. Three patients had classic HHV8-positive, Epstein-Barr virus (EBV)-positive primary effusion lymphoma (PEL); five were diagnosed with HHV8-positive/EBV-negative visceral large B-cell lymphoma with PEL-like phenotype; and six developed plasmablastic lymphoma/leukaemia [21]. This is a 15-fold increase in lymphoma risk above that seen in the general HIV-infected population. In another study of 61 patients [32], at diagnosis, four patients (7%) had histological evidence of coexisting lymphoma, and one developed lymphoma 2 years after treatment. The incidence of lymphoma is 28 per 1000 patient-years. The pathogenesis of these lymphomas probably differ, with the plasmablastic type driven by the expansion of plasmablastic microlymphomas seen in MCD lesions [32,33]. In contrast, the PEL and PEL-like lymphomas may be driven by the cytokine-rich environment with high

levels of IL-6 and IL-10, which are known to enhance cell growth of PEL cell lines [34].

Cattaneo *et al.* [35], in a retrospective study showed that cART did not improve the outcome in HIV-related MCD. Thirty-five patients over a 21-year period (nine pre-cART and 26 post-cART) were compared. Overall survival of the entire series was 28 months without significant differences between pre- and post-cART era. Causes of death were evaluable in 18: non-Hodgkin lymphoma (NHL) (7), MCD (6), opportunistic infections (1), liver cirrhosis (1), acute myocardial infarction (1), KS (1) and therapy-related toxicity (1). NHL and MCD were the most frequent cause of death in the post-cART era (4 and 5 of the 10 cases, respectively). The authors concluded that the prognosis of HIV-related MCD remains poor even after the advent of cART. Unlike other lymphoproliferative disorders, cART did not impact on outcome of HIV-related MCD, suggesting that MCD can 'escape' immune reconstitution. A concomitant diagnosis of NHL and uncontrolled MCD seemed to be the main reason for an unfavourable outcome, particularly in the post-cART era. New therapeutic approaches, including rituximab, should therefore aim at avoiding NHL transformation and controlling 'MCD-related cytokine storm'.

#### 11.4.1 Observations

- The risk of lymphoma in patients diagnosed with MCD is high (level of evidence 2C).
- cART does not prevent MCD (level of evidence 2D).
- A rise in plasma HHV8 level can predict relapse (level of evidence 2D).

### 11.5 Management

There are no definitive gold-standard treatments for MCD. Apart from a randomized controlled trial of valganciclovir treatment for suppression of HHV8 replication [36], the best evidence is derived from single-centre cohort studies. Follow-up is generally short.

### 11.6 Combination antiretroviral therapy (cART)

The effect of cART, chiefly in combination with cytotoxic chemotherapy, has been described in seven patients with MCD and HIV infection [37]. Six patients responded to chemotherapy, and immune reconstitution was described in five patients. However, patients continued to require long-term maintenance chemotherapy to prevent recurrence. The median survival was 48 months, longer than in the pre-cART era. Therefore, the principle that HIV should be fully controlled during and after treatment for MCD

should be adhered to in order to try to prevent relapse of MCD and other HIV-related conditions.

### 11.7 Rituximab

The use of an anti-CD20 monoclonal antibody, rituximab, routinely prescribed as therapy for B-cell lymphomas and autoimmune diseases, to target HHV8-infected plasmablasts in MCD is a novel and potentially beneficial approach to the treatment of this disease. It was initially the subject of several case reports. These patients were often pretreated with chemotherapy and follow-up was brief; nine of 11 experienced a complete response [38–44].

The efficacy and safety of rituximab in 21 consecutive patients with plasmablastic MCD have been investigated [45]. These individuals received four infusions of rituximab 375 mg/m<sup>2</sup> at weekly intervals and, of 20 evaluable patients, all achieved clinical remission with biochemical and haematological normalization, and 70% achieved a radiological response. The overall survival and disease-free survival at 2 years were 95% and 79%, respectively, and in three patients who relapsed, retreatment with rituximab was successful [46]. These data corroborate the benefit seen in the aforementioned case reports and demonstrate that rituximab therapy results in an impressive clinical, biochemical and radiological sustained response in HIV-related MCD.

In a further study of 24 patients dependent on chemotherapy for a median time of 13 months, sustained remission was achieved in 70% with this regimen of rituximab and cessation of chemotherapy at day 60 (the primary endpoint) [12]. In each of these large series, one patient died soon after rituximab administration as a result of overwhelming disease, and the main adverse event seen in these patients was reactivation of KS, which is intriguing and may have been attributable to the rapid B-cell depletion that is observed during rituximab therapy, or an immune reconstitution inflammatory syndrome to hitherto latent antigens [47]. Bower *et al.* [48] demonstrated after successful rituximab therapy, a significant reduction from baseline of the CD19 B-cell count, and reductions in the levels of the inflammatory cytokines IL-5, IL-6 and IL-10.

In the largest study to date [49], Bower *et al.* identified 61 HIV-positive patients with histologically confirmed MCD (median follow-up, 4.2 years). Since 2003, 49 patients with newly diagnosed MCD have been treated with rituximab with ( $n = 14$ ) or without ( $n = 35$ ) etoposide. With rituximab-based treatment, the overall survival was 94% (95% CI: 87–100%) at 2 years and was 90% (95% CI: 81–100%) at 5 years compared with 42% (95% CI: 14–70%) and 33% (95% CI: 6–60%) in 12 patients treated before introduction of rituximab (log-rank  $p < 0.001$ ). Four of 49



rituximab-treated patients have died; three died as a result of MCD within 10 days of diagnosis, and one died as a result of lymphoma in remission of MCD. Eight of 46 patients who achieved clinical remission suffered symptomatic, histologically confirmed MCD relapse. The median time to relapse was 2 years, and all have been successfully re-treated and are alive in remission. The 2- and 5-year progression-free survival rates for all 49 patients treated with rituximab-based therapy were 85% (95% CI: 74–95%) and 61% (95% CI: 40–82%), respectively.

Gerard *et al.* [50] compared the incidence of NHL between patients who had received rituximab or not over 4.2 years of follow-up. In the group that did not receive rituximab ( $n = 65$ ), 17 patients developed patient developed NHL (incidence, 4.2 of 1000 person-years). Based on the propensity score-matching method, a significant decrease in the incidence of NHL was observed in patients who had been treated with rituximab (hazard ratio 0.09, 95% CI: 0.01–0.70). Ten Kaposi sarcoma (KS) exacerbations and one newly diagnosed KS were observed in nine patients after rituximab therapy. Rituximab was associated with an 11-fold lower risk of developing lymphoma. KS exacerbation was the most challenging adverse event after rituximab therapy.

Data from Stebbing *et al.* [30] showing that rising levels of HHV8 predicted relapses, suggested that combination therapy including rituximab should be considered.

### 11.8 Chemotherapy

For immunocompetent patients the chemotherapy regimens for MCD are based on lymphoma schedules such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) [51]. Although there is little evidence on which to base treatment strategies in HIV-associated MCD, many centres use single-agent chemotherapy with vinblastine or etoposide to induce remission in aggressive forms of MCD. This may be followed by maintenance [52].

### 11.9 Immunotherapy (excluding rituximab)

Specific immunotherapy has also been used as treatment for MCD. Interferon-alpha (IFN- $\alpha$ ) has been administered either alone or in combination with cART or chemotherapy for patients with MCD both to induce remission and as maintenance therapy [51,53,54]. IFN- $\alpha$  used in combination with vinblastine and splenectomy contributed to the long-term remission of two of three patients [51]. In a case report a patient was initially treated with antiviral therapy and splenectomy followed by chemotherapy to induce remission and, after relapse, IFN- $\alpha$  therapy [54] led to remission for over a year. A further case report of treatment of MCD with cART and low-dose IFN- $\alpha$  alone has shown

a sustained remission of 24 months [55]. The case for steroid treatment, other than as an adjunct for chemotherapy regimens is unproven, although many practitioners advocate their use to prevent or lessen the effects of a cytokine 'storm'.

As the pathogenesis of MCD is related to HHV8 virus and its viral oncogenes, particularly vIL-6, monoclonal anti-IL-6 therapy has also been used in the treatment of MCD. Seven HIV-negative patients were treated with atlizumab, a humanized monoclonal anti-IL-6 receptor antibody in patients with either multicentric plasma cell or mixed variant Castleman's disease. They had resolution of their immediate symptoms and, by 3 months, all had reduction in lymphadenopathy and hypergammaglobulinaemia with improvement of renal function, the result of secondary amyloidosis. This remission was not sustained [56]. These studies have been expanded to a multicentre clinical trial in Japan [57] but there are no reports of the use of atlizumab in persons with HIV. In an ongoing Phase I study, neutralization of IL-6 activity by siltuximab has led to a high objective tumour response rate (52%) and clinical benefit rate (78%) in subjects with MCD with a favourable safety profile. These results have prompted a trial to definitively assess the efficacy and safety of siltuximab in combination with best supportive care (BSC) *versus* placebo + BSC which has not yet been published [58].

Recent case reports of treatment with thalidomide also showed resolution of systemic manifestations of MCD, and the patients included one with HIV [59,60]. Thalidomide is known to have a powerful anticytokine effect and inhibits tumour necrosis factor and other pro-inflammatory cytokines.

### 11.10 Anti-human herpes virus-8 therapy

As MCD has been shown to be a virally driven disease, with the presence of viral genes such as vIL-6 having an effect on pathogenesis, the effect of anti-herpesvirus therapy to reduce the KSHV viral load and alleviate disease has been examined in HHV8-associated diseases in the HIV setting. In HIV-positive patients, KS incidence was reduced when prophylactic ganciclovir or foscarnet were used to prevent cytomegalovirus (CMV) retinitis [61,62]. Furthermore, antiviral treatment, which has led to a clinical improvement, has been shown to reduce HHV8 viral load in patients with KS [63], PEL and haemophagocytic syndrome [64]. In a series of three patients treated with ganciclovir, there was a reduction in the frequency of acute symptoms of MCD for two patients treated with oral and intravenous ganciclovir [65]. For the third patient, there was resolution of pulmonary and renal failure with intravenous ganciclovir. All the patients had a reduction in HHV8 viral load with the



ganciclovir therapy, accompanying the resolution of their symptoms. However, the use of foscarnet and cidofovir antiviral therapy was ineffective in an HIV-negative MCD patient with proven HHV8 viraemia and treatment with corticosteroids in combination with chlorambucil chemotherapy was required to achieve a clinical response [66]. Furthermore, the HHV8 viral load rose in this patient with the commencement of anti-herpesvirus therapy; this may indicate that the antiviral therapy was ineffective in this case, or that, once the MCD is established, HHV8 has a less prominent role and antiviral therapy is less effective than immunotherapy or chemotherapy.

Casper *et al.* [36] randomized 26 men with HHV8 infection to receive 8 weeks of valganciclovir administered orally (900 mg once per day) or 8 weeks of placebo. After a 2-week washout period, participants in each group received the study drug they had not yet taken (either valganciclovir or placebo), for 8 additional weeks. Oral swab samples were collected daily during the study, and HHV8 and CMV DNA were quantified by real-time PCR. A total of 16 HIV-positive men and 10 HIV-negative men enrolled in, and completed the study. Of the 3439 swab samples that participants had been expected to provide, 3029 (88%) were available for analysis. HHV8 was detected on 44% of swabs collected from participants who were receiving placebo, compared with 23% of swabs collected from participants who were receiving valganciclovir (relative risk [RR] 0.54, 95% CI: 0.33–0.90;  $p = 0.02$ ). Valganciclovir reduced oropharyngeal shedding of cytomegalovirus by 80% (RR: 0.20, 95% CI: 0.08–0.48;  $p < 0.001$ ). Shedding of HHV8 and shedding of cytomegalovirus were independent. Haematological, renal, or hepatic toxicities were no more common among participants who received the active drug, compared with those who received placebo, though participants who received valganciclovir reported more days of diarrhoea. Valganciclovir administered orally once per day is well tolerated and significantly reduces the frequency and quantity of HHV8 replication.

A further study [67] compared the efficacy of valaciclovir, famciclovir and cART in reducing HHV8 oropharyngeal shedding in 6036 swabs from 58 participants. After adjusting for baseline HIV viral load and cART use, an 18% reduction in HHV8 shedding frequency was found in participants on valaciclovir and a 30% reduction on famciclovir. cART use was associated with an 89% reduction in HHV8 shedding. Neither antiviral nor antiretroviral therapy was associated with decreased HHV8 quantity. Valaciclovir and famciclovir were associated with modest but significant reductions in HHV8 oropharyngeal shedding frequency. In contrast, HAART was a potent inhibitor of HHV8 replication.

A novel therapeutic approach using zidovudine and valganciclovir to affect cells within which HHV8 lytic replication is occurring by targeting the HHV8 lytic genes ORF36 and ORF 21, which phosphorylate these drugs to toxic moieties, was reported by Uldrick *et al.* [68] in 14 HIV-positive patients with symptomatic HHV8-MCD. A total of 86% of patients attained major clinical responses and 50% attained major biochemical responses. Median progression-free survival was 6 months. With 43 months of median follow-up, overall survival was 86% at 12 months and beyond. At the time of best response, the patients showed significant improvements in C-reactive protein, albumin, platelets, human IL-6, IL-10, and KSHV viral load. The most common toxicities were haematological.

### 11.11 Surgery

Although surgery is the mainstay of treatment for LCD [69] with complete removal of the mediastinal lesions often curative, this has a limited role in MCD. Splenectomy, in addition to establishing the histological diagnosis, may have a therapeutic benefit as a debulking procedure, as some of the haematological sequelae such as thrombocytopenia and anaemia may in part be caused by splenomegaly. Following splenectomy there is often resolution of the constitutional symptoms but this may be short-lived, approximately 1–3 months, and some form of maintenance therapy is needed to prevent relapse [51].

### 11.12 Recommendations

- We suggest that histological confirmation requires immunocytochemical staining for HHV8 and IgM lambda (level of evidence 2B).
- We suggest that all patients should have their blood levels of HHV8 measured to support the diagnosis (level of evidence 2C).
- We suggest that the risk of lymphoma in patients diagnosed with MCD is high (level of evidence 2C).
- We suggest that cART does not prevent MCD (level of evidence 2D).
- We suggest that a rise in plasma HHV8 level can predict relapse (level of evidence 2D).
- We recommend that rituximab should be first-line treatment for MCD (level of evidence 1B).
- We recommend that chemotherapy should be added to rituximab for patients with aggressive disease (level of evidence 1C).
- We recommend re-treatment with rituximab-based therapy for relapsed MCD (level of evidence 1C).
- We suggest clinical monitoring for patients in remission should include measurement of blood HHV8 levels (level of evidence 2C).

### 11.13 Auditable outcomes

- Proportion of patients with MCD treated with rituximab as first-line treatment
- Proportion of patients with aggressive MCD treated with rituximab and chemotherapy
- Proportion of patients with relapsed MCD re-treated with rituximab

### 11.14 References

- 1 Castleman B, Towne VW. Case records of the Massachusetts General Hospital: case no. 40231. *N Engl J Med* 1954; **250**: 1001–1005.
- 2 Castleman B, Iverson L, Menendez V. Localized mediastinal lymph-node hyperplasia resembling thymoma. *Cancer* 1956; **9**: 822–830.
- 3 Dupin N, Diss TL, Kellam P *et al*. HHV-8 is associated with a plasmablastic variant of Castleman's disease that is linked to HHV-8-positive plasmablastic lymphoma. *Blood* 2000; **95**: 1406–1412.
- 4 Bouvresse S, Marcelin AG, Franck N *et al*. The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient. *AIDS* 2007; **21**: 1492–1494. (Erratum in *AIDS* 2007; **21**: 2257.)
- 5 Drolet J-P, Lefebvre M-A, Bernard C *et al*. Multicentric Castleman disease in a child with primary immunodeficiency. *Pediatr Blood Cancer* 2010; **55**: 1198–1200.
- 6 Fardet L, Blum L, Kerob D *et al*. Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients. *Clin Infect Dis* 2003; **37**: 285–291.
- 7 Apoola A, Ross J, Duddy MJ *et al*. Central pontine myelinolysis complicating treatment of multicentric Castleman's disease and Kaposi's sarcoma in a patient with AIDS. *Sex Transm Infect* 2003; **79**: 179–184.
- 8 Day JR, Bew D, Ali M, Dina R, Smith PL. Castleman's disease associated with myasthenia gravis. *Ann Thorac Surg* 2003; **75**: 1648–1650.
- 9 Bardwick PA, Zvaifler NJ, Gill GN *et al*. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. *Medicine(Baltimore)* 1980; **59**: 311–322.
- 10 Ascoli V, Signoretti S, Onetti-Muda A *et al*. Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. *J Pathol* 2001; **193**: 200–209.
- 11 Chadburn A, Hyjek EM, Tam W *et al*. Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD). *Histopathology* 2008; **53**: 513–524.
- 12 Gerard L, Berezne A, Galicier L *et al*. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. *J Clin Oncol* 2007; **25**: 3350–3356.
- 13 Lachant NA, Sun NC, Leong LA *et al*. Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). *Am J Clin Pathol* 1985; **83**: 27–33.
- 14 Chang Y, Cesarman E, Pessin MS *et al*. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* 1994; **266**: 1865–1869.
- 15 Soulier J, Grollet L, Oksenhendler E *et al*. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. *Blood* 1995; **86**: 1276–1280.
- 16 Powles T, Stebbing J, Bazeos A *et al*. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. *Ann Oncol* 2009; **20**: 775–779.
- 17 Alzahrani M, Hull MC, Sherlock C *et al*. Clinical presentation, treatment and outcome of HIV-associated multicentric Castleman disease. *Blood* 2010; **116**. Available at: <https://ash.confex.com/ash/2010/webprogram/Paper29716.html> (accessed January 2014).
- 18 Westrop SJ, Lagos D, Boshoff C *et al*. African ancestry and innate immunity contribute to the incidence of multicentric Castleman's disease in HIV-1/Kaposi's sarcoma herpesvirus-coinfected individuals. *Future Virology* 2012; **7**: 729–734.
- 19 Algada J, Navani N, Taylor M *et al*. High prevalence of malignancy in HIV infected patients with enlarged mediastinal lymphadenopathy. *Thorax* 2010; **65**: A169–A170.
- 20 Du MQ, Liu H, Diss TC *et al*. Kaposi's sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman's disease and associated lymphoproliferative disorders. *Blood* 2001; **97**: 2130–2136.
- 21 Oksenhendler E, Boulanger E, Galicier L *et al*. High incidence of Kaposi's sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman's disease. *Blood* 2002; **99**: 2331–2336.
- 22 Arce J, Huang C, Levin M *et al*. Human herpes virus 8 viral load in multicentric Castleman's disease. *Lab Invest* 2010; **90**: 285A.
- 23 Menke DM, Chadburn A, Cesarman E *et al*. Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of Castleman disease at low risk for HIV infection. *Am J Clin Pathol* 2002; **117**: 268–275.

- 24 Bacon CM, Miller RF, Noursadeghi M *et al.* Pathology of bone marrow in human herpes virus-8 (HHV8)-associated multicentric Castleman disease. *Br J Haematol* 2004; **127**: 585–591.
- 25 Grandadam M, Dupin N, Calvez V *et al.* Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. *J Infect Dis* 1997; **175**: 1198–1201.
- 26 Chilton DN, Raja F, Lee SM *et al.* HIV-associated Multicentric Castleman's disease (MCD) may present in the context of immune reconstitution (IR); highly active antiretroviral therapy (HAART) alone can modify clinical response and is associated with radiological response and suppression of Kaposi Sarcoma Herpes Virus (KSHV) viraemia. *HIV Med* 2009; **10**(Suppl 1): 49 [Abstract P132].
- 27 Fish R, Paul J, Hargreaves S *et al.* Can KSHV viral load be used to differentiate multicentric Castleman's disease from Kaposi's sarcoma? *HIV Med* 2010; **11**(Suppl 1): 12 [Abstract O32].
- 28 Sayer R, Paul J, Tuke PW *et al.* Can plasma HHV8 viral load be used to differentiate multicentric Castleman disease from Kaposi sarcoma? *Int J STD AIDS* 2011; **22**: 585–589.
- 29 Polizzotto MN, Uldrick TS, Wang V *et al.* Distinct human and viral interleukin-6 profiles and other viral and immunologic abnormalities in KSHV-associated multicentric Castleman disease: Relationship with disease activity and individual disease manifestations. *Blood (ASH Annual Meeting Abstracts)* 2011; **118**: Abstract 1573.
- 30 Stebbing J, Adams C, Sanitt A *et al.* Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. *Blood* 2011; **118**: 271–275.
- 31 Barker R, Kazmi F, Stebbing J *et al.* FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease. *Eur J Nucl Med Mol Imaging* 2009; **36**: 648–652.
- 32 Dargent J-L, Lespagnard L, Sirtaine N *et al.* Plasmablastic microlymphoma occurring in human herpesvirus 8 (HHV-8)-positive multicentric Castleman's disease and featuring a follicular growth pattern. *APMIS* 2007; **115**: 869–874.
- 33 Eaton C, Dorer R, Abouafia DM. Human herpesvirus-8 infection associated with Kaposi sarcoma, multicentric Castleman's disease, and plasmablastic microlymphoma in a man with AIDS: a case report with review of pathophysiologic processes. *Patholog Res Int* 2010; **2011**: 647518.
- 34 Jones KD, Aoki Y, Chang Y *et al.* Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. *Blood* 1999; **94**: 2871–2879.
- 35 Cattaneo C, Vaccher E, Re A *et al.* HAART does not improve the outcome of HIV-related multicentric Castleman disease: Results of a multicentric retrospective study. *Blood* 2011; **118**: 4918.
- 36 Casper C, Krantz EM, Corey L *et al.* Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. *J Infect Dis* 2008; **198**: 23–30.
- 37 Aaron L, Lidove O, Yousry C *et al.* Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. *Clin Infect Dis* 2002; **35**: 880–882.
- 38 Corbellino M, Bestetti G, Scalapogna C *et al.* Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. *Blood* 2001; **98**: 3473–3475.
- 39 Marcelin A-G, Aaron L, Mateus C *et al.* Rituximab therapy for HIV-associated Castleman disease. *Blood* 2003; **102**: 2786–2788.
- 40 Newsom-Davis T, Bower M, Wildfire A *et al.* Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. *Leuk Lymphoma* 2004; **45**: 1939–1941.
- 41 Marrache F, Larroche C, Memain N *et al.* Prolonged remission of HIV-associated multicentric Castleman's disease with an anti-CD20 monoclonal antibody as primary therapy. *AIDS* 2003; **17**: 1409–1410.
- 42 Kofteridis DP, Tzagarakis N, Mixaki I *et al.* Multicentric Castleman's disease: prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patient. *AIDS* 2004; **18**: 585–586.
- 43 Neuville S, Agbalika F, Rabian C *et al.* Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. *Am J Hematol* 2005; **79**: 337–339.
- 44 Casquero A, Barroso A, Fernandez Guerrero ML, Gorgolas M. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. *Ann Hematol* 2006; **85**: 185–187.
- 45 Bower M, Powles T, Williams S *et al.* Brief communication: rituximab in HIV-associated multicentric Castleman disease. *Ann Intern Med* 2007; **147**: 836–839.
- 46 Powles T, Stebbing J, Montoto S *et al.* Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease [4]. *Blood* 2007; **110**: 4132–4133.
- 47 Bower M, Nelson M, Young AM *et al.* Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. *J Clin Oncol* 2005; **23**: 5224–5228.
- 48 Bower M, Veraitch O, Szydlo R *et al.* Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. *Blood* 2009; **113**: 4521–4524.

- 49 Bower M, Newsom-Davis T, Naresh K *et al.* Clinical features and outcome in HIV-associated multicentric Castleman's disease. *J Clin Oncol* 2011; **29**: 2481–2486.
- 50 Gerard L, Michot J-M, Burcheri S *et al.* Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. *Blood* 2012; **119**: 2228–2233.
- 51 Oksenhendler E, Duarte M, Soulier J *et al.* Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. *AIDS* 1996; **10**: 61–67.
- 52 Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. *Am J Hematol* 2001; **66**: 148–150.
- 53 Strohal R, Tschachler E, Breyer S *et al.* Reactivation of Behcet's disease in the course of multicentric HHV8-positive Castleman's disease: long-term complete remission by a combined chemo/radiation and interferon-alpha therapy regimen. *Br J Haematol* 1998; **103**: 788–790.
- 54 Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman's disease. *Int J STD AIDS* 2003; **14**: 61–62.
- 55 Kumari P, Schechter GP, Saini N, Benator DA. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. *Clin Infect Dis* 2000; **31**: 602–604.
- 56 Nishimoto N, Sasai M, Shima Y *et al.* Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. *Blood* 2000; **95**: 56–61.
- 57 Nishimoto N, Kanakura Y, Aozasa K *et al.* Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. *Blood* 2005; **106**: 2627–2632.
- 58 Fingerle-Rowson G, Vermeulen J, Qi M *et al.* A randomized, double-blind, placebo-controlled study to assess the effectivity and safety of IL-6 inhibition by siltuximab (CNTO-328) in patients with multicentric Castleman's disease. *Onkologie* 2010; **33**: 253–254.
- 59 Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. *Am J Hematol* 2003; **73**: 48–53.
- 60 Jung CP, Emmerich B, Goebel FD, Bogner JR. Successful treatment of a patient with HIV-associated multicentric Castleman's disease (MCD) with thalidomide. *Am J Hematol* 2004; **75**: 176–177.
- 61 Martin DF, Kuppermann BD, Wolitz RA *et al.* Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. *N Engl J Med* 1999; **340**: 1063–1070.
- 62 Mazzi R, Parisi SG, Sarmati L *et al.* Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. *AIDS* 2001; **15**: 2061–2062.
- 63 Low P, Neipel F, Rascu A *et al.* Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. *Eur J Med Res* 1998; **3**: 461–464.
- 64 Luppi M, Barozzi P, Rasini V *et al.* Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. *Transplantation* 2002; **74**: 131–132.
- 65 Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman's disease with ganciclovir treatment. *Blood* 2004; **103**: 1632–1634.
- 66 Senanayake S, Kelly J, Lloyd A *et al.* Multicentric Castleman's disease treated with antivirals and immunosuppressants. *J Med Virol* 2003; **71**: 399–403.
- 67 Cattamanchi A, Saracino M, Selke S *et al.* Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. *J Med Virol* 2011; **83**: 1696–1703.
- 68 Uldrick TS, Polizzotto MN, Aleman K *et al.* High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. *Blood* 2011; **117**: 6977–6986.
- 69 Talat N, Belgaumkar AP, Schulte K-M. Surgery in Castleman's disease: a systematic review of 404 published cases. *Ann Surg* 2012; **255**: 677–684.

## 12 Non-AIDS-defining malignancies

### 12.1 Introduction

This section aims to address the evidence-based guidelines for non-AIDS-defining cancers in people with HIV infection. It will exclude Hodgkin disease and anal cancer, which have been covered already. The cancers it will specifically address are:

- Testicular germ cell tumours
- Non-small cell lung cancer (NSCLC)
- Hepatocellular cancer (HCC)

There is very limited data available on:

- Colon cancer
- Head and neck cancer
- Melanoma
- Other urological cancers
- Haematological cancers
- Breast cancer

Therefore, these patients should be managed by oncologists and HIV doctors together, according to standard guidelines for HIV-negative patients. We suggest that careful attention to the drug interactions between cytotoxic chemotherapy and antiretroviral agents is needed, as well as focus on opportunistic infection prophylaxis.

### 12.2 Testicular germ cell cancers

#### 12.2.1 Introduction

It appears that only seminoma (as opposed to non-seminoma germ cell tumours) occurs more frequently in HIV infection [1]. There is no clear consensus on the exact relative risk but it ranges between approximately 3 and 7 [1–5]. There is no evidence that the incidence is increasing in the era of HAART [1]. The cause for this increased incidence is unclear although chronic immune suppression has been suggested. Patients present with only moderate immune suppression and they appear to be about 10 years younger than their HIV-negative counterparts [1]. There is conflicting evidence that patients present with more advanced disease. This may be because of the increased incidence of para-aortic lymphadenopathy in HIV disease incorrectly up-staging patients from stage I to stage II disease [6]. Patients with HIV-related testicular cancer have a similar cancer-free outcome compared to their HIV-

negative counterparts if treated in an identical manner in the HAART era [1]. This contradicts early reports in the pre-HAART era [7].

#### 12.2.2 Diagnosis, staging, prognostic factors

Diagnosis should follow an identical path regardless of HIV status and all patients should be tested for HIV infection. A testicular mass must be treated with the utmost suspicion and an ultrasound scan (or MRI) and tumour markers (AFP, HCG) should follow. LDH is nonspecific and should only be used to prognosticate patients with metastatic disease. False-positive AFP can be related to HAART/hepatitis-related liver disease, while there are many causes of a false positive LDH [1].

The differential diagnosis for a testicular mass in this setting includes orchitis and lymphoma. A CT scan of the chest abdomen and pelvis should be performed for full staging. MRI scanning for para-aortic lymph nodes is an alternative for the abdomen and pelvis. There is no clear role for FDG-PET in these patients regardless of HIV serostatus.

#### 12.2.3 Management

##### 12.2.3.1 Stage I disease

Patients with stage I disease (seminomas or NSGCT) can be safely treated with surveillance alone and have a similar outcome to their HIV-negative counterparts [1]. Alternatively, adjuvant carboplatin (AUC7) can be offered to the seminoma patients (we advise one cycle), while two cycles of adjuvant BEP can be offered to the NSGCT [1]. It appears three cycles of BEP suppresses the CD4 cell count by between 25 and 50%, and it is probable that two cycles of BEP will also be suppressive. Therefore low-risk NSGCT patients should be offered surveillance and adjuvant therapy should only be considered for high-risk NSGCT [6]. Additionally it has been suggested that adjuvant therapy should be considered in patients with a haphazard lifestyle (who are unlikely to co-operate with an intensive surveillance programme) [6]. Patients should receive HAART during adjuvant or metastatic chemotherapy [1]. Prophylactic antifungal agents should be considered, especially for patients receiving two cycles of BEP [6].

##### 12.2.3.2 Metastatic disease

Patients should be risk stratified according to the IGCCC guidelines in an identical manner to HIV-negative patients



[8]. Good-risk patients should be offered three cycles of standard 5-day BEP with concurrent HAART and prophylactic antifungals should be considered [1,6]. One should expect a 50% drop in the CD4 cell count with chemotherapy [6,9]. Treatment modifications should follow the HIV-negative model. Those with extensive pulmonary limitation from previous infection can alternatively have four cycles of EP chemotherapy [8]. Carboplatin should not be used as a substitute for cisplatin and dose modifications/delays should be avoided where possible. Growth factors such as G-CSF should be considered where appropriate [8].

Patients with intermediate- and poor-risk disease should be offered four cycles of standard 5-day BEP chemotherapy [1,6]. Those with extensive pulmonary limitation from previous infection can alternatively have four cycles of VIP chemotherapy. The two regimens have a similar outcome in HIV-negative patients but VIP is more myelosuppressive in HIV-negative patients [8]. Other regimens for poor-risk patients (such as high-dose therapy and dose-dense therapy) have not been shown to be superior to four cycles of BEP in HIV-negative patients. Patients should receive concurrent HAART and chemotherapy; antifungal prophylaxis should be considered where appropriate.

#### 12.2.3.3 Relapsed disease

There are very few data on the treatment of relapsed disease [1]. Patients should be treated in an identical manner to HIV-negative patients. The TIP regimen seems appropriate for patients who relapsed 6 months after initial diagnosis [8]. High-dose chemotherapy followed by autologous peripheral blood stem-cell transplant is generally considered the only curative option after two or more treatment regimens in HIV-negative patients, and although data are limited in HIV-positive patients this treatment should be considered for early relapse [10]. Third-line therapy is usually palliative and there are no data regarding this in men living with HIV/AIDS. It is clear that single-agent therapy has little activity in this setting in HIV-negative patients.

#### 12.2.4 Summary

Seminoma of the testis is more common in men living with HIV infection.

- We suggest germ cell tumours of the testis should be treated in an identical manner regardless of HIV status (level of evidence 2C).
- We suggest men living with HIV who require chemotherapy for germ cell tumours should receive concomitant HAART and opportunistic infection prophylaxis (level of evidence 2C).

- We suggest surveillance for stage I disease is safe (level of evidence 2C).
- We suggest bleomycin can be avoided if necessary in the management of these patients (level of evidence 2D).

### 12.3 Non-small cell lung cancer

#### 12.3.1 Introduction

It appears that the incidence of non-small cell lung cancer (NSCLC) is increased in people living with HIV infection [11,12]. Not all of this increase in incidence can be attributed to smoking cigarettes [12] although cessation of smoking should be recommended for people living with HIV/AIDS. There is no evidence of an increased incidence of small cell lung cancer (SCLC) in HIV and no specific data on this issue [11,12]. It is recommended that patients with SCLC are treated in an identical manner to their HIV-negative counterparts. What anecdotal data are available suggest these patients do badly.

Patients with HIV-related NSCLC present at a younger age and with more advanced disease than their HIV-negative counterparts [11–13]. The rise in incidence of adenocarcinoma in the HIV-negative population has also been seen in people living with HIV/AIDS [14].

#### 12.3.2 Prognosis

Studies in the pre-HAART era showed HIV-positive NSCLC patients have a significantly worse outcome compared to their HIV-negative counterparts. These studies were small and were not all age- or stage-matched; however, the results were compelling with a median survival of only 3 months [15,16]. Although initial reports did not suggest that HAART had a huge impact, with average survival still only 4 months, later studies have found a median survival of up to 9 months in advanced stage disease although this is still less than that reported in clinical trials from the general population [13,17]. This poorer outcome may just reflect more advanced disease and, when this taken in account, the true prognosis may well be similar in HIV-positive and -negative populations [13]. It is clear that there is a delay in the diagnosis of HIV-positive lung cancer patients and this may in part be due to the wide differential diagnosis of an HIV patient with a mass in the lungs [14].

#### 12.3.3 Management

As HIV patients with NSCLC present at a younger age than their HIV-negative counterparts, a mass on chest X-ray should raise the suspicion of NSCLC. It is recommended that in addition to a tissue diagnosis, patients should have a CT



of the chest and abdomen (including adrenals), and bone scan. If an individual is still potentially operable then a mediastinoscopy should be performed. In view of the possible decreased specificity and lack of data regarding FDG-PET in HIV-positive lung cancer, PET results should be interpreted with caution. Patients should not necessarily be deemed inoperable on the evidence of FDG-PET alone. The results of FDG-PET should be considered in conjunction with HIV status (HIV history, opportunistic infections, viral load and CD4 cell counts). Cranial imaging is indicated in patients eligible for loco-regional treatment, or in the presence of clinical symptoms.

#### 12.3.3.1 Operable disease

Those with operative disease should be offered curative surgery, once staging investigations are complete; however, studies suggest that a small minority of HIV-positive lung cancer patients are actually offered this [14]. This is due to a combination of patients presenting with advanced disease and comorbidity. Although 30-day post-operative mortality is comparable to that in the general population, there is an increase in complications and recurrence, whilst overall survival is reduced [18]. The latter are most pronounced if the CD4 cell count is below 200 cells/ $\mu$ L.

There are no data regarding the use of adjuvant chemotherapy in HIV-related lung cancer, therefore these patients should follow the HIV-negative lung cancer guidelines. Chemotherapy should consist of standard regimens and doses. HAART should continue throughout treatment. Follow-up should be as with HIV-negative patients.

#### 12.3.3.2 Locally advanced disease

There are no data specifically addressing this issue. Patients with locally advanced disease should be offered chemoradiation according to HIV-negative guidelines. It is noteworthy that grade 3/4 treatment-associated toxicities have been reported in 60% of HIV-positive lung cancer patients, whilst chemoradiotherapy is associated with profound immunosuppression in other HIV-positive tumours [19,20]. Patients should therefore continue/commence HAART and antifungal prophylaxis where appropriate.

#### 12.3.3.3 Metastatic disease

The presence of activating mutations within the epidermal growth factor receptor (EGFR) gene of lung cancer cells makes these tumours highly sensitive to EGFR-targeting tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib [21,22]. The incidence of such mutations in HIV-associated lung cancer is not known; however, individual cases treated with EGFR TKIs have been reported, demonstrating the feasibility of this approach [23]. Consequently all patients with advanced stage NSCLC should be screened

for EGFR mutations as in the general population. Use of EGFR TKIs requires caution due to potential interaction with HAART through induction of cytochrome P450 isoenzyme CYP3A4. Data from KS suggest that TKIs do indeed potentiate the side effects of HAART [24].

In the absence of an activating EGFR mutation, standard chemotherapy regimens are indicated in the first-line setting. Experience shows that treatment tends to be tolerated poorly and response rates are low (<30%), with deaths attributable to cancer and not opportunistic infections [17]. There are currently no data on second- and third-line chemotherapy for metastatic NSCLC. Management should therefore follow guidelines for the HIV-negative population.

#### 12.3.4 HAART

Good control of HIV infection is important because median survival is improved if the CD4 cell count is >200 cells/ $\mu$ L [20,25,26]. However, concurrent use of HAART and chemotherapy can be problematic, with a significant increase in myelosuppression reported for patients also taking protease inhibitors [26].

#### 12.3.5 Screening

CT screening for lung cancer in the HIV-negative population is associated with a 20% decrease in lung cancer mortality. Although large-scale data from the HIV-positive population are lacking, CT screening in this patient group is feasible, whilst concerns about poor specificity may be unfounded [27,28]. However, in the absence of a national programme, screening is not recommended with either CXR or CT.

#### 12.3.6 Summary

- We recommend HIV-positive patients should be encouraged to stop smoking cigarettes (level of evidence 1B).
- We suggest patients should be offered potentially curative surgery where appropriate (level of evidence 2C).
- We suggest patients should be screened for activating EGFR mutations and treated with EGFR TKIs by a team experienced in the use of HAART (level of evidence 2D).
- We suggest there is currently no role for screening for lung cancer in people living with HIV (GPP).

### 12.4 Hepatocellular cancer

#### 12.4.1 Introduction

There is debate as to whether there is an increased incidence of HCC in HIV-positive individuals. This uncertainty is primarily because HBV and HCV act as confounding

factors in this setting. In view of the long delay between development of cirrhosis and subsequent HCC in both HIV-positive and HIV-negative populations, an increase in the incidence of this disease in HIV may have not occurred yet [29].

In Western countries approximately 30% of people with HIV are coinfecting with HCV, rising to approximately 75% in IV drug users [30]. HIV affects the natural history of HCV infection in two important ways: first, it increases the likelihood of chronic infection following the acute episode and second, it hastens the development of cirrhosis once chronic infection is established. This has important implications for the subsequent development of HCC and screening strategy [29].

HBV is directly carcinogenic and may promote the development of HCC in the absence of cirrhosis, especially in populations where HBV may have been acquired at birth and in early childhood [31]. It has also become evident that high HBV viral loads may be linked to the development of HCC [32]. It is probable that a lower CD4 cell count, particularly in the context of HBV coinfection, is associated with a higher risk of HCC [33].

HIV coinfection also accelerates the progression of HBV infection [34]. There is a large regional variation in the proportion of people with HIV who have previously been exposed to HBV (10–90%). Retrospective series suggest that HBV is responsible for a much smaller proportion of HCC compared to HCV in HIV-positive individuals [29,30].

#### 12.4.2 Presentation and diagnosis

HIV-positive HCC patients are younger and are more often HCV positive [30,35–37]. The majority of the HIV cohort has HCV and cirrhosis. The great majority of HIV-positive HCC patients are on HAART at diagnosis and consequently they tend to be only moderately immunosuppressed [30,35]. There appears to be no significant difference between HIV-positive and -negative patients in the Barcelona Clinic Liver Cancer (BCLC) stage at presentation [35].

Most HCCs are identified with ultrasound scanning and AFP levels [30]. The degree of cirrhosis should be assessed prior to any definitive treatment using the Child–Pugh classification. HIV-positive HCC patients are more likely to have compensated liver disease (Child–Pugh A). A CT scan of the chest, abdomen and pelvis is required to exclude metastatic disease.

#### 12.4.3 Management

Initial series in HIV-positive individuals with HCC showed that the majority of patients were not being offered active

treatment and that consequently outcome was poor [30]. Although more recent work has shown an improvement in the situation [35], others report that one-third of patients remain untreated and even in those with potentially curable disease, one-quarter receive less effective treatment than is indicated [38]. When HIV patients are offered active treatment they have a similar survival to their HIV-negative counterparts [35,37,39–41].

Whether HIV status is itself related to survival remains uncertain. One series comparing 65 HIV-positive and 267 HIV-negative patients with HCC found that HIV status negatively influenced outcome in both treated and untreated patients [42], whilst HIV-associated HCC patients have a higher drop-out rate pre-transplantation and appear to have a more aggressive overall disease course [36]. In contrast others report no difference in survival with respect to HIV status, and that prognosis is instead governed by liver function, tumour bulk and cancer treatment [35].

Control of HIV infection in HCC is important. Patients with a CD4 cell count >200 cells/ $\mu$ L have lower AFP levels, are more likely to receive active treatment, and have a better median survival (11.7 months *vs.* 5.2 months) [43]. Correspondingly, an undetectable HIV RNA viral load (<400 copies/mL) is associated with a lower Child–Pugh score and a better median overall survival. The latter is only seen in untreated patients [44]. The degree of immunosuppression does not appear to correlate with BCLC stage [43,44]. Since use of HAART correlates with better overall survival, it is recommended for HIV-positive HCC patients [42].

##### 12.4.3.1 Localized therapies

In the HIV-negative population, solitary or a small number of HCC lesions are resectable. If complete resection is possible this should be performed without biopsy. These patients should have category A cirrhosis according to Child–Pugh classification [45]. This approach is associated with a 5-year survival of 60–70% in the HIV-negative population [46] and so HIV-positive patients should be considered for such treatments. Other options for patients with localized disease in whom resection is not possible include ethanol injection, radiofrequency ablation or trans-arterial chemo-embolization.

##### 12.4.3.2 Transplantation

It appears that transplantation may have superior results to resection alone in HIV-negative patients [47]. According to the Milan criteria, transplantation should be considered if there are three liver lesions less than 3 cm or one lesion less than 5 cm in diameter. Several series have reported on liver transplantation for HIV-associated HCC. Eligible patients

tend to be younger and, although there is a higher drop-out rate compared to HIV-negative patients, there is no significant difference in overall survival or relapse between the two groups [48]. Overall survival at 3 years of 74% and 3-year relapse free survival of 69% are reported [48]. Consequently HIV-positive patients should be considered for transplantation in the same way as HIV-negative patients. HIV status itself is not a prognostic factor for HCC patients undergoing liver transplantation [48].

Special attention is required for HIV-positive liver transplants due to the potential interaction between HAART and immunosuppressive therapy such as tacrolimus. This is particularly true for inhibitors of cytochrome P450 such as protease inhibitors.

#### 12.4.3.3 Sorafenib

Sorafenib, an oral multi-TKI targeting the Raf cascade as well as vascular endothelial growth factor/platelet-derived growth factor receptors on tumour cells, significantly prolongs survival in HIV-negative patients with advanced, treatment-naïve HCC [49]. Early case studies/reports of sorafenib in HIV-positive HCC suggested synergy with HAART, with impressive response rates but more marked toxicity [50]. The largest series of HIV-positive HCC treated with sorafenib involves 27 patients and reported partial response in 11% and stable disease in 44% [51]. In contrast to the earlier case studies, there were no reports of complete responses. Median time to progression was 5.1 months and median overall survival was 12.8 months from start of sorafenib. Toxicities, principally diarrhoea and hand-foot syndrome, were more severe than expected suggesting possible interaction with concomitant use of HAART [51]. Pharmacokinetic studies of HAART and sorafenib are ongoing.

#### 12.4.4 Screening for HCC in patients with hepatitis and HIV coinfection

Recommendations for screening for patients with hepatitis and HIV coinfection exist in BHIVA [52] as well as European Association for Study of the Liver (EASL) [53] and American Association for the Study of Liver Disease (AASLD) guidelines [54]. Screening programmes utilizing serum AFP and 6-monthly ultrasound scans have demonstrated improved survival in non-HIV-infected patients [55]. Although AFP may not add to the value of ultrasound scans if the latter is done twice or more a year, this frequency of scans is often impractical and therefore AFP is still used. HBV is potentially oncogenic, and so even in the absence of cirrhosis it is advised that all HIV/HBV coinfecting patients have 6-monthly ultrasound scans even in the absence of cirrhosis.

Adherence to published guidelines is poor, and many at-risk cohorts do not receive adequate ultrasound screening [56]. Surveillance for HCC needs to be tailored to specific risk [57]. Some patients may warrant more intensive surveillance with shorter frequency [58] or different imaging modalities as ultrasound screening is associated with an appreciable false-negative rate [59].

#### 12.4.5 Summary

- We suggest that people living with HIV with HCC should be treated in a similar manner to their HIV-negative counterparts (level of evidence 2C).
- We suggest that liver transplantation should be considered for appropriate cases, as in the HIV-negative population (level of evidence 2D).
- We suggest that sorafenib is a treatment option in advanced, nonoperable HCC (level of evidence 2D).
- Noncirrhotic HBV coinfecting patients should be considered for HCC screening (GPP).
- We recommend HCC screening with liver ultrasound (level of evidence 1A) and suggest 6-monthly AFP (level of evidence 2C) be offered to all cirrhotic patients with HBV and HCV coinfections.

## 12.5 Other cancers

### 12.5.1 Colorectal cancer

The largest prospective study to date compared 136 asymptomatic HIV-positive patients to 272 HIV-negative patients and found an increased incidence of neoplastic lesions (adenomas, adenocarcinomas) in the former [60]. HIV-positive patients with colorectal adenocarcinoma were significantly younger, had more advanced disease and had an increased prevalence of right-sided tumours [60], all of which is in keeping with findings from smaller studies [61–63]. Evidence for the treatment of HIV-positive colorectal cancer (CRC) patients is limited to small retrospective case studies and so specific recommendations are not possible. However, it appears that standard chemotherapy in combination with HAART for patients with metastatic disease is feasible with no apparent increase in toxicity, no opportunistic infections during or after treatment, and an overall response rate of 50% [64]. Treatment of CRC reduces cellular immunity so use of HAART and prophylaxis against opportunistic infection is recommended [65].

Although some studies have found a poorer survival in HIV-positive CRC patients, others report no difference compared to matched HIV-negative controls [61,63]. Larger prospective studies investigating all disease stages are required. The increased incidence of colorectal cancer in

HIV-positive patients suggests a role for screening in this patient group although no particular programmes can be recommended [60].

### 12.5.2 Skin cancer

Primary skin malignancies constitute the most frequent non-AIDS-defining malignancies (NADMs) amongst HIV-positive people [66–69]. Patients and physicians need education in risk reduction and prophylaxis, early diagnosis and management.

HIV-positive patients have a two- to five-fold risk of developing a nonmelanoma skin cancer and the ratio of squamous cell carcinoma to basal cell carcinoma in HIV-infected individuals is 1:7, compared to 1.8:1 in renal transplant patients [70,71]. Melanoma is probably two to three times more common [66–69,71–75] and related to immunosuppression [73–76] but one UK and one Australian study have found a decreased incidence [75,77]. Sun exposure is possibly more important in causation than immunosuppression [71,78,79]. The role of HPV in anogenital and oral cancer, epidermoplasia verruciformis and nail unit squamous cell carcinoma is established, but it is unlikely (although controversial) to be critical in most cutaneous HIV-associated squamous cell carcinoma [70,80–82].

Clinically, actinic keratoses are very common; an atypical presentation should prompt more vigorous assessment and more aggressive treatment [78].

Squamous cell carcinoma may present atypically, at a younger age, at unusual not classically sun-exposed cutaneous sites (e.g., the nail fold), affect the mouth, genitalia and perineum, and be multifocal and aggressive with a high risk of recurrence and metastasis with a high mortality [82–86].

Basal cell carcinoma may be multiple and is commonly of the superficial type. Infundibulocystic, micronodular neurotropic and morpheiform variants, and even metastatic basal cell carcinoma have been reported. Generally, basal cell carcinoma was *not* thought to behave more aggressively in the HIV-infected population [87–89] but consensus is changing [86,90,91].

Porokeratosis is associated with immunosuppression, sun damage and HIV [92]. Anogenital squamous cancer and precancer is related to HPV [69,92–94].

Melanoma may present atypically, appearing as ‘normal’ naevi or ‘benign macules’ or multiple ‘nevus lesions’, and behave more aggressively with decreased disease-free and overall survival rates; low CD4 cell counts indicate a poorer prognosis although the Breslow thickness appears unrelated to the CD4 cell count at presentation; more research is needed [70,95–98].

Conventional treatment protocols should be followed for the management of actinic keratosis [78], basal cell carcinoma [99], squamous cell carcinoma [91] and melanoma [76] in HIV. Cases of basal cell carcinoma, squamous cell carcinoma and malignant melanoma should be discussed by a specialist skin MDT aware of the enhanced malignancy potential of these cancers and higher recurrence rates of non melanoma skin cancer [100] and give assiduous attention to local excisional margin control, order more extensive investigation for regional or disseminated disease and mandate closer follow-up [76,99–103].

Basal cell carcinoma and squamous cell carcinoma have been reported to remit with HAART [104,105]. Topical imiquimod has been used for treatment of basal cell carcinoma in HIV [106] and is useful for the common scenario of multifocal superficial basal cell carcinomas. Topical ingenol is under evaluation.

Patients receiving HAART and therefore surviving HIV longer, even indefinitely, need to have careful dermatological evaluation and follow-up, including of the anogenital skin and mucosa. They should be warned about the possible synergistic risk of the sun and HIV. All new or changing skin lesions should be evaluated assiduously, with a low threshold for biopsy.

Chronically photodamaged white-skinned patients probably require follow-up in dedicated dermatology clinics, as happens now routinely for renal (and other) transplant patients where the mortality from squamous cell carcinoma reached 10% before nondermatologists realised the risks. Access to specific dermatology expertise is necessary for HIV centres, particularly high-quality skin cancer and precancer care, for example Mohs surgery and photodynamic therapy.

### 12.5.3 Merkel cell carcinoma (MCC)

MCC is classically associated with chronic lymphocytic leukaemia, transplantation, immunosuppressive drugs and HIV, but the relative risks have not been quantified. Treatment is controversial but guidelines are emerging [107].

### 12.5.4 Cutaneous lymphoma

A spectrum of involvement of the skin with lymphoma is seen in HIV/AIDS [66]. HIV-associated Hodgkin disease differs from non-HIV-associated disease by manifesting ‘B’ symptoms, i.e., including pruritus. Cutaneous T cell lymphoma (mycosis fungoides and Sézary syndrome) may be associated with HIV/AIDS. Subcutaneous panniculitis-like T cell lymphoma has been reported. Castleman’s disease is discussed above. Cutaneous presentation and management should engage and involve specialized dermatology



services and follow extant and emerging national and international guidelines [108,109].

#### 12.5.5 Penis precancer and cancer

Penis cancer is five-to-six times commoner in HIV despite antiretroviral treatments [110]. The incidence rates for the various types of penile intraepithelial neoplasia (PeIN) are not known. The uncircumcised state, poor hygiene, smoking, lichen sclerosus and HPV are the principal risk factors. Uncircumcised men with HIV should be counselled and questioned at diagnosis and during management about genital health and smoking, have their genitalia examined at follow-up and preputial ill health should evoke a low threshold for circumcision [110–113]. PeIN and established penile cancer should be managed by specialized MDTs in specialized urological centres according to established guidelines [110–113]. The focus is on preventative or curative tissue conserving treatment and assessment of the regional lymphatics with an established role for sentinel node biopsy.

#### 12.5.6 Others

Only case reports and small retrospective series exist for other malignancies. HIV-positive acute myeloid leukaemia patients achieve remission with intensive treatment but this is poorly tolerated and most succumb to non-opportunistic infections. Survival is generally worse and CD4 cell count is a strong predictor of poor prognosis [114]. Head and neck cancers and breast cancers may be more aggressive than in their HIV-negative counterparts, although radiation therapy in the former appears to be well tolerated with expected toxicity profiles [115,116].

There is the decreased incidence of prostate and breast cancer in HIV, the reason for which does not appear to be related to hormone deficiency [2,117]. The reduced incidence of prostate cancer may be explained by differential PSA screening in the HIV-positive and general populations [118]. Small case studies suggest that HIV-positive patients with prostate cancer should be managed similarly to their HIV-negative counterparts and that outcomes are not significantly altered by HIV status [119,120].

We recommend that patients with these less well-described cancers are offered the standard care offered to HIV-negative patients. Treatment should be given in conjunction with HIV doctors. Prospective databases are required for this group.

#### 12.5.7 Summary

- We recommend that the management of people living with HIV with non-AIDS-defining malignancy should be

in a centre with adequate experience and requires a joint MDT including both oncologists with experience of managing HIV-related malignancy and HIV physicians (level of evidence 1C).

- We recommend that patients with NADM should be offered the standard care given to HIV-negative patients (level of evidence 1C).
- We recommend that all potential interactions between HAART, opportunistic infection prophylaxis and cancer therapy should be considered (level of evidence 1C).

## 12.6 References

- 1 Powles T, Bower M, Shamash J *et al.* Outcome of patients with HIV-related germ cell tumours: a case-control study. *Br J Cancer* 2004; **90**: 1526–1530.
- 2 Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. *JAMA* 2001; **285**: 1736–1745.
- 3 Herida M, Mary-Krause M, Kaphan R *et al.* Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. *J Clin Oncol* 2003; **21**: 3447–3453.
- 4 Serraino D, Boschini A, Carrieri P *et al.* Cancer risk among men with, or at risk of, HIV infection in southern Europe. *AIDS* 2000; **14**: 553–559.
- 5 Clifford GM, Polesel J, Rickenbach M *et al.* Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. *J Natl Cancer Inst* 2005; **97**: 425–432.
- 6 Powles T, Nelson M, Bower M. HIV-related testicular cancer. *Int J STD AIDS* 2003; **14**: 24–27.
- 7 Wilson WT, Frenkel E, Vuitch F, Sagalowsky AI. Testicular tumors in men with human immunodeficiency virus. *J Urol* 1992; **147**: 1038–1040.
- 8 Krege S, Beyer J, Souchon R *et al.* European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. *Eur Urol* 2008; **53**: 497–513.
- 9 Powles T, Imami N, Nelson M *et al.* Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. *AIDS* 2002; **16**: 531–536.
- 10 Hentrich M, Schiel X, Niedermeier A *et al.* Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor. *Ann Oncol* 2009; **20**: 1900–1901.
- 11 Engels EA, Brock MV, Chen J *et al.* Elevated incidence of lung cancer among HIV-infected individuals. *J Clin Oncol* 2006; **24**: 1383–1388.

- 12 Bower M, Powles T, Nelson M *et al.* HIV-related lung cancer in the era of highly active antiretroviral therapy. *AIDS* 2003; **17**: 371–375.
- 13 D'Jaen GA, Pantanowitz L, Bower M *et al.* Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. *Clin Lung Cancer* 2010; **11**: 396–404.
- 14 Powles T, Nelson M, Bower M. HIV-related lung cancer – a growing concern? *Int J STD AIDS* 2003; **14**: 647–651.
- 15 Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. *Lung Cancer* 1996; **15**: 325–339.
- 16 Sridhar KS, Flores MR, Raub WA Jr, Saldana M. Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. *Chest* 1992; **102**: 1704–1708.
- 17 Powles T, Thirwell C, Newsom-Davis T *et al.* Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? *Br J Cancer* 2003; **89**: 457–459.
- 18 Hooker CM, Meguid RA, Hulbert A *et al.* Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. *Ann Thorac Surg* 2012; **93**: 405–412.
- 19 Powles T, Powles J, Nelson M *et al.* Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus. *J Laryngol Otol* 2004; **118**: 207–212.
- 20 Pakkala S, Chen Z, Rimland D *et al.* Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. *Cancer* 2012; **118**: 164–172.
- 21 Mok TS, Wu YL, Thongprasert S *et al.* Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009; **361**: 947–957.
- 22 Zhou C, Wu YL, Chen G *et al.* Erlotinib *versus* chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 2011; **12**: 735–742.
- 23 Okuma Y, Yanagisawa N, Takagi Y *et al.* Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection. *Int J Clin Oncol* 2012; **17**: 462–469.
- 24 Koon HB, Bublely GJ, Pantanowitz L *et al.* Imatinib-induced regression of AIDS-related Kaposi's sarcoma. *J Clin Oncol* 2005; **23**: 982–989.
- 25 Lavole A, Chouaid C, Baudrin L *et al.* Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. *Lung Cancer* 2009; **65**: 345–350.
- 26 Makinson A, Tenon JC, Eymard-Duvernay S *et al.* Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. *J Thorac Oncol* 2011; **6**: 1022–1029.
- 27 Hulbert A, Craig Hooker C, Travis Brown T *et al.* Preliminary results from a patient group, excluded from the National Lung Cancer Screening Trial, who are at high risk for lung cancer- heavy smokers with HIV. *Cancer Res* 2011; **71**: S1.
- 28 Sigel K, Brown S, Wisnivesky J *et al.* Chest CT scan findings and implications for lung cancer screening in HIV infected patients. *Clinical and Translational Science* 2012; **5**: 168.
- 29 Powles T, Macdonald D, Nelson M, Stebbing J. Hepatocellular cancer in HIV-infected individuals: tomorrow's problem? *Expert Rev Anticancer Ther* 2006; **6**: 1553–1558.
- 30 Puoti M, Bruno R, Soriano V *et al.* Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. *AIDS* 2004; **18**: 2285–2293.
- 31 Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005; **42**: 1208–1236.
- 32 Chen CJ, Yang HI, Su J *et al.* Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; **295**: 65–73.
- 33 Clifford GM, Rickenbach M, Polesel J *et al.* Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. *AIDS* 2008; **22**: 2135–2141.
- 34 Thio CL, Seaberg EC, Skolasky R Jr *et al.* HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). *Lancet* 2002; **360**: 1921–1926.
- 35 Cantarini MC, Verucchi G, Costagliola P *et al.* Outcome of hepatocellular carcinoma in HIV-infected patients with chronic liver disease: A comparison with HIV negative controls. *J Hepatol* 2009; **50**: S286.
- 36 Joshi D, Maggs J, Karani J *et al.* Hepatocellular carcinoma in HIV positive patients: a more aggressive disease course? *Hepatology* 2010; **52**: 1150A.
- 37 Yopp AC, Subramanian M, Jain MK *et al.* Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. *Clin Gastroenterol Hepatol* 2012; **10**: 1284–1290.
- 38 Merchante N, Kikuchi L, Marks K *et al.* Barcelona-Clinic-Liver-Cancer (BCLC) staging and actual therapy received in HIV-infected patients with hepatocellular carcinoma (HCC), comparing diagnosis pre-2006 and 2006 and later. *J Hepatol* 2011; **54**: S259–S260.
- 39 Ragni MV, Belle SH, Im K *et al.* Survival of human immunodeficiency virus-infected liver transplant recipients. *J Infect Dis* 2003; **188**: 1412–1420.



- 40 Neff GW, Bonham A, Tzakis AG *et al.* Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. *Liver Transpl* 2003; **9**: 239–247.
- 41 Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. *Semin Liver Dis* 2006; **26**: 273–284.
- 42 Berretta M, Garlassi E, Ventura P *et al.* Clinical outcomes and survival in patients with hepatocellular carcinoma and HIV infection. *J Clin Oncol* 2010; **28**: Abstract 4132.
- 43 Jain M, Palys E, Qazi N *et al.* Influence of CD4+ cell count on hepatocellular carcinoma in HIV-infected patients. *Hepatology* 2010; **52**: 1190A.
- 44 Brau N, Kikuchi L, Nunnez M *et al.* Improved survival for hepatocellular carcinoma (HCC) in HIV-infected patients with undetectable HIV RNA. *J Hepatol* 2010; **52**: S219.
- 45 Ettorre GM, Vennarecci G, Boschetto A *et al.* Resection and transplantation: evaluation of surgical perspectives in HIV positive patients affected by end-stage liver disease. *J Exp Clin Cancer Res* 2003; **22**: 167–169.
- 46 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003; **362**: 1907–1917.
- 47 Yao FY, Ferrell L, Bass NM *et al.* Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. *Liver Transpl* 2002; **8**: 765–774.
- 48 Vibert E, Duclos-Vallee JC, Ghigna MR *et al.* Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. *Hepatology* 2011; **53**: 475–482.
- 49 Llovet JM, Ricci S, Mazzaferro V *et al.* Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378–390.
- 50 Chelis L, Ntinou N, Souftas V *et al.* Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART? A case report. *Med Oncol* 2011; **28**(Suppl 1): S165–168.
- 51 Berretta M, Di Benedetto F, Dal Maso L *et al.* Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. *Anticancer Drugs* 2013; **24**: 212–218.
- 52 Wilkins E, Nelson M, Agarwal K *et al.* British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. *HIV Med* 2013; **14**(Suppl 4): 1–71.
- 53 European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908–943.
- 54 Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020–1022.
- 55 Zhang BH, Yang BH, Tang JY *et al.* Randomised controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2004; **130**: 417–422.
- 56 Fenkel J, Navarro V. Assessment of adherence to guidelines for hepatocellular carcinoma screening in HIV/HCV coinfecting patients. *Gastroenterology* 2011; **140**: 922.
- 57 Salmon D, Bani-Sadr F, Loko MA *et al.* Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. *J Hepatol* 2012; **56**: 862–868.
- 58 Bourcier V, Winnock M, Ait Ahmed M *et al.* Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavir and CO12 Cirvir). *Clin Res Hepatol Gastroenterol* 2012; **36**: 214–221.
- 59 Gay H, Raman L, Davies C *et al.* Is ultrasound an effective screening tool for the diagnosis of hepatocellular carcinoma in patients coinfecting with HIV and hepatitis B or hepatitis C? *HIV Med* 2012; **13**(Suppl 1): 41 [Abstract P93].
- 60 Bini EJ, Green B, Poles MA. Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects. *Gut* 2009; **58**: 1129–1134.
- 61 Berretta M, Cappellani A, Di Benedetto F *et al.* Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study. *Onkologie* 2009; **32**: 319–324.
- 62 Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L. Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. *Clin Colorectal Cancer* 2009; **8**: 215–219.
- 63 Kumar A, Shah N, Modi Y *et al.* Characteristics of colorectal cancer in the human immunodeficiency virus-infected African American population. *Med Oncol* 2012; **29**: 1773–1779.
- 64 Berretta M, Lleshi A, Cappellani A *et al.* Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. *Curr HIV Res* 2010; **8**: 218–222.
- 65 Alfa-Wali M, Tait D, Allen-Mersh T *et al.* Colorectal cancer in HIV positive individuals: the immunological effects of treatment. *Eur J Cancer* 2011; **47**: 2403–2407.
- 66 Bunker CB, Gotch F. HIV and AIDS. In: Burns T, Breathnach S, Cox N and Griffiths C (eds). *Rook's Textbook of Dermatology*. 8th edn. Wiley-Blackwell, New York; 2010.
- 67 Pantanowitz L, Schlecht HPO, Dezube BJ. The growing problem of non-AIDS-defining malignancies in HIV. *Curr Opin Oncol* 2006; **18**: 469–472.
- 68 Hessol NA, Pipkin S, Schwarcz S *et al.* The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. *Am J Epidemiol* 2007; **165**: 1143–1153.

- 69 Burgi A, Brodine S, Wegner S *et al.* Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. *Cancer* 2005; **104**: 1505–1511.
- 70 Wilkins K, Turner R, Dolev JC *et al.* Cutaneous malignancy and human immunodeficiency virus disease. *J Am Acad Dermatol* 2006; **54**: 189–206.
- 71 Patel P, Hanson DL, Sullivan P *et al.*; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. *Ann Intern Med* 2008; **148**: 728–736.
- 72 Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. *AIDS* 2009; **23**: 875–885.
- 73 Silverberg MJ, Chao C, Leyden WA *et al.* HIV infection, immunodeficiency, viral replication, and the risk of cancer. *Cancer Epidemiol Biomarkers Prev* 2011; **20**: 2551–2559.
- 74 Silverberg MJ, Chao C, Leyden WA *et al.* HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. *J Natl Cancer Inst* 2013; **105**: 350–360.
- 75 Newnham A, Harris J, Evans HS *et al.* The risk of cancer in HIV-infected people in southeast England: a cohort study. *Br J Cancer* 2005; **92**: 194–200.
- 76 Marsden JR, Newton-Bishop JA, Burrows L *et al.*; British Association of Dermatologists Clinical Standards Unit. Revised UK guidelines for the management of cutaneous melanoma 2010. *Br J Dermatol* 2010; **163**: 238–256.
- 77 van Leeuwen MT, Vajdic CM, Middleton MG *et al.* Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. *AIDS* 2009; **23**: 2183–2190.
- 78 de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. *Br J Dermatol* 2007; **156**: 222–230.
- 79 de Boer WA, Danner SA. HIV infection and squamous cell carcinoma of sun exposed skin. *AIDS* 1990; **4**: 91.
- 80 Kreuter A, Weiland U, Brockmeyer NH, German Network of Competence HIV/AIDS. Genital human papillomavirus-associated (pre-) malignant skin diseases drastically increase in the era of highly active antiretroviral therapy for HIV infection. *J Am Acad Dermatol* 2006; **55**: 1116–1117.
- 81 Maurer TA, Christian KV, Kerschmann RL *et al.* Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. *Arch Dermatol* 1997; **133**: 577–583.
- 82 Kreuter A, Brockmeyer NH, Pfister H *et al.* Competence Network HIV/AIDS. Human papillomavirus type 26-associated periungual squamous cell carcinoma *in situ* in a HIV-infected patient with concomitant penile and anal intraepithelial neoplasia. *J Am Acad Dermatol* 2005; **53**: 737–739.
- 83 Fearfield LA, Nelson M, Francis N, Bunker CB. Cutaneous squamous cell carcinoma with zosteriform metastases in a human immunodeficiency virus-infected patient. *Br J Dermatol* 2000; **142**: 573–574.
- 84 Neves-Motta R, Ferry FR, Basilio-de-Oliveira CA *et al.* Highly aggressive squamous cell carcinoma in an HIV-infected patient. *Rev Soc Bras Med Trop* 2004; **37**: 496–498.
- 85 Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. *Arch Dermatol* 2002; **138**: 758–763.
- 86 Hausauer AK, Maurer T, Leslie KS *et al.* Recurrence after treatment of cutaneous basal cell and squamous cell carcinomas in patients infected with human immunodeficiency virus. *JAMA Dermatol* 2013; **149**: 239–241.
- 87 Kagen MH, Hirsch RJ, Chu P *et al.* Multiple infundibulocystic basal cell carcinomas in association with human immunodeficiency virus. *J Cutan Pathol* 2000; **27**: 316–318.
- 88 Wu ML, Guitart J. Unusual neurotropism. *Am J Dermatopathol* 2000; **22**: 468–469.
- 89 Johnson DF, Keppen M, Sitz KV. Metastatic basal cell carcinoma in acquired immunodeficiency syndrome-related complex. *JAMA* 1987; **257**: 340–343.
- 90 Garlassi E, Harding V, Weir J *et al.* Nonmelanoma skin cancers among HIV-infected persons in the HAART era. *J Acquir Immune Defic Syndr* 2012; **60**: e63–65.
- 91 Motley R, Kersey P, Lawrence C *et al.* Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. *Br J Dermatol* 2002; **146**: 18–25.
- 92 Rodriguez EA, Jakubowicz S, Chinchilla DA *et al.* Porokeratosis of Mibelli and HIV-infection. *Int J Dermatol* 1996; **35**: 402–404.
- 93 Kotlarewsky M, Freeman JB, Cameron W, Grikmar LJ. Anal intraepithelial dysplasia and squamous carcinoma in immunosuppressed patients. *Can J Surg* 2001; **44**: 450–454.
- 94 Welton ML, Sharkey FE, Kahlenberg MS. The etiology and epidemiology of anal cancer. *Surg Oncol Clin N Am* 2004; **13**: 263–275.
- 95 Pereira F, Carey W, Shibata H *et al.* Multiple nevoid malignant melanomas in a patient with AIDS: the role of proliferating cell nuclear antigen in the diagnosis. *J Am Acad Dermatol* 2002; **47**(Suppl 2): S172–174.

- 96 Hoffmann C, Horst HA, Weichenthal M, Hauschild A. Malignant melanoma and HIV infection: aggressive course despite immune reconstitution. *Onkologie* 2005; **28**: 35–37.
- 97 Agnieszka W, Kubica, BS, Brewer JD. Melanoma in immunosuppressed patients. *Mayo Clin Proc* 2012; **87**: 991–1003.
- 98 Crum-Cianflone N, Hullsiek KH, Satter E *et al.* Cutaneous malignancies among HIV-infected persons. *Arch Intern Med* 2009; **169**: 1130–1138.
- 99 Telfer NR, Colver GB, Morton CA; British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. *Br J Dermatol* 2008; **159**: 35–48.
- 100 Rodrigues LK, Klencke BJ, Vin-Christian K *et al.* Altered clinical course of malignant melanoma in HIV-positive patients. *Arch Dermatol* 2002; **138**: 765–770.
- 101 Sass U, Kolivras A, André J. Malignant ‘animal-type’ melanoma in a seropositive African man. *J Am Acad Dermatol* 2006; **54**: 547–548.
- 102 Webster RM, Sarwar, N, Bunker CB, Brock CS. A case series of HIV-positive patients with malignant melanoma. *J HIV Therapy* 2007; **12**: 75–78.
- 103 Wilkins K, Dolev JC, Turner R *et al.* Approach to the treatment of cutaneous malignancy in HIV-infected patients. *Dermatol Ther* 2005; **18**: 77–86.
- 104 Chan SY, Madan V, Lear JT, Helbert M. Highly active antiretroviral therapy-induced regression of basal cell carcinomas in a patient with acquired immunodeficiency and Gorlin syndrome. *Br J Dermatol* 2006; **154**: 1079–1080.
- 105 Honda KS. HIV and skin cancer. *Dermatol Clin* 2006; **24**: 521–530.
- 106 Scott DR. Eradication of basal cell cancer in an HIV positive patient with topical imiquimod. *J Drugs Dermatol* 2004; **3**: 602.
- 107 Han SY, North JP, Canavan T *et al.* Merkel cell carcinoma. *Hematol Oncol Clin North Am* 2012; **26**: 1351–1374.
- 108 Whittaker SJ, Marsden JR, Spittle M *et al.* Joint British Association of Dermatologists, UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. *Br J Dermatol* 2003; **149**: 1095–1107.
- 109 Willemze R, Dreyling M; ESMO Guidelines Working Group. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2009; **20**(Suppl 4): 115–118.
- 110 Bunker CB, Neill SA. The genital, perianal and umbilical regions. In: Burns T, Breathnach S, Cox N and Griffiths C (eds). *Rook’s Textbook of Dermatology*. 8th edn. Wiley-Blackwell, New York; 2010.
- 111 Porter, WM, Francis N, Hawkins D, Dinneen M, Bunker CB. Penile intraepithelial neoplasia: clinical spectrum and treatment of 35 cases. *Br J Dermatol* 2002; **147**: 1159–1165.
- 112 Shim TN, Hawkins D, Muneer A *et al.* Male genital dermatoses in immunocompromised patients. *Br J Dermatol* 2013; **169** (Suppl 1): 99.
- 113 Shim TN, Hawkins D, Muneer A *et al.* Male genital dermatoses in HIV. *Sex Transm Infect* 2013; **89**(Suppl 1): A1–A428.
- 114 Evans MW, Sung AD, Gojo I *et al.* Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia. *Leuk Lymphoma* 2012; **53**: 660–664.
- 115 Sanfilippo NJ, Mitchell J, Grew D, DeLacure M. Toxicity of head-and-neck radiation therapy in human immunodeficiency virus-positive patients. *Int J Radiat Oncol Biol Phys* 2010; **77**: 1375–1379.
- 116 Klein EA, Guiou M, Farwell DG *et al.* Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus. *Int J Radiat Oncol Biol Phys* 2011; **79**: 60–64.
- 117 Goedert JJ, Schairer C, McNeel TS *et al.* Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. *Br J Cancer* 2006; **95**: 642–648.
- 118 Shiels MS, Goedert JJ, Moore RD *et al.* Reduced risk of prostate cancer in U.S. men with AIDS. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 2910–2915.
- 119 Kahn S, Jani A, Edelman S *et al.* Matched cohort analysis of outcomes of definitive radiotherapy for prostate cancer in human immunodeficiency virus-positive patients. *Int J Radiat Oncol Biol Phys* 2012; **83**: 16–21.
- 120 Pantanowitz L, Bohac G, Cooley TP *et al.* Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. *BJU Int* 2008; **101**: 1519–1523.

## 13 Opportunistic infection prophylaxis in HIV-associated malignancy

### 13.1 Introduction

HIV infection causes immunosuppression, CD4 lymphocyte count loss and a progressive risk of opportunistic infection and tumours. Similarly chemotherapy and radiotherapy for HIV-related malignancies is associated with an increased risk of infection secondary to the myelosuppression and additional CD4 lymphocyte count loss [1–3]. The risk of infection is further raised by the presence of central venous catheters [4–7], neutropenia associated with HIV infection [8,9] and many of the therapies utilized to treat HIV and its complications [10–12]. These factors all combine to produce a significant risk of opportunistic infection in people living with HIV who are undergoing treatment for cancer.

Guidelines for the initiation of opportunistic infection prophylaxis and highly active antiretroviral therapy (HAART) are available [13] but these treatments should be started at higher CD4 cell counts in patients who are to undergo chemotherapy and radiotherapy. We recommend that all patients with AIDS-defining malignancies should start HAART (level of evidence 1B) [13]. We suggest that all patients with non-AIDS-defining malignancies who are due to start chemotherapy or radiotherapy should be started on HAART unless contraindicated (level of evidence 2C) [13]. This is based on the well-documented decline in CD4 cell counts associated with chemotherapy and radiotherapy. Although guidelines suggest initiation of prophylaxis against opportunistic infections based on CD4 cell count, this differs in those with malignancies due to the possible profound immunosuppression associated with chemotherapy and radiotherapy.

### 13.2 PCP prophylaxis

Prophylaxis against *Pneumocystis jirovecii* pneumonia (PCP) is recommended for those who have a CD4 count less than 200 cells/ $\mu$ L (level of evidence 1A) and should be considered at higher levels in all patients starting chemotherapy or radiotherapy (GPP) [14]. Chemotherapy and radiotherapy are associated with profound falls in CD4 cell counts even in patients on HAART and the degree of decline in CD4 cell count may be unpredictable [1–3]. The treatment of choice is cotrimoxazole, which may have additional benefits in reducing the incidence of bacterial infections (respiratory, gastrointestinal especially salmonella and possibly CNS infections) [15–18] and toxoplasmosis [19,20].

Alternative prophylaxis should be with dapsone or pentamidine via nebuliser.

### 13.3 MAC prophylaxis

Prophylaxis against MAC is recommended for individuals with a CD4 cell count less than 50 cells/ $\mu$ L (level of evidence 1B) [14]. Individuals who have or are at risk of a CD4 cell count falling below this level should be considered for MAC prophylaxis. The treatment of choice is azithromycin 1.25 g once per week or clarithromycin with rifabutin being considered as an alternative [21–24].

### 13.4 Fungal prophylaxis

People living with HIV who have low CD4 cell counts are at risk of fungal infections, most commonly oral and oesophageal candida and cryptococcosis; whilst those with prolonged very low CD4 cell counts are also at risk of pulmonary aspergillosis. In individuals with central venous catheters *in situ* and profound neutropenia, invasive fungal infections are a considerable cause of morbidity and mortality.

A systematic review and meta-analysis of 31 trials of antifungal prophylaxis in cancer patients after chemotherapy or haematopoietic stem-cell transplantation (HSCT), showed that antifungal prophylaxis significantly decreases all-cause mortality (RR: 0.84, 95% CI: 0.84–0.95) and the effect estimates were greater in studies with more rigorous methodology [25]. Antifungal prophylaxis was also found to be of benefit in the secondary outcomes including risk of fungal-related death (RR: 0.55, 95% CI: 0.41–0.74), documented invasive fungal infection (IFI) (RR: 0.5, 95% CI: 0.41–0.61), any (documented, probable and possible) IFI (RR: 0.64, 95% CI: 0.56–0.73), and the use of empiric antifungal therapy (RR: 0.83, 95% CI: 0.78–0.88) [25].

Within the meta-analysis, seven trials [26–32] compared fluconazole with itraconazole; overall there was no significant difference in all cause mortality, fungal-related mortality, documented IFI, or invasive *Candida* or *Aspergillus* infections [25]. Itraconazole use, however, was associated with significantly more adverse events causing discontinuation of the drug. Itraconazole also interacts with vinca alkaloids so should be avoided in regimens containing vincristine, vinblastine, vindesine or vinorelbine [33].

Two trials have compared posaconazole to oral fluconazole or itraconazole [34,35]. Posaconazole use resulted in a reduction of all cause mortality of borderline significance

(RR: 0.77, 95% CI: 0.59–1.01). There was a significant reduction in fungal-related mortality (RR: 0.25, 95% CI: 0.11–0.57) and documented invasive *Aspergillus* infections (RR: 0.22, 95% CI: 0.11–0.42) but no difference in adverse reactions leading to discontinuation of the antifungal drug [25]. Posaconazole also has adverse interactions with vinca alkaloid chemotherapy [33].

The efficacy of voriconazole compared with fluconazole was examined in a large ( $n = 600$ ) randomized double-blind trial of allogeneic HSCT recipients [36]. No difference in fungal-free survival was found but there was a trend towards lower incidence of *Aspergillus* infections, incidence of IFI, and less use of empirical antifungal therapy. Voriconazole use, however, may be associated with severe photosensitivity and other adverse events [37–39] and also has adverse interactions with vinca alkaloid chemotherapy [33].

Although the evidence for systemic azole antifungal prophylaxis comes from haematological malignancy in the HIV seronegative or untested population, there is an added risk of invasive fungal infection in people living with HIV. We recommend that systemic azole antifungal prophylaxis should be used in all patients receiving chemotherapy or radiotherapy for HIV-associated malignancy (level of evidence 1D), especially those at risk of profound neutropenia and with central venous lines *in situ*. The potential drug interactions of itraconazole, posaconazole and voriconazole may outweigh the enhanced activity against invasive *Aspergillus* and fluconazole is the agent of choice.

### 13.5 Bacterial prophylaxis

Systemic anticancer therapy and radiotherapy are associated with febrile neutropenia and bacterial sepsis. This risk is increased both by drugs used to treat HIV and its complications and by HIV infection itself [8–12]. Prophylactic G-CSF has been shown to reduce the nadir neutrophil count and the duration of neutropenia in people living with HIV [40,41]. In people at risk of neutropenia, other myelosuppressive agents, such as zidovudine and ganciclovir should be avoided.

Prophylactic antibiotics to reduce the incidence of life-threatening bacterial infection in chemotherapy-induced neutropenia remain controversial. Prophylactic fluoroquinolones are advocated for patients undergoing very high-risk chemotherapy who are likely to have prolonged (>1 week) and profound (absolute neutrophil count <0.5 cells/mL) neutropenia, including those undergoing allogeneic stem cell transplantation and induction chemotherapy for acute leukaemia [42,43]. Some centres do not follow this practice, because of the concern of selecting antibiotic resistance and other side-effects, and instead have a low

threshold for treatment of neutropenic sepsis. In lower-risk patients, the benefits of prophylactic fluoroquinolone have been shown in randomized controlled studies [44,45]; however, the numbers needed to treat to prevent one infection have been high, there are antibiotic-related adverse events, susceptibility to superinfection with *Clostridium difficile* amongst others, and risk of selecting antibiotic resistance [46]. We do not recommend routine fluoroquinolone prophylaxis in low-risk patients [47] and the use of cotrimoxazole to prevent PCP may provide some protection against bacterial infection for patients living with HIV (level of evidence 1C).

### 13.6 Antiviral prophylaxis

The incidence of herpes simplex virus (HSV) and varicella-zoster virus (VZV) seropositivity in people living with HIV is high. The disruption of the cellular immune response associated with HIV and with chemotherapy means reactivation of latent herpes viruses is common. Prophylactic aciclovir or valaciclovir has been shown to reduce viral reactivation in randomized trials of HSV and VZV seropositive individuals undergoing intensive chemotherapy [48–50]. We recommend HSV prophylaxis in people living with HIV with a history of HSV infection who are starting chemotherapy to reduce the incidence and severity of reactivations (level of evidence 1D).

Reactivation of cytomegalovirus infection with conventional chemotherapy is rare and moreover, ganciclovir, the most effective agent, causes significant myelosuppression. Prophylaxis against CMV is not recommended even in the context of allogeneic stem cell transplantation where weekly monitoring of CMV replication is recommended for at least 100 days post transplant [51]. Regular monitoring can trigger pre-emptive antiviral therapy and lower rate of CMV infection and mortality but practice varies between centres [52,53].

Active malignant disease is associated with a higher risk of influenza, parainfluenza and respiratory syncytial virus (RSV) infection. Although vaccine response can be highly variable and generally low in people with cancer [54], annual influenza vaccination is recommended as per the BHIVA opportunistic infection guidelines (level of evidence 1B) [14]. Optimal timing for immunization has not been established, so vaccination is generally performed at least 2 weeks before chemotherapy starts or at least 1 week after the last cycle [43]. Similarly, people living with HIV and cancer should be vaccinated against pneumococcus and hepatitis B virus (level of evidence 2D) [55].

At least half the people living with HIV have serum markers of previous hepatitis B virus (HBV) infection [56]. Occult hepatitis B, in which there is viral replication in the



absence of surface antigen, is well documented in HIV-positive patients [57,58]. Reactivation of HBV and a rise in HBV DNA can occur at low CD4 cell counts, and has been documented in both HIV-positive and HIV-negative patients receiving immunosuppressive chemotherapy [59–66]. In one study of HBV surface antigen, of the HIV-positive patients treated with chemotherapy for lymphoma who did not receive antiviral prophylaxis, 32% experienced HBV reactivation of whom 41% progressed to fatal fulminant hepatitis [67]. The risk of HBV reactivation appears to be particularly high in patients treated with rituximab containing chemotherapy regimens [68].

The use of prophylactic lamivudine in people at risk of HBV reactivation who were treated for lymphoma with chemotherapy reduces the incidence of HBV reactivation, severe hepatitis and the disruptions to chemotherapy compared to historical controls [69]. A meta-analysis of 14 studies involving a total of 275 at-risk patients receiving chemotherapy who were treated with prophylactic lamivudine showed that it reduced the risk of HBV reactivation and HBV-related hepatitis by 80–100% [70].

Patients with antibodies against hepatitis B core antigen (HBcAb) should be treated with prophylactic antivirals in line with BHIVA hepatitis guidelines (level of evidence 1B) [71] and this should be continued for at least 6 months after completion of anticancer therapy [72].

People living with HIV and malignancies should receive immunizations in line with the BHIVA immunization guidelines [55] and those who have had a splenectomy should receive vaccinations and antibiotic prophylaxis in line with national asplenic guidelines [73].

### 13.7 Recommendations

- We recommend that all patients with AIDS-defining malignancies should start HAART (level of evidence 1B).
- We suggest that all patients with non-AIDS-defining malignancies who are due to start chemotherapy or radiotherapy should be started on HAART unless contraindicated (level of evidence 2C).
- We recommend that prophylaxis against *Pneumocystis jirovecii* pneumonia (PCP) should be started for those who have a CD4 cell count less than 200 cells/ $\mu$ L (level of evidence 1A) and should be considered at higher levels in all patients starting chemotherapy or radiotherapy (GPP).
- We recommend prophylaxis against MAC for individuals with a CD4 cell count less than 50 cells/ $\mu$ L (level of evidence 1B) and in those whose treatment puts their CD4 count at risk of falling below this level.
- We recommend that systemic azole antifungal prophylaxis should be used in all patients receiving chemo-

therapy or radiotherapy for HIV-associated malignancy (level of evidence 1D).

- We do not recommend routine fluoroquinolone prophylaxis in low-risk patients and the use of cotrimoxazole to prevent PCP may provide some protection against bacterial infection for patients living with HIV (level of evidence 1C).
- We recommend HSV prophylaxis in people living with HIV with a history of HSV infection who are starting chemotherapy to reduce the incidence and severity of reactivations (level of evidence 1D).
- We recommend annual influenza vaccination (level of evidence 1B).
- We recommend vaccination against pneumococcus and hepatitis B virus (level of evidence 1D).
- We recommend that patients with antibodies against hepatitis B core antigen (HBcAb) should be treated with prophylactic antivirals in line with BHIVA hepatitis guidelines (level of evidence 1B).

### 13.8 References

- 1 Powles T, Imami N, Nelson M *et al*. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. *AIDS* 2002; **16**: 531–536.
- 2 Esdaile B, Davis M, Portsmouth S *et al*. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma. *AIDS* 2002; **16**: 2344–2347.
- 3 Alfa-Wali M, Allen-Mersh T, Antoniou A *et al*. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. *Ann Oncol* 2012; **23**: 141–147.
- 4 Moore DA, Gazzard BG, Nelson MR. Central venous line infections in AIDS. *J Infect* 1997; **34**: 35–40.
- 5 Dega H, Eliaszewicz M, Gisselbrecht M *et al*. Infections associated with totally implantable venous access devices (TIVAD) in human immunodeficiency virus-infected patients. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996; **13**: 146–154.
- 6 Tacconelli E, Tumbarello M, de Gaetano Donati K *et al*. Morbidity associated with central venous catheter-use in a cohort of 212 hospitalized subjects with HIV infection. *J Hosp Infect* 2000; **44**: 186–192.
- 7 Meynard JL, Guiguet M, Arsac S *et al*. Frequency and risk factors of infectious complications in neutropenic patients infected with HIV. *AIDS* 1997; **11**: 995–998.
- 8 Levine AM, Karim R, Mack W *et al*. Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. *Arch Intern Med* 2006; **166**: 405–410.

- 9 Israel DS, Plaisance KI. Neutropenia in patients infected with human immunodeficiency virus. *Clin Pharm* 1991; 10: 268–279.
- 10 Moyle G, Sawyer W, Law M *et al.* Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. *Clin Ther* 2004; 26: 92–97.
- 11 Medina I, Mills J, Leoung G *et al.* Oral therapy for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole *versus* trimethoprim-dapsone. *N Engl J Med* 1990; 323: 776–782.
- 12 Lalezari J, Lindley J, Walmsley S *et al.* A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. *J Acquir Immune Defic Syndr* 2002; 30: 392–400.
- 13 Williams I, Churchill D, Anderson J *et al.* British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. *HIV Med* 2012; 13(Suppl 2): 1–85.
- 14 Nelson M, Dockrell D, Edwards S *et al.* British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. *HIV Med* 2011; 12(Suppl 2): 1–140.
- 15 Nelson MR, Shanson DC, Hawkins DA, Gazzard BG. *Salmonella*, *Campylobacter* and *Shigella* in HIV-seropositive patients. *AIDS* 1992; 6: 1495–1498.
- 16 DiRienzo AG, van Der Horst C, Finkelstein DM *et al.* Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. *AIDS Res Hum Retroviruses* 2002; 18: 89–94.
- 17 Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. *Lancet Infect Dis* 2004; 4: 445–455.
- 18 Kohli R, Lo Y, Homel P *et al.* Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. *Clin Infect Dis* 2006; 43: 90–98.
- 19 Ribera E, Fernandez-Sola A, Juste C *et al.* Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients. *Clin Infect Dis* 1999; 29: 1461–1466.
- 20 Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. *Clin Infect Dis* 2001; 33: 1747–1755.
- 21 Havlir DV, Dube MP, Sattler FR *et al.* Prophylaxis against disseminated *Mycobacterium avium* complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. *N Engl J Med* 1996; 335: 392–398.
- 22 Pierce M, Crampton S, Henry D *et al.* A randomized trial of clarithromycin as prophylaxis against disseminated *Mycobacterium avium* complex infection in patients with advanced acquired immunodeficiency syndrome. *N Engl J Med* 1996; 335: 384–391.
- 23 Cohn DL. Prevention strategies for *Mycobacterium avium-intracellulare* complex (MAC) infection. A review of recent studies in patients with AIDS. *Drugs* 1997; 54: 8–15; discussion 28–19.
- 24 Benson CA, Williams PL, Cohn DL *et al.* Clarithromycin or rifabutin alone or in combination for primary prophylaxis of *Mycobacterium avium* complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Bein Community Programs for Clinical Research on AIDS 009 Protocol Team. *J Infect Dis* 2000; 181: 1289–1297.
- 25 Robenshtok E, Gafter-Gvili A, Goldberg E *et al.* Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. *J Clin Oncol* 2007; 25: 5471–5489.
- 26 Annaloro C, Oriana A, Tagliaferri E *et al.* Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. *Haematologica* 1995; 80: 512–517.
- 27 Huijgens PC, Simoons-Smit AM, van Loenen AC *et al.* Fluconazole *versus* itraconazole for the prevention of fungal infections in haemato-oncology. *J Clin Pathol* 1999; 52: 376–380.
- 28 Morgenstern GR, Prentice AG, Prentice HG *et al.* A randomized controlled trial of itraconazole *versus* fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group. *Br J Haematol* 1999; 105: 901–911.
- 29 Winston DJ, Maziarz RT, Chandrasekar PH *et al.* Intravenous and oral itraconazole *versus* intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. *Ann Intern Med* 2003; 138: 70–713.
- 30 Marr KA, Crippa F, Leisenring W *et al.* Itraconazole *versus* fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. *Blood* 2004; 103: 1527–1533.
- 31 Oren I, Rowe JM, Sprecher H *et al.* A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. *Bone Marrow Transplant* 2006; 38: 127–134.

- 32 Glasmacher A, Cornely O, Ullmann AJ *et al.* An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. *J Antimicrob Chemother* 2006; **57**: 317–325.
- 33 Moriyama B, Henning SA, Leung J *et al.* Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. *Mycoses* 2012; **55**: 290–297.
- 34 Cornely OA, Maertens J, Winston DJ *et al.* Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007; **356**: 348–359.
- 35 Ullmann AJ, Lipton JH, Vesole DH *et al.* Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med* 2007; **356**: 335–347.
- 36 Wingard JR, Carter SL, Walsh TJ *et al.* Randomized, double-blind trial of fluconazole *versus* voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. *Blood* 2010; **116**: 5111–5118.
- 37 McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. *Clin Infect Dis* 2007; **44**: e55–56.
- 38 Cowen EW, Nguyen JC, Miller DD *et al.* Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. *J Am Acad Dermatol* 2010; **62**: 31–37.
- 39 Miller DD, Cowen EW, Nguyen JC *et al.* Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. *Arch Dermatol* 2010; **146**: 300–304.
- 40 Kuritzkes DR, Parenti D, Ward DJ *et al.* Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. *AIDS* 1998; **12**: 65–74.
- 41 Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. *Clin Infect Dis* 2000; **30**: 256–260.
- 42 Tomblyn M, Chiller T, Einsele H *et al.* Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant* 2009; **15**: 1143–1238.
- 43 Freifeld AG, Bow EJ, Sepkowitz KA *et al.* Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2011; **52**: e56–93.
- 44 Cullen M, Steven N, Billingham L *et al.* Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. *N Engl J Med* 2005; **353**: 988–998.
- 45 Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. *J Clin Oncol* 1998; **16**: 1179–1187.
- 46 Baden LR. Prophylactic antimicrobial agents and the importance of fitness. *N Engl J Med* 2005; **353**: 1052–1054.
- 47 Flowers CR, Seidenfeld J, Bow EJ *et al.* Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2013; **31**: 794–810.
- 48 Saral R, Burns WH, Laskin OL *et al.* Acyclovir prophylaxis of herpes-simplex-virus infections. *N Engl J Med* 1981; **305**: 63–67.
- 49 Saral R, Ambinder RF, Burns WH *et al.* Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. *Ann Intern Med* 1983; **99**: 773–776.
- 50 Boeckh M, Kim HW, Flowers ME *et al.* Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. *Blood* 2006; **107**: 1800–1805.
- 51 Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *MMWR Recomm Rep* 2000; **49**(RR-10): 1–125 CE121–127.
- 52 Einsele H, Ehninger G, Hebart H *et al.* Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. *Blood* 1995; **86**: 2815–2820.
- 53 Boeckh M, Gooley TA, Myerson D *et al.* Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir *versus* ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. *Blood* 1996; **88**: 4063–4071.
- 54 Beck CR, McKenzie BC, Hashim AB *et al.* Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. *J Infect Dis* 2012; **206**: 1250–1259.
- 55 Geretti AM, Brook G, Cameron C *et al.* British HIV Association guidelines for immunization of HIV-infected adults 2008. *HIV Med* 2008; **9**: 795–848.
- 56 Konopnicki D, Mocroft A, de Wit S *et al.* Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. *AIDS* 2005; **19**: 593–601.
- 57 Lo Re V 3rd, Frank I, Gross R *et al.* Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among

- HIV-infected patients. *J Acquir Immune Defic Syndr* 2007; 44: 315–320.
- 58 Shire NJ, Rouster SD, Stanford SD *et al.* The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. *J Acquir Immune Defic Syndr* 2007; 44: 309–314.
- 59 Vento S, di Perri G, Luzzati R *et al.* Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. *Lancet* 1989; 1: 332–333.
- 60 Lok AS, Liang RH, Chiu EK *et al.* Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. *Gastroenterology* 1991; 100: 182–188.
- 61 Maruyama T, Iino S, Koike K *et al.* Serology of acute exacerbation in chronic hepatitis B virus infection. *Gastroenterology* 1993; 105: 1141–1151.
- 62 Yeo W, Chan PK, Zhong S *et al.* Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. *J Med Virol* 2000; 62: 299–307.
- 63 Bani-Sadr F, Maillard A, Ponscarne D *et al.* Reactivation of HBV replication in HIV-HBV infected patients. *Am J Med* 2003; 114: 768–769.
- 64 Yeo W, Zee B, Zhong S *et al.* Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. *Br J Cancer* 2004; 90: 1306–1311.
- 65 Zhong S, Yeo W, Schroder C *et al.* High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. *J Viral Hepat* 2004; 11: 55–59.
- 66 Stebbing J, Atkins M, Nelson M *et al.* Hepatitis B reactivation during combination chemotherapy for AIDS-related lymphoma is uncommon and does not adversely affect outcome. *Blood* 2004; 103: 2431–2432.
- 67 Leaw SJ, Yen CJ, Huang WT *et al.* Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. *Ann Hematol* 2004; 83: 270–275.
- 68 Evens AM, Jovanovic BD, Su YC *et al.* Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. *Ann Oncol* 2011; 22: 1170–1180.
- 69 Li YH, He YF, Jiang WQ *et al.* Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. *Cancer* 2006; 106: 1320–1325.
- 70 Loomba R, Rowley A, Wesley R *et al.* Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. *Ann Intern Med* 2008; 148: 519–528.
- 71 Brook G, Main J, Nelson M *et al.* British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. *HIV Med* 2010; 11: 1–30.
- 72 Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. *J Gastroenterol Hepatol* 2010; 25: 864–871.
- 73 Davies JM, Lewis MP, Wimperis J *et al.* Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. *Br J Haematol* 2011; 155: 308–317.

## 14 Acknowledgements

The writing group thanks the following for their comments and contributions to the guideline:

Kirit Ardesbna  
 Aravind Arumainathan  
 Robin Grant  
 Sharon Jay  
 Alistair Miller  
 Josie Shew  
 Lindsay Short  
 Kate Templeton  
 Laura Waters (on behalf of the BASHH HIV Special Interest Group)

### 14.1 Conflicts of interest statements

Prof Mark Bower has received lecture fees, honoraria and advisory board attendance fees from Abbott, Bristol-Myers Squibb, Gallen, Gilead, Janssen & ViiV.

Dr Adrian Palfreeman has no conflicts of interest to declare.

Dr Maryam Alfa-Wali has no conflicts of interest to declare.

Prof Chris Bunker has no conflicts of interest to declare.

Dr Fiona Burns has received speaker fees from Janssen and an educational travel grant from Gilead.

Dr Duncan Churchill has, in the past year, received sponsorship from Janssen to attend a conference, and has sat on advisory boards for Gilead.

Mr Simon Collins has no conflicts of interest to declare.

Dr Kate Cwynarski has received advisory board honoraria/travel/registration reimbursement from Roche.

Dr Simon Edwards has received speaker, advisory and conference attendance fees from Merck Sharp and Dohme, Gilead, Abbott, ViiV and Janssen.

Dr Paul Fields has no conflicts of interest to declare.

Dr Kate Fife has no conflicts of interest to declare.

Dr Eve Gallop-Evans has received ad board honoraria from Galen.

Dr Shireen Kassam has no conflicts of interest to declare.

Dr Ranjababu Kulasegaram has received speaker and advisory fees from Merck Sharp and Dohme, Abbott, ViiV and Janssen. He has received research funding from Boehringer Ingelheim, Pfizer, ViiV and Gilead. He has received educational travel grants from Janssen, ViiV and Bristol-Myers Squibb.

Prof Charles Lacey has received speaker fees from Sanofi Pasteur MSD

Dr Robert Marcus has received lecture fees, honoraria and advisory board attendance fees from Roche and Napp Pharmaceuticals.

Dr Silvia Montoto has no conflicts of interest to declare.

Dr Mark Nelson has received lecture fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Merck Sharp & Dohme, Tibotec and ViiV and consultancy fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Idenix, Merck Sharp & Dohme, Pfizer, Tibotec and ViiV. His department has received research grants from Abbott, Aspen Pharmaceuticals, Bristol-Myers Squibb, Gilead, Merck Sharp & Dohme, Tibotec and ViiV.

Dr Tom Newsom-Davis has received advisory board honoraria, speaker fees and travel/registration reimbursement from Eli Lilly, Hoffman La Roche, Boehringer Ingelheim, Sinclair IS Pharma, Astra Zeneca, Otsuka and ViiV, and has received research funding from ViiV.

Dr Chloe Orkin has received advisory board honoraria, speaker fees, research funding and travel/registration reimbursement from Bristol-Myers Squibb, Abbott, AbbVie, GlaxoSmithKline, ViiV, Merck Sharp & Dohme, Boehringer Ingelheim, Janssen, and Johnson & Johnson. She is also a trials investigator for all of these companies.

Ms Kate Shaw has no conflicts of interest to declare.

Dr Melinda Tenant-Flowers has no conflicts of interest to declare.

Dr Andrew Webb has received advisory board honoraria and travel reimbursement from Roche.

Dr Sarah Westwell has received advisory board honoraria/ speaker fees/ travel/registration reimbursement from Roche, Bristol-Myers Squibb, Astra Zeneca and Sanofi.

Mr Matt Williams has no conflicts of interest to declare.



## 15 List of appendices

The appendix can be found on the BHIVA website (<http://www.bhiva.org/Malignancy-2014.aspx>)

Appendix 1: Summary modified GRADE system